<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001162" GROUP_ID="SCHIZ" ID="914099072912340157" MERGED_FROM="" MODIFIED="2012-10-17 20:39:04 +0100" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.2.3&lt;br&gt;Perhaps should have mentioned some of the comments points in the text itself - the Levo-sulpiride was a good point and is not really addressed in the body of the text.&lt;/p&gt;&lt;p&gt;The odd comparisons was another that should have been mentioned in the body of the text.....and more&lt;/p&gt;&lt;p&gt;&lt;br&gt;More or less ready for submission 21/2/00&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-04-26 13:51:36 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0023" REVMAN_SUB_VERSION="5.0.1" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2012-10-17 20:39:04 +0100" MODIFIED_BY="Claire Irving">
<TITLE>Sulpiride for schizophrenia</TITLE>
<CONTACT MODIFIED="2012-10-17 20:39:04 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="9639" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bernardo</FIRST_NAME><MIDDLE_INITIALS>GO</MIDDLE_INITIALS><LAST_NAME>Soares</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>bgosoares@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT><ORGANISATION>Universidade Federal de São Paulo</ORGANISATION><ADDRESS_1>Rua Pedro de Toledo 598</ADDRESS_1><CITY>São Paulo</CITY><ZIP>04039-001</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5575 2970</PHONE_1><FAX_1>+55 11 5579 0469</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-10-17 20:39:04 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="9639" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bernardo</FIRST_NAME><MIDDLE_INITIALS>GO</MIDDLE_INITIALS><LAST_NAME>Soares</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>bgosoares@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT><ORGANISATION>Universidade Federal de São Paulo</ORGANISATION><ADDRESS_1>Rua Pedro de Toledo 598</ADDRESS_1><CITY>São Paulo</CITY><ZIP>04039-001</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5575 2970</PHONE_1><FAX_1>+55 11 5579 0469</FAX_1></ADDRESS></PERSON><PERSON ID="7447" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Mark</FIRST_NAME><LAST_NAME>Fenton</LAST_NAME><POSITION>Editor</POSITION><EMAIL_1>mark.fenton@nice.org.uk</EMAIL_1><ADDRESS><DEPARTMENT>Database of Uncertainties about the Effects of Treatments (DUETs)</DEPARTMENT><ORGANISATION>National Institute for Health and Clinical Excellence</ORGANISATION><ADDRESS_1>Level 1A, City Tower, Piccadilly Plaza</ADDRESS_1><ADDRESS_2>Middle Way</ADDRESS_2><CITY>Manchester</CITY><ZIP>M1 4BD</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)161 219 3788</PHONE_1><PHONE_2>+44(0)1789 552225</PHONE_2></ADDRESS></PERSON><PERSON ID="1184E61F82E26AA201DC7B3E21933F3B" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Pierre</FIRST_NAME><LAST_NAME>Chue</LAST_NAME><POSITION>Senior Psychiatrist, Community Living Program</POSITION><EMAIL_1>pchue@gpu.srv.ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>3rd Floor 108th Street Building</ADDRESS_1><ADDRESS_2>9942-108 Street</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T5K 2J5</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 403 428 1776</PHONE_1><FAX_1>+1 403 425 9317</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-04-26 14:52:39 +0200" MODIFIED_BY="Tessa Jane Grant" NOTES="&lt;p&gt;Minor update: 18/01/00&lt;/p&gt;&lt;p&gt;Feedback added: 28/10/99&lt;/p&gt;&lt;p&gt;Response to feedback added: 18/01/00&lt;/p&gt;&lt;p&gt;Reformatted: 28/07/99&lt;/p&gt;">
<UP_TO_DATE>
<DATE DAY="24" MONTH="11" YEAR="1998"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="11" YEAR="1998"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="1999"/>
</DATES>
<WHATS_NEW MODIFIED="2012-10-17 20:39:04 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-10-17 20:39:04 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="17" MONTH="10" YEAR="2012"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2012-10-17 20:39:04 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-10-17 20:39:04 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="13" MONTH="4" YEAR="2011"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-04-13 17:55:18 +0200" MODIFIED_BY="Claire Irving"><DATE DAY="11" MONTH="11" YEAR="2009"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-11 11:40:07 +0100" MODIFIED_BY="Claire Irving">
<DATE DAY="26" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="24" MONTH="11" YEAR="1998"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Edmonton, Alberta</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Universidade Federal de Pelotas</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>NHS Centre for Reviews and Dissemination</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Cochrane Schizophrenia Group General Fund</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-04-26 13:51:36 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-04-26 13:51:36 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-04-26 13:51:36 +0100" MODIFIED_BY="[Empty name]">Sulpiride for schizophrenia</TITLE>
<SUMMARY_BODY>
<P>Synopsis pending.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>The antipsychotic drug sulpiride was formulated over 20 years ago and was marked as having a low incidence of adverse effects and an effect on the negative symptoms of schizophrenia. This relatively inexpensive antipsychotic drug has a similar neuropharmacological profile to several novel atypical drugs. <BR/>
</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To estimate the clinical efficacy and tolerability of sulpiride.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Electronic searches of Biological Abstracts (1982-1997), CINAHL (1982-1998), Cochrane Schizophrenia Group's Register (March 1998), Cochrane Library (Issue 1, 1998), EMBASE (1980-1998), MEDLINE (1966-1998), PsycLIT (1974-1997), SIGLE (1994-1998), and Sociofile (1974-1997) were supplemented by reference searching, contacting authors and the manufacturers of sulpiride.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised or quasi-randomised clinical trials focusing on the use of different doses of sulpiride or comparing sulpiride to (i) placebo; (ii) typical antipsychotic drugs; or (iii) atypical antipsychotic drugs, for those with schizophrenia or serious mental illness were selected.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Trials were reliably selected and quality rated. Data were independently extracted, by two reviewers (BGOS, MF), and analysed on an intention-to-treat basis. It was assumed that people who did not complete the follow up had no improvement. Authors of trials were contacted for additional and missing data. Relative risk (RR) and 95% confidence intervals (CI) of dichotomous data were calculated with the random effects model and weighted mean difference (WMD) was calculated for continuous data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>The review currently includes 18 studies (30 citations). Studies are generally small and of poor quality. Limited evidence suggests that there is little difference between sulpiride and other drugs although the incidence of side effects may be less for sulpiride. There are no clear findings relating to negative symptoms.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Sulpiride may be an effective antipsychotic drug but evidence is limited and data relating to claims for its value against negative symptoms is not trial-based.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>The effectiveness of drugs such as chlorpromazine and haloperidol for symptoms of schizophrenia, led to the theory that a specific action on the brain (D2 blockade) was the reason for their anti-psychotic properties and that other actions simply led to unwanted side effects (<LINK REF="REF-Johnstone-1978" TYPE="REFERENCE">Johnstone 1978</LINK>). The natural progression of this hypothesis was the formulation of sulpiride, a drug with an unusually specific mode of action on the D2 receptor sites (<LINK REF="REF-Jenner-1981" TYPE="REFERENCE">Jenner 1981</LINK>, <LINK REF="REF-Caley-1995" TYPE="REFERENCE">Caley 1995</LINK>). It was developed in France in the mid-1960s and has been used for the treatment of schizophrenia since that time (<LINK REF="STD-Carrere-1968" TYPE="STUDY">Carrere 1968</LINK>, <LINK REF="STD-Nishiura-1976" TYPE="STUDY">Nishiura 1976</LINK>). These D2 specific properties and a reputed lower tendency for induction of movement disorders (parkinsonism and tardive dyskinesia) makes sulpiride different from other antipsychotic drugs (<LINK REF="REF-Azorin-1992" TYPE="REFERENCE">Azorin 1992</LINK>). Chemically, it is a substituted benzamide derivative related to metoclopramide and trimethobenzamide. It has had other uses including treatment of peptic ulcer, vomiting and vertigo (<LINK REF="STD-Edwards-1980" TYPE="STUDY">Edwards 1980</LINK>, <LINK REF="STD-Bratfos-1979" TYPE="STUDY">Bratfos 1979</LINK>). </P>
<P>It has been suggested that sulpiride may be more effective than drugs such as chlorpromazine and haloperidol, for treating negative symptoms of schizophrenia (poverty of speech, lack of motivation, apathy, emotional impoverishment) (<LINK REF="REF-Gerlach-1991" TYPE="REFERENCE">Gerlach 1991</LINK>, <LINK REF="REF-Azorin-1992" TYPE="REFERENCE">Azorin 1992</LINK>) and that this effect is best seen when low doses are used (<LINK REF="STD-Petit-1987" TYPE="STUDY">Petit 1987</LINK>, <LINK REF="REF-Mauri-1996" TYPE="REFERENCE">Mauri 1996</LINK>). High-dose sulpiride is said to be effective for both negative and positive symptoms (delusions, hallucinations). This higher level of dosing may be safe for elderly people where the cardiovascular effects of other antipsychotics can be problematic (<LINK REF="REF-Mauri-1994" TYPE="REFERENCE">Mauri 1994</LINK>, <LINK REF="REF-Mauri-1996" TYPE="REFERENCE">Mauri 1996</LINK>).</P>
<P>Drugs such as chlorpromazine are prone to cause dry mouth, constipation, urinary retention (anticholinergic effects), tremor, rigidity, restlessness, parkinsonism (extrapyramidal effects) and sedation (antihistaminic effects) (<LINK REF="REF-Thornley-1999" TYPE="REFERENCE">Thornley 1999</LINK>). Sulpiride is reported to have lower adverse effects compared to these drugs (<LINK REF="STD-Svestka-1990" TYPE="STUDY">Svestka 1990</LINK>, <LINK REF="REF-Gerlach-1991" TYPE="REFERENCE">Gerlach 1991</LINK>). It is, however, known to elevate prolactin (a hormone) which may be associated with impotence, lowering of libido and unwanted production of breast milk (galactorrhoea) (<LINK REF="REF-Weizman-1985" TYPE="REFERENCE">Weizman 1985</LINK>, <LINK REF="STD-Liu-1996" TYPE="STUDY">Liu 1996</LINK>). The new generation of antipsychotic drugs, the 'atypicals', are also said to have a moderate side effect profile compared to the older drugs, but whether sulpiride is a real alternative to these expensive drugs is unknown.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To estimate the clinical effects and tolerability of sulpiride compared to placebo, typical and atypical antipsychotic drugs for those with schizophrenia or similar illnesses. It was also proposed to: (i) investigate whether standard or high dose sulpiride was effective for negative symptoms; and (ii) to highlight the effects of sulpiride on elderly people.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All relevant randomised or quasi-randomised controlled trials. See 'Methods' for management of quasi-randomised studies.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with the diagnosis of schizophrenia, however diagnosed. Those with 'serious/chronic mental illness' or 'psychotic illness' were also included. If possible, people with schizoaffective disorder, dementing illnesses, depression and primarily problems associated with substance misuse were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. Sulpiride: any dose and mode or pattern of administration. If a high/low dichotomy was not provided within the trial, high dose was defined as &gt;800 mg/day and low dose as any lesser dose. If different doses of sulpiride were randomised these studies were also of interest.</P>
<P>2. Placebo.</P>
<P>3. Typical antipsychotic drugs: any dose and mode or pattern of administration. Examples of such drugs are chlorpromazine and haloperidol.</P>
<P>4. Atypical antipsychotic drugs: any dose and mode or pattern of administration. Examples of such drugs are clozapine, olanzapine, quetiapine, and risperidone. </P>
<P>Where sulpiride was used within a combination drug, for example combined with a benzodiazapine, as in the 'Sulpan' preparation marketed in South America, these studies were presented within a separate comparison.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>1. Death: suicide or natural causes.</P>
<P>2. Service utilization outcomes<BR/>2.1 Hospital admission.<BR/>2.2 Days in hospital.</P>
<P>3. Global outcomes<BR/>3.1 Clinically significant response in global state - as defined by each of the studies.<BR/>3.2 Average score/change in global state.</P>
<P>4. Mental state<BR/>4.1 Clinically significant response in mental state - as defined by each of the studies.<BR/>4.2 Average score/change in mental state.<BR/>4.3 Clinically significant response on negative symptoms - as defined by each of the studies.<BR/>4.4 Average score/change in negative symptoms.<BR/>4.5 Relapse as defined in the study.</P>
<P>5. Behaviour<BR/>5.1 Leaving the study early.<BR/>5.2 Clinically significant response in behaviour - as defined by each of the studies.<BR/>5.3 Average score/change in behaviour.</P>
<P>6. Extrapyramidal side effects<BR/>6.1 Incidence of use of antiparkinson drugs.<BR/>6.2 Clinically significant extrapyramidal side effects- as defined by each of the studies.<BR/>6.3 Average score/change in extrapyramidal side effects.</P>
<P>7. Other adverse effects, general and specific<BR/>7.1 Number of people dropping out due to adverse affects;<BR/>7.2 Cardiac effects;<BR/>7.3 Anticholinergic effects;<BR/>7.4 Antihystamine effects;<BR/>7.5 Prolactin related symptoms.</P>
<P>8. Social functioning<BR/>8.1 Clinically significant response in social functioning - as defined by each of the studies.<BR/>8.2 Average score/change in social functioning.</P>
<P>9. Economic outcomes.</P>
<P>10. Quality of life/ satisfaction with care for either recipients of care or carers<BR/>10.1 Significant change in quality of life/ satisfaction - as defined by each of the studies.<BR/>10.2 Average score/change in quality of life/ satisfaction.<BR/>10.3 Employment status.</P>
<P>11. Cognitive functioning.</P>
<P>As schizophrenia is often a life-long illness, and sulpiride is used as an ongoing treatment, outcomes were grouped according to time periods: short term (less than 3 months), medium term (3-12 month) and long term (more than 1 year).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>Sulpiride is known by many names, and the following search phrase was constructed to assist identification:</P>
<P>(sulpiride-phrase) = (abilit or championyl or coolspan or col-sulpir or digton or dixibon or dobren or dogmatil or dolmatil or drominetas or eglonyl or equilid or eusulpid or guastil or isnamid or kapiride or lavodina or lebopride or lusedan or miradol or mirbanil or misulvan or neuromyfar or normum or omperan or psicocen or quiridil or sato or sernevin or sicofrenol or sulpiride or sulpisedan or suprium or sursumid or tepavil or tonofit or ulpir or vipral) </P>
<P>A. Electronic searching<BR/>Relevant randomised trials were identified by searching the follow electronic databases:<BR/>
<BR/>1. Biological Abstracts (January 1982 to December 1997) was searched using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and for schizophrenia (see Group search strategy) combined with:</P>
<P>[and (sulpiride-phrase)]</P>
<P>2. CINAHL (January 1982 to March 1998) was searched using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and for schizophrenia (see Group search strategy) combined with:</P>
<P>[and (sulpiride-phrase)]</P>
<P>3. Cochrane Schizophrenia Group's Register (March 1998) was searched using:</P>
<P>[(sulpiride-phrase) or #42=110 or #42=563]</P>
<P>(#42 is the field in the Register where each intervention is coded. 110 is sulpiride and 563 Dogmatil or Dolmatil).</P>
<P>4. Cochrane Library (Issue 1, 1998) was searched using:</P>
<P>[(sulpiride-phrase) or SULPIRIDE/explode in MeSH] <BR/>
<BR/>5. EMBASE (January 1980 to January 1998) was searched using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and for schizophrenia (see Group search strategy) combined with:</P>
<P>[and ((sulpiride-phrase) or explode SULPIRIDE / all)]</P>
<P>6. MEDLINE (January 1966 to April 1998) was searched using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and for schizophrenia (see Group search strategy) combined with:<BR/>
<BR/>[and ((sulpiride-phrase) or SULPIRIDE / explode in MeSH)] </P>
<P>7. PsycLIT (January 1974 to September 1997) was searched using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and for schizophrenia (see Group search strategy) combined with:</P>
<P>[and ((sulpiride-phrase) or SULPIRIDE / explode in MeSH)] </P>
<P>8. SIGLE (January 1994 to December 1997) was searched using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and for schizophrenia (see Group search strategy) combined with:</P>
<P>[and (sulpiride-phrase)]</P>
<P>9. Sociofile (January 1974 to December 1997) was searched using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and for schizophrenia (see Group search strategy) combined with:</P>
<P>[and (sulpiride-phrase)]</P>
<P>B. Reference searching <BR/>The references of all identified studies were also inspected for more studies. SCISEARCH - Science Citation Index (1974 to 1998) was used to trace papers that had cited included trials. These reports were inspected in order to identify further studies. </P>
<P>C. Personal contact <BR/>The first author of each included study was contacted for information regarding unpublished trials. </P>
<P>D. Drug company <BR/>The manufacturers of sulpiride (Lorex Synthelabo Ltd, Bristol-Myers Pharmaceuticals, Pharmacia and Upjohn) were contacted for additional data.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>1. Selection of trials<BR/>All reports of identified studies were inspected by the principal reviewer (BGOS). The downloaded material from electronic sources did not include details of author, institution or journal of publication. All reports were re-inspected by MF and PC in order to ensure reliability of selection. Where disagreement occurred this was resolved by discussion, or when there was still doubt, reviewers acquired the full article for further inspection. Once the full articles were obtained BGOS, MF and PC independently, decided whether they met review criteria. At this stage the reviewers did not attempt to blind themselves to study author, institution and journal. Again, where disagreement occurred this was resolved by discussion and when this was not possible further information was sought. These trials were added to the list of those awaiting assessment pending acquisition of further information.</P>
<P>2. Assessment of the methodological quality of included trials<BR/>Reviewers used criteria in the Cochrane Collaboration Handbook (<LINK REF="REF-Mulrow-1999" TYPE="REFERENCE">Mulrow 1999</LINK>) to assess trial quality. This simple set of criteria is based on evidence of a strong association between overestimate of effect and poor concealment of allocation, and is defined as follows:<BR/>A. Low risk of bias (adequate allocation concealment);<BR/>B. Moderate risk of bias (some doubt about the results);<BR/>C. High risk of bias (inadequate allocation concealment).<BR/>If allocation within the trial was by quasi-random means, such as by day of week or hospital record number, this was noted and the study was given a 'C' quality rating. If the data from such studies did not differ from the results of higher grade trials, these were presented.</P>
<P>3. Data collection<BR/>Data from selected trials were independently extracted by BGOS and, should many studies have been identified it was envisaged that MF and PC should re-extract information from a randomly selected 10% sample. However, as few studies were identified MF re-extracted from all trials in order to ensure reliability. When disputes arose reviewers attempted resolution by discussion. If this was impossible and further information was necessary to resolve the dilemma, reviewers did not enter the data and added them to the list of those awaiting assessment.</P>
<P>4. Data synthesis<BR/>4.1 Incomplete data.<BR/>With the exception of the outcome of leaving the study early, trial outcomes were not included if more than 40% of people were not reported in the final analysis. Reviewers felt that such a degree of attrition would threaten the validity of any findings.</P>
<P>4.2 Dichotomous - yes/no - data.<BR/>The review presents an intention to treat analysis. As long as over 60% of people completed the study, everyone allocated to the intervention was counted, whether or not they completed follow up. It was assumed that those who dropped out had a negative outcome, with the exception of death.</P>
<P>The review uses relative risk (RR) and 95% confidence interval (CI) based on the random effects model, as this takes into account any differences between studies even if heterogeneity is not statistically significant, as the preferred statistic for summation. Data were inspected to see if analysis using a Mantel-Haenszel odds ratio and fixed effects models made any substantive difference. Where possible, reviewers estimated the number needed to treat (NNT). </P>
<P>4.3 Continuous data.<BR/>4.3.1 Rating scales: A wide range of instruments are available to measure mental health outcomes. These instruments vary in quality and many are not valid, or even ad hoc. For outcome instruments some minimum standards have to be set. They were that: (i) the psychometric properties of the instrument should have been described in a peer-reviewed journal; (ii) the instrument should either be: (a) a self report, or (b) completed by an independent rater or relative (not the therapist); and (iii) the instrument should be a global assessment of an area of functioning. </P>
<P>4.3.2 Normal data: Mental health continuous data is often not 'normally' distributed. To avoid the pitfall of applying parametric tests to non-parametric data the following standards were applied to all data before inclusion: (i) standard deviations and means were reported in the paper or were obtained from the authors; (ii) if the data were finite measures from, for example 0-100, when the standard deviation was multiplied by two, the result should be less than the mean. Otherwise the mean was unlikely to be an appropriate measure of the centre of the distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). Non-normally distributed data were reported in the 'Other data types' tables.</P>
<P>Endpoint scale-derived data is finite, ranging from one score to another. Change data is more problematic and for it the rule described above does not hold. Although most change scores are likely to be skewed it cannot be proven so they were presented in MetaView. Where both endpoint and change were available for the same outcome the reviewers presented the former in preference. </P>
<P>4.4 Sensitivity analyses<BR/>Three separate sensitivity analyses were hoped to be undertaken for the outcome of relapse, service utilisation, global improvement, and mental state clinically important improvement. </P>
<P>This review compared results for (i) people treated with high doses (see 'Types of interventions') to those for low doses; (ii) people over 65 years of age to those for younger people; and (iii) an intention to treat analysis compared to 'completer' analysis alone.</P>
<P>5. Heterogeneity<BR/>Reviewers assessed heterogeneity between trial results both by inspection of graphical presentations and by calculating a Chi square test of heterogeneity. If heterogeneity was present the reviewers undertook a sensitivity analysis to the presence or absence of these data.</P>
<P>6. Addressing publication bias<BR/>Data from all identified and selected trials were entered into a funnel graph (trial effect vs. trial size) in an attempt to investigate overt publication bias.</P>
<P>7. Tables and figures<BR/>Where possible, data were entered into RevMan so the area to the left of the line of no effect indicated a favourable outcome for sulpiride.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>For substantive descriptions of studies please see 'Included and Excluded studies tables. </P>
<P>Excluded studies<BR/>Most excluded studies were not randomised. Five relevant crossover studies (<LINK REF="STD-Alfredsson-1989" TYPE="STUDY">Alfredsson 1989</LINK>, <LINK REF="STD-Gerlach-1985" TYPE="STUDY">Gerlach 1985</LINK>, <LINK REF="STD-Lewis-1983" TYPE="STUDY">Lewis 1983</LINK>, <LINK REF="STD-Svestka-1990" TYPE="STUDY">Svestka 1990</LINK>, <LINK REF="STD-Xia-Chia-1995" TYPE="STUDY">Xia Chia 1995</LINK>) did not report any for the first arm of the trial. <LINK REF="STD-Hayano-1993" TYPE="STUDY">Hayano 1993</LINK> did not adequately report relevant clinical data. Two randomised trials used levo-sulpiride, not sulpiride, as the intervention of interest (<LINK REF="STD-Catapano-1991" TYPE="STUDY">Catapano 1991</LINK>, <LINK REF="STD-Guazelli-1995" TYPE="STUDY">Guazelli 1995</LINK>) and <LINK REF="STD-Vaisanen-1975" TYPE="STUDY">Vaisanen 1975</LINK> randomised participants with learning disability, not schizophrenia.</P>
<P>Included studies - 18 studies<BR/>Duration of trial<BR/>The most common length of study was eight weeks (range 3-52 weeks).</P>
<P>Setting<BR/>Most studies (14/18) randomised people in hospital and just one, <LINK REF="STD-Nishikawa-1989" TYPE="STUDY">Nishikawa 1989</LINK>, included only those who were in the community. Three studies did not describe setting.</P>
<P>Participants<BR/>Over 900 people have been randomised in sulpiride trials for schizophrenia. Fourteen out of eighteen studies used an operational diagnosis of schizophrenia. On the other hand, <LINK REF="STD-Bratfos-1979" TYPE="STUDY">Bratfos 1979</LINK> included those with "schizophrenia, reactive psychosis and paranoid psychosis", <LINK REF="STD-Dreyfus-1985" TYPE="STUDY">Dreyfus 1985</LINK>, "acute psychosis or acute episodes of chronic schizophrenia" (<LINK REF="STD-Dreyfus-1985" TYPE="STUDY">Dreyfus 1985</LINK>), and <LINK REF="STD-Taverna-1972" TYPE="STUDY">Taverna 1972</LINK>, "syndrome dissociatif". One trial (<LINK REF="STD-Rama-Rao-1981" TYPE="STUDY">Rama Rao 1981</LINK>) included two people (total n=30) who had epileptic seizures as well as schizophrenia. Three trials randomised those with acute illness (<LINK REF="STD-Dreyfus-1985" TYPE="STUDY">Dreyfus 1985</LINK>, <LINK REF="STD-Mahadevan-1991" TYPE="STUDY">Mahadevan 1991</LINK>, <LINK REF="STD-Wiesel-1984" TYPE="STUDY">Wiesel 1984</LINK>) and 10 solely people with chronic illness (<LINK REF="STD-Asada-1976" TYPE="STUDY">Asada 1976</LINK>, <LINK REF="STD-Blanco-1972" TYPE="STUDY">Blanco 1972</LINK>, <LINK REF="STD-Edwards-1980" TYPE="STUDY">Edwards 1980</LINK>, <LINK REF="STD-Nishikawa-1989" TYPE="STUDY">Nishikawa 1989</LINK>, <LINK REF="STD-Rama-Rao-1981" TYPE="STUDY">Rama Rao 1981</LINK>, <LINK REF="STD-Shiloh-1997" TYPE="STUDY">Shiloh 1997</LINK>, <LINK REF="STD-Soni-1990" TYPE="STUDY">Soni 1990</LINK>, <LINK REF="STD-Toru-1972" TYPE="STUDY">Toru 1972</LINK>, <LINK REF="STD-Yamagami-1988" TYPE="STUDY">Yamagami 1988</LINK>, <LINK REF="STD-Yamagami-1993" TYPE="STUDY">Yamagami 1993</LINK>).</P>
<P>One trial included women alone (<LINK REF="STD-Rama-Rao-1981" TYPE="STUDY">Rama Rao 1981</LINK>) but otherwise the sex distribution was reasonably even (55% male). <LINK REF="STD-Blanco-1972" TYPE="STUDY">Blanco 1972</LINK> gave no information on sex of participants. The age ranged from 18-75 years.</P>
<P>Intervention<BR/>High doses were used in six studies and low doses in another six. It was not possible to dichotomise in five studies. One trial (<LINK REF="STD-Petit-1987" TYPE="STUDY">Petit 1987</LINK>) compared sulpiride in low (150mg/day) and normal (1200mg/day) doses.</P>
<P>Sulpiride was compared to: bromperidol (n=1); chlorpromazine (n=4); clocapramine (n=1); haloperidol (n=3); perphenazine (n=2); placebo (n=3); timiperone (n=1); trifluoperazine (n=1) and zuclopenthixol dihydrocloride (n=1). No direct comparison of the 'atypical' antipsychotic drugs was made. <LINK REF="STD-Shiloh-1997" TYPE="STUDY">Shiloh 1997</LINK>, however, used sulpiride or placebo augmentation in people with schizophrenia already taking clozapine.</P>
<P>Outcomes<BR/>Outcomes were either dichotomous, as reported by trialists, scale data dichotomised by the reviewers or continuous scale-derived figures. Two rating scales were devised by authors of the studies (<LINK REF="REF-Yamagami-1985" TYPE="REFERENCE">Yamagami 1985</LINK>, <LINK REF="STD-Yamagami-1988" TYPE="STUDY">Yamagami 1988</LINK>) and did not seem to have been published and peer reviewed at the time of the reporting. Continuous data from these scales are not presented but the trialists also dichotomised into 'improved' or 'not improved' using these scales. The reviewers have presented these figures. One study (<LINK REF="STD-Toru-1972" TYPE="STUDY">Toru 1972</LINK>) used the 'Three Universities Rating Scale' modified by one of the authors. How this affects the validity of the results is not known.</P>
<P>The following scales were used in relevant studies.</P>
<P>Global impression<BR/>Clinical Global Impression - CGI (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>A rating instrument that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. A seven-point scoring system is usually used with low scores indicating decreased severity and/or greater recovery.</P>
<P>Mental state symptoms<BR/>1. Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1961" TYPE="REFERENCE">Overall 1961</LINK>)<BR/>A brief rating scale used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The scale has 16 items, and each item can be defined on a seven-point scale varying from 'not present' to 'extremely severe'. High score is poor.</P>
<P>2. Comprehensive Psychopathological Rating Scale - CPRS (<LINK REF="REF-Asberg-1978" TYPE="REFERENCE">Asberg 1978</LINK>)<BR/>A 65-item scale reflecting a wide spectrum of reported or observed psychopathological symptoms. High score is poor.</P>
<P>3. Final Global Improvement Rating - FGIR (<LINK REF="STD-Yamagami-1988" TYPE="STUDY">Yamagami 1988</LINK>)<BR/>The nature and validity of this scale are unclear. The reviewers are seeking further information. Continuous data have not been entered.<BR/>
<BR/>4. Inpatient Multidimensional Psychiatric Scale - IMPS (<LINK REF="REF-Lorr-1963" TYPE="REFERENCE">Lorr 1963</LINK>).<BR/>This psychopathology scale yields scores for ten syndromes which define the psychotic state. High score is poor.</P>
<P>5. Manchester Scale (<LINK REF="REF-Krawiecka-1977" TYPE="REFERENCE">Krawiecka 1977</LINK>)<BR/>Used to assess general psychopathology, including negative and positive symptoms. The negative symptom subset consists of flattening of affect and poverty of speech and the positive includes delusions, hallucinations, incoherence/irrelevance of speech and incongruity of affect. High score is poor.</P>
<P>6. Psychiatric Rating Scale - PRS (<LINK REF="REF-Yamagami-1985" TYPE="REFERENCE">Yamagami 1985</LINK>)<BR/>The nature and validity of this scale are unclear. The reviewers are seeking further information. Continuous data have not been entered.</P>
<P>7. Scale for the Assessment of Negative Symptoms - SANS (<LINK REF="REF-Andreasen-1983" TYPE="REFERENCE">Andreasen 1983</LINK>)<BR/>This six-point scale gives a global rating of the following negative symptoms: alogia, affective blunting, avolition-apathy, anhedonia-asociality and attention impairment. Higher scores indicate more symptoms.</P>
<P>8. Scale for the Assessment of Positive Symptoms - SAPS (<LINK REF="REF-Andreasen-1984" TYPE="REFERENCE">Andreasen 1984</LINK>)<BR/>This six-point scale gives a global rating of positive symptoms such as delusions, hallucinations and disordered thinking. Higher scores indicate more symptoms.</P>
<P>Behaviour<BR/>1. Current Behaviour Schedule - CBS (<LINK REF="REF-Owens-1980" TYPE="REFERENCE">Owens 1980</LINK>)<BR/>A scale rating social behaviour, activity, overactivity, exhibited abnormal behaviour, antisocial acts, incontinence, stability of behaviour and management of medication. High score is good.</P>
<P>2. Goodrich Rating Scale modified by Taverna (<LINK REF="STD-Taverna-1972" TYPE="STUDY">Taverna 1972</LINK>)<BR/>A behaviour rating scale of 28 items, which were divided into five groups (mental state, cognitive functions, behaviour, emotional state and thought content) by Taverna. Each item classified from one (worse) to four (symptom free).</P>
<P>3. Nurses Observational Scale of Inpatients Evaluation - NOSIE (<LINK REF="REF-Honigfeld-1965" TYPE="REFERENCE">Honigfeld 1965</LINK>)<BR/>An 80-item scale with items rated on a five-point scale from zero (not present) to four (always present). Ratings are taken from behaviour over the previous three days. The seven headings are social competence, social interest, personal neatness, co-operation, irritability, manifest psychosis and psychotic depression. Scoring ranges from 0-320.</P>
<P>4. Wing's Ward Behaviour Scale (<LINK REF="REF-Wing-1961" TYPE="REFERENCE">Wing 1961</LINK>)<BR/>This scale is completed by nurses. It was designed for use with people in hospital with schizophrenia. There are 12 items, each of which has a three-point grading and rate behaviour such as slowness of movement, overactivity, withdrawal and posturing. High score is poor.<BR/>
<BR/>Side Effects<BR/>1. Abnormal Involuntary Movement Scale - AIMS (<LINK REF="REF-NIMH-1975" TYPE="REFERENCE">NIMH 1975</LINK>)<BR/>The Abnormal Involuntary Movement Scale has been used to assess tardive dyskinesia, a long-term, drug-induced movement disorder. However, using this scale in short-term treatment may be also helpful in assessing some short-term abnormal movement disorders such as tremor.</P>
<P>2. Extrapyramidal Rating Scale - EPS (Osaka and Hirsch - unpublished).<BR/>This scale rates parkinsonian symptoms, akathisia and acute dystonic reactions. As it is, as far as the reviewers can tell, unpublished data are not presented. </P>
<P>3. Side Effects Checklist (<LINK REF="REF-Ghose-1977" TYPE="REFERENCE">Ghose 1977</LINK>)<BR/>This seems to be a symptom list rather than a scale of severity of symptoms or signs serving simply as a reminder to raters. It is not scored. </P>
<P>4. Simpson and Angus Scale (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>This ten-item scale, with a scoring system of 0-4 for each item, is used to measure drug-induced parkinsonism, a short-term drug-induced movement disorder. A low score indicates low levels of parkinsonism.</P>
<P>Missing outcomes<BR/>Economic outcomes and issues of quality of life and satisfaction with care were not addressed in the included studies.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Randomisation<BR/>Three studies described adequate concealment of allocation. <LINK REF="STD-Yamagami-1988" TYPE="STUDY">Yamagami 1988</LINK> and <LINK REF="STD-Yamagami-1993" TYPE="STUDY">Yamagami 1993</LINK> stated that an independent 'controller' randomly assigned and sealed the intervention codes in envelopes. <LINK REF="STD-Soni-1990" TYPE="STUDY">Soni 1990</LINK> described how allocation was conducted by staff of the hospital pharmacy who kept codes concealed throughout the study. <LINK REF="STD-Bratfos-1979" TYPE="STUDY">Bratfos 1979</LINK> used some sort of coding system to conceal allocation but explicit description is not available.</P>
<P>
<LINK REF="STD-Bratfos-1979" TYPE="STUDY">Bratfos 1979</LINK> used "randomized lists" to generate the order of allocation, <LINK REF="STD-Shiloh-1997" TYPE="STUDY">Shiloh 1997</LINK> a "table of random numbers", <LINK REF="STD-Edwards-1980" TYPE="STUDY">Edwards 1980</LINK> a "random code", <LINK REF="STD-Cassano-1975" TYPE="STUDY">Cassano 1975</LINK> a "randomized experimental design", <LINK REF="STD-Blanco-1972" TYPE="STUDY">Blanco 1972</LINK> allocated "al azar", and <LINK REF="STD-Asada-1976" TYPE="STUDY">Asada 1976</LINK> "sans crainte de distorsion". One study (<LINK REF="STD-Taverna-1972" TYPE="STUDY">Taverna 1972</LINK>) was 'quasi randomised' using a "technique psychometrique". No further details are available, and <LINK REF="STD-Taverna-1972" TYPE="STUDY">Taverna 1972</LINK> is included in the analysis as it did not show differences when compared to fully randomised studies. </P>
<P>Blinding<BR/>Thirteen studies used a double-blind design. Three studies described that they undertook a "double-dummy technique" (<LINK REF="STD-Edwards-1980" TYPE="STUDY">Edwards 1980</LINK>, <LINK REF="STD-Wiesel-1984" TYPE="STUDY">Wiesel 1984</LINK>, <LINK REF="STD-Rama-Rao-1981" TYPE="STUDY">Rama Rao 1981</LINK>). The reviewers have assumed that this refers to double blinding. No study tested blinding.</P>
<P>Description of those leaving early<BR/>Most included studies described those who were unable to complete the trial protocol. Two studies did not report withdrawal (<LINK REF="STD-Shiloh-1997" TYPE="STUDY">Shiloh 1997</LINK>, <LINK REF="STD-Yamagami-1988" TYPE="STUDY">Yamagami 1988</LINK>) but the data imply, and reviewers have assumed that there were no people lost to follow up. Five (<LINK REF="STD-Asada-1976" TYPE="STUDY">Asada 1976</LINK>, <LINK REF="STD-Bratfos-1979" TYPE="STUDY">Bratfos 1979</LINK>, <LINK REF="STD-Cassano-1975" TYPE="STUDY">Cassano 1975</LINK>, <LINK REF="STD-Dreyfus-1985" TYPE="STUDY">Dreyfus 1985</LINK>, <LINK REF="STD-Mahadevan-1991" TYPE="STUDY">Mahadevan 1991</LINK>) excluded those who left early from analysis. </P>
<P>Outcome reporting<BR/>Many outcomes were presented in graphical form, which made it impossible to acquire raw data for synthesis. Trials commonly reported mean values without the variance.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>The search<BR/>The electronic search found 202 citations, 82 of which were obtained. The reviewers identified 46 six different studies from these citations and 15 provide useable relevant data. Twenty-one more citations to 13 studies were found through searching references of included studies. Three of these reported useful data (<LINK REF="STD-Mahadevan-1991" TYPE="STUDY">Mahadevan 1991</LINK>, <LINK REF="STD-Shiloh-1997" TYPE="STUDY">Shiloh 1997</LINK>, <LINK REF="STD-Taverna-1972" TYPE="STUDY">Taverna 1972</LINK>), four did not (<LINK REF="STD-Bjerkenstedt-1979" TYPE="STUDY">Bjerkenstedt 1979</LINK>, <LINK REF="STD-Carrere-1968" TYPE="STUDY">Carrere 1968</LINK>, <LINK REF="STD-Halpern-1973" TYPE="STUDY">Halpern 1973</LINK>, <LINK REF="STD-Pinto-1972" TYPE="STUDY">Pinto 1972</LINK>) and six await assessment - <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> (<LINK REF="STD-Amakusa-1973" TYPE="STUDY">Amakusa 1973</LINK>, <LINK REF="STD-Bellomo--1972" TYPE="STUDY">Bellomo 1972</LINK>, <LINK REF="STD-Carranza-1971" TYPE="STUDY">Carranza 1971</LINK>, <LINK REF="STD-Ishimaru-1971" TYPE="STUDY">Ishimaru 1971</LINK>, <LINK REF="STD-Souto-Silveira-1972" TYPE="STUDY">Souto Silveira 1972</LINK>, <LINK REF="STD-Zann-1986" TYPE="STUDY">Zann 1986</LINK>). No additional studies were identified by contact with Pharmacia &amp; Upjohn Limited, or through use of the Science Citation Index.</P>
<P>COMPARISON 1. SULPIRIDE versus PLACEBO<BR/>Three trials compare sulpiride to placebo (<LINK REF="STD-Blanco-1972" TYPE="STUDY">Blanco 1972</LINK>, <LINK REF="STD-Soni-1990" TYPE="STUDY">Soni 1990</LINK>, <LINK REF="STD-Shiloh-1997" TYPE="STUDY">Shiloh 1997</LINK>). The latter, <LINK REF="STD-Shiloh-1997" TYPE="STUDY">Shiloh 1997</LINK>, was unusual in that it used sulpiride to supplement treatment with clozapine. </P>
<P>Global impression: no improvement<BR/>Only <LINK REF="STD-Shiloh-1997" TYPE="STUDY">Shiloh 1997</LINK> (n=28) reported this outcome and found in favour of sulpiride supplementation of clozapine treatment (RR 0.55 CI 0.32-0.92).</P>
<P>Mental state<BR/>Summation is impossible for these limited data and it cannot be said with any confidence from trial data, that sulpiride is effective for improving overall mental state or 'positive' or 'negative' symptom subsets.<BR/>
<BR/>Behaviour<BR/>Trials reported very low rates of attrition from each group (6%) with no difference between sulpiride and placebo. </P>
<P>Side effects<BR/>Very limited adverse event data is reported within this comparison. No difference was found between sulpiride and placebo for abnormal involuntary movements or hypersalivation.<BR/>
<BR/>COMPARISON 2. SULPIRIDE versus TYPICAL ANTIPSYCHOTICS<BR/>Death<BR/>
<LINK REF="STD-Wiesel-1984" TYPE="STUDY">Wiesel 1984</LINK> reported a single suicide in the typical antipsychotic (chlorpromazine) group (RR 0.33, CI 0.01-7.81).</P>
<P>Global impression<BR/>Studies presented data on global impression in several ways and the reviewers have tried to order these by degree of improvement. For the outcomes of 'not completely improved', 'not discharged from hospital', 'no improvement' and 'severely ill or worse' there was no difference between sulpiride and typical antipsychotic drugs. All data slightly favoured sulpiride but no result reached conventional levels of statistical significance.</P>
<P>Mental state<BR/>For the specific symptoms of anxiety, euphoria and irritability there were some data but no differences between sulpiride and the typical antipsychotics. When depression was rated by one small trial (n=61) the finding was in favour of sulpiride (RR 0.06 CI 0.01-0.46). All other direct measures of mental state are continuous and scale-derived. Both overall scores and 'negative' and 'positive' symptom sub-scores are skewed and reported in 'Other data tables'. No trial, however, reported statistically significant differences between interventions.</P>
<P>Behaviour<BR/>A single study (<LINK REF="STD-Taverna-1972" TYPE="STUDY">Taverna 1972</LINK>, n=40) reported that sulpiride tended to lessen the risk of problematic behaviour (RR 0.2 CI 0.03-1.56). Sulpiride showed no clear advantage, or disadvantage, when compared to typical antipsychotics for the specific problems of agitation, restlessness and weakness. No statistically significant difference is seen between typical antipsychotics and sulpiride for the use of additional sedating medication although the risk is slightly increased for those allocated to sulpiride (RR 1.2 CI 0.9-1.6). Various reasons were reported for leaving studies early, but, overall, those allocated to sulpiride had slightly less risk of leaving early (RR 0.81 CI 0.62-1.06). When side effects were cited as the reason for early withdrawal, the risk was more in favour of sulpiride (RR 0.48, CI 0.22-1.05), although still not to a statistically significant extent.</P>
<P>Side effects<BR/>Movement disorders - specific problems (akathisia, dyskinesia, rigidity and tremor) were all less frequent in those taking sulpiride. The use of antiparkinson drugs was also less frequent in the sulpiride group (RR 0.73, CI 0.59-0.90). </P>
<P>Anticholinergic effects - for side effects such as blurred vision, constipation, dizziness, hypotension, palpitations and problems with salivation, all problematic with the typical antipsychotics, the data generally favoured sulpiride although few results attained statistical significance. </P>
<P>Prolactin-related problems - few studies reported usable data. Those taking sulpiride were not more likely to suffer amenorrhea that those on the typical antipsychotics. Even with the small numbers of studies reporting galactorrhoea, it was reported as a significant problem in 11/51 allocated to sulpiride, and 5/51 allocated to its comparator (RR 1.9 CI 0.6-5.8).<BR/>
<BR/>Gastrointestinal problems - probably as a result of its low anticholinergic effect, those taking sulpiride are at somewhat less risk of constipation than people taking typical antipsychotics but there is no difference for other problems such as anorexia and weight change.</P>
<P>Sleep problems - sulpiride may cause less drowsiness/sedation than typical antipsychotics but the difference is not great (RR 0.81, CI 0.6-1.06). </P>
<P>Others - the incidence of skin problems and headache was not different for the sulpiride and other typical antipsychotic group. </P>
<P>Missing outcomes<BR/>No study addressed the issues of economics, quality of life or satisfaction with care.</P>
<P>COMPARISON 3. HIGH DOSE SULPIRIDE versus LOW DOSE SULPIRIDE</P>
<P>One small study (N=17) compared 150mg/day to 1200mg/day dose regimens of sulpiride (<LINK REF="STD-Petit-1987" TYPE="STUDY">Petit 1987</LINK>). There were no differences between the groups on the only usable outcome of leaving the study early (RR 1.7 CI 0.4-7.7).</P>
<P>SENSITIVITY ANALYSIS 1: HIGH OR LOW DOSE SULPIRIDE<BR/>It was impossible to define the mean dose in five trials. In six, however, the dose range was high (&gt;800mg and over) (<LINK REF="STD-Blanco-1972" TYPE="STUDY">Blanco 1972</LINK>, <LINK REF="STD-Cassano-1975" TYPE="STUDY">Cassano 1975</LINK>, <LINK REF="STD-Dreyfus-1985" TYPE="STUDY">Dreyfus 1985</LINK>, <LINK REF="STD-Edwards-1980" TYPE="STUDY">Edwards 1980</LINK>, <LINK REF="STD-Rama-Rao-1981" TYPE="STUDY">Rama Rao 1981</LINK>, <LINK REF="STD-Wiesel-1984" TYPE="STUDY">Wiesel 1984</LINK>) and in four it was low (&lt;800mg/day) (<LINK REF="STD-Mahadevan-1991" TYPE="STUDY">Mahadevan 1991</LINK>, <LINK REF="STD-Nishikawa-1989" TYPE="STUDY">Nishikawa 1989</LINK>, <LINK REF="STD-Taverna-1972" TYPE="STUDY">Taverna 1972</LINK>, <LINK REF="STD-Yamagami-1993" TYPE="STUDY">Yamagami 1993</LINK>). </P>
<P>Global impression: no improvement<BR/>No clear difference was found between high and low dose schemes. </P>
<P>Behaviour: leaving the study early<BR/>Low doses were associated with fewer people leaving early due to side effects.</P>
<P>Side effects: movement disorders<BR/>The incidence of akathisia and use of antiparkinson drugs were less for the low dose trials.</P>
<P>SENSITIVITY ANALYSIS: 2: OVER or UNDER 65 YEARS OLD<BR/>It was not possible to undertake this analysis as trials included a range of ages and did not present data on specific age groups.</P>
<P>SENSITIVITY ANALYSIS: 3: INTENTION-TO-TREAT or COMPLETER-ONLY ANALYSIS<BR/>Global impression: no improvement<BR/>It was only possible to undertake the sensitivity analysis for the 'global impression' outcomes. There was no difference between the intention-to-treat and completer-only analysis for any of the 'global impression' outcomes so the former is presented.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Methodological quality<BR/>Only three out of 18 trials reported the methods used to randomise participants. It is feasible that all studies undertook adequate means of allocation, but it has been shown that this methodological component substantially effects the odds of 'significant outcomes'. Poor reporting of randomisation is associated with an overestimate of effect (<LINK REF="REF-Chalmers-1983" TYPE="REFERENCE">Chalmers 1983</LINK>, <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>, <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). This alone should encourage caution for those interpreting the results.</P>
<P>Despite the small numbers of participants in the trials, some researchers removed people from analysis post-randomisation, without indicating the original group of allocation. This makes intention to treat analysis impossible.</P>
<P>Quality of reporting<BR/>Many of the papers failed to report important basic information, such as the participant groups' demographic or illness details and numbers of people leaving early. Frequently outcomes were presented only in graphical format, and the variance of continuous data were unreported. This renders data useless for this review and it impossible to verify the claims of trialists.</P>
<P>Generalisability<BR/>Included studies mainly fell into the 'short term' category, with only one trial just meeting the 'long term' criteria (<LINK REF="STD-Nishikawa-1989" TYPE="STUDY">Nishikawa 1989</LINK>). Schizophrenia is an illness that affects young people and is life long. The lack of long term studies is unfortunate.</P>
<P>Participants in the trials seem broadly similar to those in clinical practice in terms of presence or absence of concurrent major depression, duration of illness, setting and age group. However, those with an organic problem, a substance-abuse habit, a suicidal tendency, or an unstable medical condition were commonly excluded. The diagnostic criteria varied, possibly reflecting variation in practice in the early 1970s, but probably increases the generalisability of the review.</P>
<P>COMPARISON 1. SULPIRIDE versus PLACEBO<BR/>Numbers of participants for outcomes in this comparison are very small making results hypothesis-generating and not definitive.</P>
<P>Global impression: No improvement<BR/>Results from a single, small (n=28) study (<LINK REF="STD-Shiloh-1997" TYPE="STUDY">Shiloh 1997</LINK>) favour sulpiride over placebo (NNT 2.4 CI 1-8). This unusual study, where sulpiride was used to supplement the use of clozapine, seems worthy of replication.</P>
<P>Mental state<BR/>It is impossible to know if the scale-derived data from the small studies really shows no effect between placebo and sulpiride or whether studies were too underpowered to show a real difference.</P>
<P>Behaviour<BR/>There is no suggestion of a clear difference between sulpiride and placebo for the outcome of attrition. That only 6% of people were lost from these studies suggests such low loss to follow up is possible for short drug trials for schizophrenia. </P>
<P>COMPARISON 2. SULPIRIDE versus TYPICAL ANTIPSYCHOTICS<BR/>A total of 975 people were randomised in relevant studies.<BR/>
<BR/>Global impression<BR/>There was a tread for results of the several 'no improvement' outcomes to favour sulpiride but none reached statistical difference. When studies are sorted by time, earlier trials are clearly the most positive. The limited data suggest that sulpiride is as effective as bromperidol, chlorpromazine, clocapramine, haloperidol, perphenazine, timiperone, trifluoperazine and zuclopenthixol dihydrochloride for these outcomes. </P>
<P>Mental state<BR/>Scale data for negative and positive symptoms were presented in four trials and although they favoured sulpiride these did not show statistically significant differences between interventions. It is surprising that sulpiride is widely reputed to have some effect on negative symptoms on the basis of these data.</P>
<P>Behaviour<BR/>Twenty seven percent of people in trials relevant to this comparison left the trials early and there was no difference between the sulpiride group and those allocated to the typical antipsychotics. Numbers leaving the studies are low compared to that from trials of atypical drugs such as quetiapine (48-61%), olanzapine (42%) and risperidone (30%). This may indicate that trial methodology may have become so rigorous latterly that compliance with study protocol is increasingly difficult. There is no evidence that sulpiride is any different than the typical antipsychotics for other aspects of behaviour (agitation, irritability, anxiety, weakness). The need for additional sedating medication was also similar in both groups (~30% in each group).</P>
<P>Side effects<BR/>Movement disorders may well be less frequent for those taking sulpiride but no result, either direct or proxy measures reached statistical significance. This also applied to reports of anticholinergic side effects. Sulpiride may well have less side effects than typical drugs but the small trials, even when combined, lack the power to highlight this. Sulpiride did seem to cause problems with increased prolactin levels, and it is likely that galactorrhoea is a real problem with this drug (<LINK REF="REF-Weizman-1985" TYPE="REFERENCE">Weizman 1985</LINK>) but trial data do not help quantify the risk of occurrence.<BR/>Sulpiride is no different from typical antipsychotics in its propensity to cause gastrointestinal upset, including constipation, drowsiness and skin problems.<BR/>
<BR/>COMPARISON 3. HIGH DOSE SULPIRIDE versus LOW DOSE SULPIRIDE<BR/>One small (n=17) study specifically compared different doses of sulpiride (<LINK REF="STD-Petit-1987" TYPE="STUDY">Petit 1987</LINK>). That there was not a difference between groups on the outcome of leaving the study early can tells us little as findings based on such tiny numbers are solely hypothesis generating for future studies, should they be warranted. </P>
<P>Missing outcomes<BR/>It is disappointing that studies did not directly assess the acceptability of treatment by questioning study participants and their carers. Data on admission rates, cognitive functioning, economic outcomes, employment, legal difficulties, and social functioning are lacking. The reviewers acknowledge that it was uncommon to see such outcomes in any studies from the early 1970s but trials from the next two decades also did not address these issues.</P>
<P>SENSITIVITY ANALYSIS 1: HIGH OR LOW DOSE SULPIRIDE versus TYPICAL ANTIPSYCHOTIC DRUGS<BR/>No difference was found between high and low dose sulpiride for the outcome of 'no improvement', 'leaving the study for any reason' or 'use of additional anti-parkinson drugs'. Low doses were associated with fewer people leaving early specifically due to side effects and a lower incidence of akathisia. There is no data relating to sulpiride's effect on negative symptoms. This fact, along with the data from Comparison 3, leads reviewers to conclude that the reputed effect of sulpiride on negative must not be based on trial-derived evidence. </P>
<P>SENSITIVITY ANALYSIS: 2: OVER or UNDER 65 YEARS OLD<BR/>Whether sulpiride is a safe, effective, drug for those over 65 years of age is unanswered.</P>
<P>SENSITIVITY ANALYSIS: 3: INTENTION-TO-TREAT or COMPLETER-ONLY ANALYSIS<BR/>Overall, loss to follow up was small and evenly distributed. The inclusion of the assumption of negative outcome for those lost to follow up, therefore, made little difference.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>People with schizophrenia<BR/>Sulpiride may be as effective and have fewer side effects as the typical antipsychotic drugs, especially in doses of less than 800mg/day. There are no clear differences for several different assessments of 'global impression' when up to 500 people are randomised.</P>
<P>For clinicians<BR/>Although sulpiride seems to be an effective antipsychotic drug the evidence for its value for treating negative symptoms is not trial-based. One can speculate that sulpiride could offer a real alternative to the atypical antipsychotic, but no direct comparison has been made.</P>
<P>For managers/policy makers<BR/>For those making economic and policy decisions there seems no reason to forget sulpiride as a useful antipsychotic that may cause less side effects than the typical antipsychotics and has never been compared to the increasingly dominant atypical drugs that are more expensive.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>General<BR/>Trials in this review preceded the CONSORT statement (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>) by up to two decades. Clear reporting of outcomes would certainly have resulted in this review being more informative.</P>
<P>Specific<BR/>Sulpiride is an interesting, inexpensive, antipsychotic that is under researched and one that could offer a real alternative to the newer atypical antipsychotics, with the exception of clozapine. The atypical antipsychotics are less accessible to people with schizophrenia from low income countries than drugs such as sulpiride. </P>
<P>Long, well conducted and reported pragmatic trials are needed and could evaluate the general and specific claims made for this compound (see Background). Dichotomous, clinically useful, data relating to mental state, both positive and negative symptoms, and behaviour should be replicated and improved upon. Information relating to cost effectiveness, employment, family burden, hospital status, and satisfaction with care are currently lacking and investigating such outcomes must be a research priority.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>BGOS would like to thanks Maurício Silva de Lima, for his encouragement and assistance in conducting this review.</P>
<P>Thanks to Pharmacia &amp; Upjohn Limited for searching the Derwent Drug File (search performed by John Borril, 28/04) and Dr Tadashi Nishikawa for sending an unpublished full report. The reviewers are also grateful to Professor Avi Weizman for replying to a letter for additional information and Dr Som D Soni for sending more details on his trial. A special thanks to the staff of the Cochrane Schizophrenia Groups Editorial Base and all those who helped by translating papers from Chinese, Czech, Japanese and Polish.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Bernardo Soares - protocol writing, searching, trial selection, data extraction, completion of report.</P>
<P>Mark Fenton - protocol writing, searching, trial selection, data extraction, completion of report.</P>
<P>Pierre Chue - protocol writing, trial selection, data extraction, completion of report.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>Cochrane Schizophrenia Group internal peer review complete (see Module).<BR/>External peer review scheduled.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Asada-1976" NAME="Asada 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asada S, Ishimaru T, Kubo S, Kodama H, Masuda K</AU>
<TI>Study of the clinical effects of sulpiride and perphenazine in 82 schizophrenic patients by the double blind method</TI>
<TO>Etude des effets cliniques du sulpiride et de la perphenazine chez 82 schizophrenes par la methode du double aveugle</TO>
<SO>Encephale</SO>
<YR>1976</YR>
<VL>2</VL>
<PG>73-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blanco-1972" NAME="Blanco 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mezquita Blanco J, Cubillo Sanchez J, Aizpiri Diaz J, Zubia Zubia B</AU>
<TI>Clinical trial with sulpiride and placebo in chronic schizophrenics study of 89 patients using the Harris-Letemendia-Willems scale</TI>
<TO>Ensayo clinico con Sulpiride y placebo en esquizofrenicos cronicos. Estudio de 89 enfermos, con aplicacion de la escala de Harris, Letemendia y Willems</TO>
<SO>Archivos de Neurobiologia - Madrid</SO>
<YR>1972</YR>
<VL>35</VL>
<PG>453-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bratfos-1979" NAME="Bratfos 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bratfos O, Haug JO</AU>
<TI>Comparison of sulpiride and chlorpromazine in psychoses. A double-blind multicentre study</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1979</YR>
<VL>60</VL>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cassano-1975" NAME="Cassano 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cassano GB, Castrogiovanni P, Conti L, Bonollo L</AU>
<TI>Sulpiride - an antipsychotic agent: comparative trial versus haloperidol</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1977</YR>
<VL>13</VL>
<PG>41-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cassano GB, Castrogiovanni P, Conti L, Bonollo L</AU>
<TI>Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trial</TI>
<SO>Current Therapeutic Research</SO>
<YR>1975</YR>
<VL>17</VL>
<PG>189-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cassano GB, Castrogiovanni P, Conti L, et al</AU>
<TI>The computer diagnosis in a multicenter study of psychoactive agents</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1976</YR>
<VL>12</VL>
<PG>22-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castrogiovanni P, Cassano GB, Conti L, Maggini C, Bonollo L, Sarteschi P</AU>
<TI>An automated diagnostic process (PDA) in clinical psychopharmacology. An exemplification of its use in a sulpiride versus haloperidol comparative trial</TI>
<SO>International Pharmacopsychiatry</SO>
<YR>1976</YR>
<VL>11</VL>
<PG>74-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dreyfus-1985" NAME="Dreyfus 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dreyfus JF</AU>
<TI>A comparative double blind multicenter trial of dogmatil versus chlorpromazine for the treatment of acute psychosis</TI>
<TO>Essai comparatif multicentrique en double insu du dogmatil et de la chlorpromazine dans le traitement de la psychose aigue</TO>
<SO>Semaine des Hopitaux</SO>
<YR>1985</YR>
<VL>61</VL>
<PG>1322-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Pichot P, Dreyfus JF</AU>
<TI>Multicentre double-blind comparison of chlorpromazine and sulpiride in acute psychosis</TI>
<SO>Abstract presented at the Six World Congress of Psychiatry. Hawaii, USA</SO>
<YR>1977</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pichot P, Dreyfus JF</AU>
<TI>Sulpiride and chlorpromazine in treatment of acute psychoses</TI>
<TO>Sulpirid und chlorpromazin in der behandlung akuter psychosen</TO>
<SO>Therapiewoche</SO>
<YR>1983</YR>
<VL>333</VL>
<PG>4571-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edwards-1980" NAME="Edwards 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guy Edwards J, Alexander JR, Alexander MS, Gordon A, Zutchi T</AU>
<TI>Controlled trial of sulpiride in chronic schizophrenic patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>137</VL>
<PG>522-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lepola-1989" NAME="Lepola 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lepola U, Koskinen T, Rimon R, Salo H, Gordin A</AU>
<TI>Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1989</YR>
<VL>80</VL>
<PG>92-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahadevan-1991" NAME="Mahadevan 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahadevan K, Gadhi HM, Suri AK, Hussain MF, Sharma VK, Sharma SK, Palia SS, Mukherjee PK, Chan-Pensley E, Ghoshal J, Ahmed W, Bhatt GS</AU>
<TI>Cross-over comparison of zuclopenthixol dihydrochloride and oral sulpiride in the treatment of schizophrenia</TI>
<SO>British Journal of Clinical Research</SO>
<YR>1991</YR>
<VL>2</VL>
<PG>13-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishikawa-1989" NAME="Nishikawa 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishikawa T, Tanaka M, Tsuda A, Koga I, Uchida Y</AU>
<TI>Prophylactic effects of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of timiperone and sulpiride</TI>
<SO>Biological Psychiatry</SO>
<YR>1989</YR>
<VL>25</VL>
<PG>861-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petit-1987" NAME="Petit 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petit M, Zann M, Colonna L</AU>
<TI>Controlled study of the disinhibiting effect of low doses of sulpiride in severe schizophrenic psychoses</TI>
<TO>Etude controlee de l'effet desinhibiteur de faibles doses de sulpiride dans les psychoses schizophreniques deficitaires</TO>
<SO>Encephale</SO>
<YR>1984</YR>
<VL>10</VL>
<PG>25-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Petit M, Zann M, Lesieur P, Colonna L</AU>
<TI>The effect of sulpiride on negative symptoms of schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>150</VL>
<PG>270-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rama-Rao-1981" NAME="Rama Rao 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rama Rao VA, Bailey J, Bishop M, Coppen A</AU>
<TI>A clinical and pharmacodynamic evaluation of sulpiride</TI>
<SO>Psychopharmacology</SO>
<YR>1981</YR>
<VL>73</VL>
<PG>77-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiloh-1997" NAME="Shiloh 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shiloh R, Zemishlany Z, Aizemberg D, Radwan M, Schwartz B, Dorfman-Etrog P, Modai I, Khaikin M, Weizman A</AU>
<TI>Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>171</VL>
<PG>569-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Soni-1990" NAME="Soni 1990" YEAR="19901">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soni SD, Mallik A, Schiff AA</AU>
<TI>Sulpiride in negative schizophrenia - a placebo-controlled double-blind assessment</TI>
<SO>Human Psychopharmacology Clinical and Experimental</SO>
<YR>1990</YR>
<VL>5</VL>
<PG>233-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taverna-1972" NAME="Taverna 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taverna P, Ghisoni T, Poggi E</AU>
<TI>Controlled study of the antipsychotic effect of sulpiride</TI>
<SO>Psychologie Medicale</SO>
<YR>1972</YR>
<VL>4</VL>
<PG>811-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toru-1972" NAME="Toru 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toru M, Shimazono Y, Miyasaka M, Kokubo T, Mori Y, Nasu T</AU>
<TI>A double-blind comparison of sulpiride with chlorpromazine in chronic schizophrenia</TI>
<SO>Journal of Clinical Pharmacology and New Drugs</SO>
<YR>1972</YR>
<VL>12</VL>
<PG>221-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiesel-1984" NAME="Wiesel 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alfredsson G, Bjerkenstedt L, Edman G, Harnryd C, Oxenstierna G, Sedvall G, Wiesel FA</AU>
<TI>Relationships between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1984</YR>
<VL>311</VL>
<PG>49-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alfredsson G, Harnryd C, Wiesel FA</AU>
<TI>Effects of sulpiride and chlorpromazine on autistic and positive psychotic symptoms in schizophrenic patients - relationship to drug concentrations</TI>
<SO>Psychopharmacology Berlin</SO>
<YR>1985</YR>
<VL>85</VL>
<PG>8-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alfredsson G, Harnryd C, Wiesel FA</AU>
<TI>Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients - relationship to drug concentrations</TI>
<SO>Psychopharmacology</SO>
<YR>1984</YR>
<VL>84</VL>
<PG>237-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harnryd C, Bjerkenstedt L, Bjork K, Gullberg B, Oxenstierna G, Sedvall G, Wiesel FA, Wik G, Aberg, Wistedt A</AU>
<TI>Clinical evaluation of sulpiride in schizophrenic patients - a double-blind comparison with chlorpromazine</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1984</YR>
<VL>311</VL>
<NO>Suppl</NO>
<PG>7-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harnryd C, Bjerkenstedt L, Gullberg B, Oxenstierna G, Sedvall G, Wiesel FA</AU>
<TI>Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1984</YR>
<VL>311</VL>
<NO>Suppl</NO>
<PG>75-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wiesel FA, Alfredsson G, Bjerkenstedt L, Harnryd C, Oxenstierna G, Sedvall G</AU>
<TI>Dogmatil for the treatment of negative symptoms in schizophrenic patients</TI>
<TO>Le dogmatil dans le traitement des symptomes negatifs chez des patients schizophrenes</TO>
<SO>Semaine des Hopitaux</SO>
<YR>1985</YR>
<VL>61</VL>
<PG>1317-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiesel FA, Bjerkenstedt L, Hanryd C, Oxenstierna G, Sedvall G</AU>
<TI>Dogmatil for the treatment of schizophrenic patients</TI>
<TO>Le dogmatil dans le traitement de sujets schizophrenes</TO>
<SO>Semaine des Hopitaux Paris</SO>
<YR>1985</YR>
<VL>61</VL>
<PG>1343-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiesel FA</AU>
<TI>A double blind comparison between sulpiride and chlorpromazine in the treatment of schizophrenic patients: relationship to drug concentrations</TI>
<SO>Nordisk Psykiatrisk Tidsskrift</SO>
<YR>1986</YR>
<VL>40</VL>
<PG>459-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamagami-1988" NAME="Yamagami 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamagami S, Kiriike N, Kawaguchi K</AU>
<TI>A single-blind study of clocapramine and sulpiride in hospitalized chronic schizophrenic patients</TI>
<SO>Drugs under Experimental and Clinical Research</SO>
<YR>1988</YR>
<VL>14</VL>
<PG>707-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamagami-1993" NAME="Yamagami 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamagami S, Hirayama E, Mui K, Okuno M, Kioka T, SomaT, Ohno K</AU>
<TI>A single-blind comparison of bromperidol and sulpiride in hospitalized schizophrenics</TI>
<SO>Acta Psychiatrica Belgica</SO>
<YR>1993</YR>
<VL>93</VL>
<PG>236-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Alfredsson-1989" NAME="Alfredsson 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alfredsson G, Wiesel FA</AU>
<TI>Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment</TI>
<SO>Psychopharmacology - Berlin</SO>
<YR>1989</YR>
<VL>99</VL>
<PG>322-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alfredsson G, Wiesel FA</AU>
<TI>Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients</TI>
<SO>Psychopharmacology</SO>
<YR>1990</YR>
<VL>101</VL>
<PG>324-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiesel FA, Alfredsson G, Jonsson E</AU>
<TI>Dose finding and serum concentrations of neuroleptics in the treatment of schizophrenic patients</TI>
<SO>Clinical Pharmacology in Psychiatry</SO>
<YR>1989</YR>
<VL>7</VL>
<PG>303-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bente-1974" NAME="Bente 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bente D, Koeller DM, Koufen H, Pietzcker A, Schulte PW</AU>
<TI>Clinico-statistical study of the effects of sulpiride, a new psychopharmacologic agent</TI>
<TO>Klinisch-statistische Untersuchung des Wirkungsbildes von Sulpirid, einem neuen Psychopharmakon</TO>
<SO>Arzneimittelforschung</SO>
<YR>1974</YR>
<VL>24</VL>
<PG>107-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bjerkenstedt-1979" NAME="Bjerkenstedt 1979" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjerkensted L, Harnryd C, Sedval G</AU>
<TI>Effect of sulpiride on monaminergic mechanism in psychotic women</TI>
<SO>Psychopharmacology</SO>
<YR>1979</YR>
<VL>64</VL>
<PG>135-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borenstein-1969" NAME="Borenstein 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borenstein P, Champion C, Cujo P, Gekiere F, Olivenstein C, Kramarz P</AU>
<TI>An original psychotropic drug: sulpiride</TI>
<TO>Un psychotrope original: le sulpiride</TO>
<SO>Semaine des Hopitaux</SO>
<YR>1969</YR>
<VL>19</VL>
<PG>1301-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruscky-1974" NAME="Bruscky 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruscky SB, Caldeira MV, Bueno JR</AU>
<TO>Ensaio clínico com sulpiride</TO>
<SO>Arquivos de Neuropsiquiatria</SO>
<YR>1974</YR>
<VL>32</VL>
<PG>234-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burchard-1972" NAME="Burchard 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burchard JM, Gross L, Kempe P</AU>
<TO>Sulpirid: stationare und ambulante behandlung psychiatrischer patienten und doppelblinduntersuchung des wirkungsspektrums</TO>
<SO>International Journal of Clinical Pharmacology, Therapy and Toxicology</SO>
<YR>1972</YR>
<VL>6</VL>
<PG>266-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carranza-1971" NAME="Carranza 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carranza J, Vargas L, Gomez J</AU>
<TI>A double blind evaluation of sulpiride: a new antipsychotic compound</TI>
<SO>American Society for Clinical Pharmacology and Therapeutics</SO>
<YR>1973</YR>
<VL>14</VL>
<PG>132-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Carranza J, Vargas L, Gomez J</AU>
<TO>Valoración doble ciega de la eficacia del sulpiride en pacientes esquizofrénicos</TO>
<SO>Congres Mondial de Psychiatrie. México</SO>
<YR>1971</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carrere-1968" NAME="Carrere 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carrere J</AU>
<TI>Study of the effects of sulpiride on the mental state of 40 mental patients</TI>
<TO>Etude des effets du Sulpiride sur l'etat psychique de quarante malades mentaux</TO>
<SO>Annales Medico Psychologiques Paris</SO>
<YR>1968</YR>
<VL>2</VL>
<PG>560-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Catapano-1991" NAME="Catapano 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Catapano F, Ventra C, Perna L, Maj M, et al</AU>
<TI>Efficacy of low versus high doses of sulpiride on negative symptoms of schizophrenia</TI>
<TO>Efficacia della l sulpiride a due differenti dosaggi sulla sintomatologia negativa della schizofrenia</TO>
<SO>Rivista di Psichiatria</SO>
<YR>1991</YR>
<VL>266</VL>
<PG>315-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colard-1970" NAME="Colard 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collard J</AU>
<TO>Le sulpiride: un neuroleptique singulier, antiautistique et thymanaleptique</TO>
<SO>Semaine des Hopitaux Paris</SO>
<YR>1969</YR>
<VL>45</VL>
<PG>3028-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collard J</AU>
<TO>Le sulpiride: un neuroleptique singulier, antiautistique et thymanaleptique</TO>
<SO>Therapeutique</SO>
<YR>1970</YR>
<VL>46</VL>
<PG>503-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Courdec-1971" NAME="Courdec 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Couderc L</AU>
<TI>Apropos of a recent clinical trial of Dogmatil</TI>
<TO>A propos d'un essai clinique recent du dogmatil</TO>
<SO>Psychopharmacologie</SO>
<YR>1971</YR>
<VL>7</VL>
<PG>19-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eckmann-1974" NAME="Eckmann 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eckmann F</AU>
<TI>Clinical studies with sulpiride in schizophrenics hospitalized for many years</TI>
<TO>Klinische Untersuchungen mit Sulpirid bei langjahrig hospitalisierten schizophren Kranken</TO>
<SO>Agressologie</SO>
<YR>1978</YR>
<VL>19</VL>
<PG>153-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eckmann F</AU>
<TI>Clinical study on sulpride in long-standing schizophrenia of hospitalized patients</TI>
<TO>Klinische Untersuchungen mit Sulpirid bei langjahrig hospitalisierten schizophrenen Kranken</TO>
<SO>Arzneimittel forschung</SO>
<YR>1974</YR>
<VL>24</VL>
<PG>993-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elizur-1975" NAME="Elizur 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elizur A, Davidson S</AU>
<TI>The evaluation of the anti-autistic activity of sulpiride</TI>
<SO>Current Therapeutic Research</SO>
<YR>1975</YR>
<VL>18</VL>
<PG>578-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerlach-1985" NAME="Gerlach 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerlach J, Behnke K, Heltberg J et al</AU>
<TI>Dogmatil and haloperidol for the treatment of schizophrenia. Double-blind cross-over study of therapeutic effectiveness, side effects and plasma concentrations</TI>
<TO>Le dogmatil et l'haloperidol dans le traitement de la schizophrenie. Etude croisee en double aveugle de láction therapeutique, des effets secondaires et des concentrations plasmatiques</TO>
<SO>Semaine des Hopitaux</SO>
<YR>1985</YR>
<VL>61</VL>
<PG>1309-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerlach J, Behnke K, Heltberg J, Munk Anderson E, Nielsen H</AU>
<TI>Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1985</YR>
<VL>147</VL>
<PG>283-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munk Andersen E, Behnke K, Heltberg J, Nielsen H, Gerlach J</AU>
<TI>Sulpiride versus haloperidol in the treatment of schizophrenia</TI>
<TO>Sulpirid versus haloperidol i behandling af skizofreni. En kort, praeliminaer rapport</TO>
<SO>Nordisk Psykiatrisk Tidsskrift</SO>
<YR>1984</YR>
<VL>38</VL>
<PG>223-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munk Andersen E, Behnke K, Heltberg J, Nielsen H, Gerlach J</AU>
<TI>Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1984</YR>
<VL>311</VL>
<PG>31-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldwurm-1978" NAME="Goldwurm 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldwurm GF, Peghini R</AU>
<TI>Therapeutic and side effects of treatment with sulpiride</TI>
<TO>Effets therapeutiques et effets secondaires par le traitement avec sulpiride</TO>
<SO>Agressologie</SO>
<YR>1978</YR>
<VL>19</VL>
<PG>157-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guazelli-1995" NAME="Guazelli 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Guazelli M, Barracchia E, Bertolino I, Casacchia M, Ciapparelli A, et al</AU>
<TI>Clinical effects of l-sulpiride versus haloperidol in acutely relapsed chronic schizophrenics: therapeutic efficacy on 'disorganization'?</TI>
<SO>8th European College of Neuropsychopharmacology Congress. Venice, Italy</SO>
<YR>September 30-October 4, 1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haase-1974" NAME="Haase 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haase HJ, Floru L, Ulrich F</AU>
<TI>A clinical neuroleptic study of N ((1 athyl pyrrolidin 2 yl) methyl) 2 methoxy 5 sulfamoyl benzamid neuroleptikums sulpirid (Dogmatil) in acute schizophrenia cases</TI>
<SO>International Pharmacopsychiatry</SO>
<YR>1974</YR>
<VL>9</VL>
<PG>77-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halpern-1973" NAME="Halpern 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halpern B, Sircovich O, Winni HZ</AU>
<TI>A clinical experiment with sulpiride</TI>
<SO>Israel Annals of Psychiatry and Related Disciplines</SO>
<YR>1973</YR>
<VL>11</VL>
<PG>1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayano-1993" NAME="Hayano 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayano T</AU>
<TI>Prediction of clinical drug effects (3) - review of double blind test between sultopride and sulpiride</TI>
<SO>Journal of the Wakayama Medical Society</SO>
<YR>1993</YR>
<VL>44</VL>
<PG>321-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-1983" NAME="Lewis 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis DM, Bond HR, Curry SH</AU>
<TI>Sulpiride trial in chronic schizophrenia with comparison of two dosage regimens</TI>
<SO>Psychopharmacology - Berlin</SO>
<YR>1983</YR>
<VL>80</VL>
<PG>259-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martins-1974" NAME="Martins 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martins C, Neves DF, Gama GAS, Gavioli HR, Carvalho IMA, Amaral MAN, Vieira NC, Oliveira RB, Leal WG, Assis LM</AU>
<TO>Ensaio com sulpiride em esquizofrênicos hospitalizados</TO>
<SO>Arquivos de Neuropsiquiatria</SO>
<YR>1974</YR>
<VL>32</VL>
<PG>228-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mielke-1977" NAME="Mielke 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mielke DH, Gallant DM, Kessler C</AU>
<TI>An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1977</YR>
<VL>134</VL>
<PG>1371-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mielke DH, Gallant DM, Roniger JJ, KesslerC, Kessler LR</AU>
<TI>Sulpiride: evaluation of antipsychotic activity in schizophrenic patients</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1977</YR>
<VL>38</VL>
<PG>569-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mouren-1970" NAME="Mouren 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mouren P, Mayet J, Larrieu A</AU>
<TI>Clinical trial of a new molecule, sulpiride, in psychiatric practice</TI>
<TO>Essai clinique d'une molecule nouvelle, le sulpiride, en pratique psychiatrique</TO>
<SO>Semaine des Hopitaux</SO>
<YR>1970</YR>
<VL>46</VL>
<PG>97-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Nishikawa-1997" NAME="Nishikawa 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishikawa T, Sato M, Hayashi T, Tanaka M, Tanaka S, Koga I, Uchida Y, Kawahara R</AU>
<TI>Intermittent withdrawal program of neuroleptics with sulpiride in remitted schizophrenic outpatients</TI>
<SO>Human Psychopharmacology</SO>
<YR>1997</YR>
<VL>12</VL>
<PG>510-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishiura-1976" NAME="Nishiura 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishiura, M</AU>
<TI>Clinico-pharmacological studies of sulpiride</TI>
<SO>Current Therapeutic Research</SO>
<YR>1976</YR>
<VL>20</VL>
<PG>164-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nurowska-1980" NAME="Nurowska 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nurowska K</AU>
<TI>Clinical evaluation of sulpiride</TI>
<TO>Ocena kliniczna sulpirydu</TO>
<SO>Psychiatrica Polska</SO>
<YR>1980</YR>
<VL>14</VL>
<PG>37-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pinto-1972" NAME="Pinto 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinto CAC</AU>
<TO>O uso do supiride em esquizofrenia (ensaio duplo cego)</TO>
<SO>Boletim de Psiquiatria</SO>
<YR>1972</YR>
<VL>5</VL>
<PG>103-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strauss-1973" NAME="Strauss 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strauss J</AU>
<TI>Therapeutic note: clinical trial of sulpiride in the treatment of the hebephrenias</TI>
<SO>Information Psychiatrique</SO>
<YR>1973</YR>
<VL>49</VL>
<PG>391-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1990" NAME="Svestka 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Rysanek R, Ceskova E, Nahunek K</AU>
<TI>Cross-over comparison of the therapeutic effects of sulpiride and perphenazine in schizophrenic and schizoaffective psychoses</TI>
<SO>Acta Nervosa Superior</SO>
<YR>1989</YR>
<VL>31</VL>
<NO>1</NO>
<PG>35-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Rysanek R, Nahunek K, Ceskova E</AU>
<TI>Therapeutic results in schizophrenic and schizoaffective psychosis with sulpiride (Eglonyl Alkaloid), as compared with perphenazine (Perfenazin Spofa)</TI>
<SO>Ceskolovenska Psychiatrie</SO>
<YR>1990</YR>
<VL>86</VL>
<PG>145-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uvod-1970" NAME="Uvod 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uvod I</AU>
<TI>Sulpiride in the treatment of chronic psychosis (our clinical experience)</TI>
<TO>Sulpiride u terapiji kronicnih psihoza (nasa klinicka iskustva)</TO>
<SO>Godisen Zbornik na Medicinskiot Fakulltet Vo Skopje</SO>
<YR>1972</YR>
<VL>18</VL>
<PG>113-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaisanen-1975" NAME="Vaisanen 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaisanen K, Kainulainen P, Paavilainen MT, Viukari M</AU>
<TI>Sulpiride versus chlorpromazine and placebo in the treatment of restless mentally subnormal patients: a double-blind cross-over study</TI>
<SO>Current Therapeutic Research</SO>
<YR>1975</YR>
<VL>17</VL>
<PG>202-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wagenaar-1988" NAME="Wagenaar 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wagenaar G, Pultiere S, Liling C</AU>
<TI>Clinical trial of high-dose Dogmatil (200 mg) in the management of productive psychoses</TI>
<TO>Etude clinique du Dogmatil fort (200 mg) dans le traitement des psychoses productives</TO>
<SO>Annales de Psychiatrie</SO>
<YR>1988</YR>
<VL>3</VL>
<PG>75-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xia-Chia-1995" NAME="Xia Chia 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xia Chia L</AU>
<TI>Flupenthixol and sulpiride in treatment of chronic schizophrenia</TI>
<SO>Chinese Journal of Nervous and Mental Disorders</SO>
<YR>1995</YR>
<VL>21</VL>
<PG>234-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamaoka-1995" NAME="Yamaoka 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamaoka K</AU>
<TI>A study of psychopharmaca effect on electrodermal activity, subjective mood change, psychotic symptoms and results of treatment</TI>
<SO>Journal Nara Medical Association</SO>
<YR>1995</YR>
<VL>46</VL>
<PG>516-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Amakusa-1973" NAME="Amakusa 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amakusa T, Majima T</AU>
<TI>Comparison of therapeutic effects of FK 880 (sulpiride) and perphenazine in schizophrenia by a double-blind controlled study</TI>
<SO>Juntendo Medical Journal</SO>
<YR>1973</YR>
<VL>19</VL>
<PG>239-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellomo--1972" NAME="Bellomo  1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellomo LM, Fernandez H</AU>
<TO>Investigation a "double essai aveugle" du Sulpiride sur des malades psychotiques. Evaluation psychiatrique et psychologique clinique</TO>
<SO>Minerva Psiquiatrica Argentina</SO>
<YR>1972</YR>
<VL>1</VL>
<PG>29-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ishimaru-1971" NAME="Ishimaru 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ishimaru T, Kubo S, Ishikawa H, Jitsuoki S, Kawamura T, Kimura N, Kodama H, Masuda K, Miyake Y, Nomura S, Sasaki T, Schimonaga R, Tsukue I, Asada S</AU>
<TI>Clinical evaluation on therapeutic effects of sulpiride, a new neuroleptic drug on schizophrenia, by double-blind controlled test</TI>
<SO>Hiroshima Journal of Medical Science</SO>
<YR>1971</YR>
<VL>19</VL>
<PG>131-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kogeorgos-1995" NAME="Kogeorgos 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Kogeorgos J, Kanellos O, Michalakeas A, Ioannidis J</AU>
<TI>Sulpiride and risperidone versus "classical neuroleptics" in schizophrenia: a follow-up study</TI>
<SO>8th European College of Neuropsychopharmacology Congress. Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-1996" NAME="Liu 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu KL, Lung FW</AU>
<TI>Difference in prolaction response of schizophrenic patients to equivalent doses of haloperidol, remoxipride and sulpiride</TI>
<SO>Kao Hsiung I Hsueh Ko Hsueh Tsa Chih</SO>
<YR>1996</YR>
<VL>12</VL>
<PG>685-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Souto-Silveira-1972" NAME="Souto Silveira 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Souto da Silveira E, Prado LC, Costa CA, Nunes de Faria R, Bertoni M</AU>
<TI>The use of sulpiride in the treatment of chronic schizophrenia</TI>
<SO>Tribuna Medica</SO>
<YR>1971</YR>
<VL>XIV/11</VL>
<PG>1-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-1988" NAME="Yang 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang W J</AU>
<TI>Three antipsychotic drugs in the treatment of schizophrenia - a controlled and double-blind study</TI>
<SO>Chung Hua Shen Ching Ching Shen Ko Tsa Chih</SO>
<YR>1988</YR>
<VL>21</VL>
<PG>277-80, 318-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zann-1986" NAME="Zann 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zann M, Colonna L, Petit M, Lesieur P</AU>
<TI>Disinhibitory effect of sulpiride in 18 hebephrenic patients: a controlled study</TI>
<TO>Etude controlee de l'effet desihibiteur du sulpiride chez 18 patients hebephrenes</TO>
<SO>Psychologie Medicale</SO>
<YR>1986</YR>
<VL>18</VL>
<PG>569-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skeweness from summary information</TI>
<SO>British Medical Journal</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SUL020600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1983" NAME="Andreasen 1983" TYPE="BOOK">
<AU>Andreasen NC</AU>
<SO>Scale for the Assessment of Negative Symptoms (SANS)</SO>
<YR>1983</YR>
<PB>The University of Iowa</PB>
<CY>Iowa City</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1984" NAME="Andreasen 1984" TYPE="BOOK">
<AU>Andreasen NC</AU>
<SO>Scale for the Assessment of Positive Symptoms (SAPS)</SO>
<YR>1984</YR>
<PB>The University of Iowa</PB>
<CY>Iowa City</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Asberg-1978" NAME="Asberg 1978" TYPE="JOURNAL_ARTICLE">
<AU>Asberg M, Montgomery S, Perris C, Schalling D, Sedvall G</AU>
<TI>CPRS - The comprehensive psychopathological scale</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1978</YR>
<VL>271</VL>
<PG>5-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Azorin-1992" NAME="Azorin 1992" NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Azorin JM, Dassa D, Jalfre M</AU>
<TI>The atypical neuroleptic concept</TI>
<TO>Le concept de neuroleptique atypique</TO>
<SO>Encephale</SO>
<YR>1992</YR>
<VL>18</VL>
<NO>3</NO>
<PG>453-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF</AU>
<TI>Improving the quality of randomized controlled trials. The CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caley-1995" NAME="Caley 1995" TYPE="JOURNAL_ARTICLE">
<AU>Caley CF, Weber SS</AU>
<TI>Sulpiride: an antipsychotic with selective dopaminergic antagonist properties</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>1995</YR>
<VL>2</VL>
<PG>153-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-1983" NAME="Chalmers 1983" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers TC, Celano P, Sacks HS, Smith H Jr</AU>
<TI>Bias in treatment assignment in controlled clinical trials</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>309</VL>
<NO>22</NO>
<PG>1358-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1984039701"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chang-1995" NAME="Chang 1995" TYPE="JOURNAL_ARTICLE">
<AU>Chang Hong W</AU>
<TI>The clinical efficacy of sulpiride in treatment of type II schizophrenia</TI>
<SO>Chinese Journal of Neurology and Psychiatry</SO>
<YR>1995</YR>
<VL>8</VL>
<PG>141-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gerlach-1991" NAME="Gerlach 1991" TYPE="JOURNAL_ARTICLE">
<AU>Gerlach J</AU>
<TI>New antipsychotics: classification, efficacy, and adverse effects</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>2</NO>
<PG>289-309</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ghose-1977" NAME="Ghose 1977" TYPE="JOURNAL_ARTICLE">
<AU>Ghose K</AU>
<TI>Lithium salts: therapeutic and unwanted effects</TI>
<SO>British Journal of Hospital Medicine</SO>
<YR>1977</YR>
<VL>18</VL>
<PG>578-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology: National Institute of Mental Health Publication No.76-33</SO>
<YR>1976</YR>
<PB>US Government Printing Office</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Honigfeld-1965" NAME="Honigfeld 1965" TYPE="JOURNAL_ARTICLE">
<AU>Honigfeld G, Klett CJ</AU>
<TI>The nurses' observation scale for inpatient evaluation. A new scale for measuring improvement in chronic schizophrenia</TI>
<SO>Journal of Clinical Psychology</SO>
<YR>1965</YR>
<VL>21</VL>
<PG>65-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jenner-1981" NAME="Jenner 1981" TYPE="JOURNAL_ARTICLE">
<AU>Jenner P, Marsden CD</AU>
<TI>Substituded benzamide drugs as selective neuroleptic agents</TI>
<SO>Neuropharmacology</SO>
<YR>1981</YR>
<VL>20</VL>
<PG>1285-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnstone-1978" NAME="Johnstone 1978" TYPE="JOURNAL_ARTICLE">
<AU>Johnstone EC, Crow TJ, Frith CD, Carney MW, Price JS</AU>
<TI>Mechanism of the antipsychotic effect in the treatment of acute schizophrenia</TI>
<SO>Lancet</SO>
<YR>1978</YR>
<VL>1</VL>
<NO>8069</NO>
<PG>848-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krawiecka-1977" NAME="Krawiecka 1977" TYPE="JOURNAL_ARTICLE">
<AU>Krawiecka M, Goldberg D, Vaughan M</AU>
<TI>A standardised psychiatric assassment scale for rating chronic psychotic patients</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1977</YR>
<VL>35</VL>
<PG>299-308</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lorr-1963" NAME="Lorr 1963" TYPE="BOOK">
<AU>Lorr M, Klett CJ, McNair DM, Lasky JJ</AU>
<SO>Inpatient multidimensional psychiatric scale</SO>
<YR>1963</YR>
<PB>Consulting Psychologists Press</PB>
<CY>Palo Alto</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mauri-1994" NAME="Mauri 1994" TYPE="JOURNAL_ARTICLE">
<AU>Mauri MC, Leva P, Coppola MT, Altamura CA</AU>
<TI>L-sulpiride in young and elderly negative schizophrenics: clinical and pharmacokinetic variables</TI>
<SO>Progress in Neuro Psychopharmacology and Biological Psychiatry</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>2</NO>
<PG>355-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mauri-1996" NAME="Mauri 1996" TYPE="JOURNAL_ARTICLE">
<AU>Mauri MC, Bravin S, Bitetto A, Rudelli R, Invernizzi, G</AU>
<TI>A risk-benefit assessment of sulpiride in the treatment of schizophrenia</TI>
<SO>Drug Safety</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>5</NO>
<PG>288-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" NAME="Moher 1998" NOTES="&lt;p&gt;:&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1998417104"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1999" NAME="Mulrow 1999" TYPE="COCHRANE_REVIEW">
<AU>Mulrow CD, Oxman AD</AU>
<TI>Cochrane Collaboration Handbook [updated March 1999]</TI>
<SO>The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration</SO>
<PB>Update Software; 1996-. Updated quarterly</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIMH-1975" NAME="NIMH 1975" TYPE="JOURNAL_ARTICLE">
<AU>National Institute of Mental Health</AU>
<TI>Psychopharmacology Research Branch. Development of a dyskinetic movement scale</TI>
<SO>Early Clinical Drug Evaluation Unit Interco</SO>
<YR>1975</YR>
<VL>4</VL>
<PG>3-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1961" NAME="Overall 1961" NOTES="&lt;p&gt;.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DE</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychology Reports</SO>
<YR>1961</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Owens-1980" NAME="Owens 1980" TYPE="JOURNAL_ARTICLE">
<AU>Owens DGC, Johnstone EC</AU>
<TI>The disabilities of chronic schizophrenia: their nature and the factors contributing to their development</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>136</VL>
<PG>384-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peselow-1982" NAME="Peselow 1982" TYPE="JOURNAL_ARTICLE">
<AU>Peselow ED, Stanley M</AU>
<TI>Clinical trials of benzamides in psychiatry</TI>
<SO>Advanced Biochemical Psychopharmacology</SO>
<YR>1982</YR>
<VL>35</VL>
<PG>163-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rolth-1995" NAME="Rolth 1995" TYPE="JOURNAL_ARTICLE">
<AU>Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY</AU>
<TI>D4 Dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs</TI>
<SO>Psychopharmacology</SO>
<YR>1995</YR>
<VL>120</VL>
<PG>365-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sanyal-1997" NAME="Sanyal 1997" TYPE="JOURNAL_ARTICLE">
<AU>Sanyal S, Van Tol HH</AU>
<TI>Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>1997</YR>
<VL>31</VL>
<NO>2</NO>
<PG>219-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmidt" NAME="Schmidt" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG</AU>
<TI>The role of 5-HT2A receptors in antipsychotic activity</TI>
<SO>Life Sciences</SO>
<YR>1995</YR>
<VL>56</VL>
<NO>25</NO>
<PG>2209-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Grimes DA, Altman DG</AU>
<TI>Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>272</VL>
<NO>2</NO>
<PG>125-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994285358"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson EN, Angus JWF</AU>
<TI>A rating scale for extrpyramidal side-effects</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thornley-1999" NAME="Thornley 1999" TYPE="COCHRANE_REVIEW">
<AU>Thornley B, Adams CE, Awad G</AU>
<TI>Chlorpromazine versus placebo for those with schizophrenia</TI>
<SO>The Cochrane Library</SO>
<YR>1999</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weizman-1985" NAME="Weizman 1985" TYPE="JOURNAL_ARTICLE">
<AU>Weizman A, Maoz B, Treves I, Asher I, Ben David M</AU>
<TI>Sulpiride-induced hyperprolactinemia and impotence in male psychiatric outpatients</TI>
<SO>Progress in Neuro Psychopharmacology and Biological Psychiatry</SO>
<YR>1985</YR>
<VL>9</VL>
<NO>2</NO>
<PG>193-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wing-1961" NAME="Wing 1961" TYPE="JOURNAL_ARTICLE">
<AU>Wing JK</AU>
<TI>A simple and reliable subclassification of chronic schizophrenia</TI>
<SO>Journal of Mental Science</SO>
<YR>1961</YR>
<VL>107</VL>
<PG>862-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yamagami-1985" NAME="Yamagami 1985" TYPE="JOURNAL_ARTICLE">
<AU>Yamagami S</AU>
<TI>A cross-over study of clocapramine and haloperidol in chronic schizophrenia</TI>
<SO>Journal of International Medical Research</SO>
<YR>1985</YR>
<VL>13</VL>
<PG>301</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Asada-1976">
<CHAR_METHODS>
<P>Allocation: randomised, "sans crainte de distorsion".<BR/>Blindness: double.<BR/>Duration: 10 weeks.<BR/>Undertaken in Japan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia.<BR/>N=82.<BR/>Age: 71% 20-39 years.<BR/>Sex: M 46, F 30.<BR/>Setting: in hospital (26% &gt;5 years).<BR/>History: 68% chronic (30% &gt;10 years).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride: dose 300-1200 mg/day. N=38.<BR/>2. Perphenazine: dose 12-48 mg/day. N=38.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>No global change.<BR/>Unable to use - <BR/>Leaving the study early (original allocation unclear).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>6 people excluded after randomisation original allocation unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Blanco-1972">
<CHAR_METHODS>
<P>Allocation: randomised, "al azar" - no further details.<BR/>Blindness: single.<BR/>Duration: 3 months.<BR/>Undertaken in Spain.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (OMS).<BR/>N=89.<BR/>Age: range 20-60 (78% &gt;41 years).<BR/>Sex: no information.<BR/>Setting: hospital (45% &gt;15 years).<BR/>History: chronic, hospitalization &gt;5 years .</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride: dose 800-1400 mg/day. N=46.<BR/>2. Placebo: vitaminic complex. N=43.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Unable to use - <BR/>Mental state (Harris, Letemendia y Willems 1967, no SD).<BR/>Side-effects (not presented by group of allocation).<BR/>Use of chlorpromazine (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bratfos-1979">
<CHAR_METHODS>
<P>Allocation: randomised list, packages with code numbers.<BR/>Blindness: double.<BR/>Duration: 4 weeks (acute psychosis), 8 weeks (chronic psychosis).<BR/>Undertaken in Norway.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, reactive psychosis, paranoid psychosis.<BR/>N=74.<BR/>Age: mean ~ 42 years.<BR/>Sex: M 34, F 37.<BR/>Setting: hospital.<BR/>History: 'chronic' 41% (sulpiride group), 23% (chlorpromazine group).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride: dose 600-1800 mg/day. N=25.<BR/>2. Chlorpromazine: dose 225-675 mg/day. N=25.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>No global change.<BR/>Use of additional medication.<BR/>Side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Reviewers dichotomized 'global change' at 'unchanged to worse'.<BR/>3 people excluded - original allocation unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cassano-1975">
<CHAR_METHODS>
<P>Allocation: "randomized experimental design" - no further details.<BR/>Blindness: double.<BR/>Duration: 30 days (preceeded by 2-7 day washout).<BR/>Setting: multicentre.<BR/>Undertaken in Italy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: paranoid or hebephrenic schizophrenia (clinical).<BR/>N=76.<BR/>Age: range 19-75, mean 38 years.<BR/>Sex: both, numbers unclear.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride: dose 100-2300 mg/day, mean 1000 mg/day. N=34.<BR/>2. Haloperidol: dose 0.5-10.5 mg/day, mean 5 mg/day. N=36.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Use of additional medication.<BR/>No improvement.<BR/>Side-effects.<BR/>Participants with &gt;1 side-effect.<BR/>Unable to use - <BR/>Mental state (BPRS, IMPS - no mean or SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>6 people excluded post randomisation for "reasons totally independant of the treatment".<BR/>Reviewers dichotomized 'no improvement' at 'no change to worse'.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dreyfus-1985">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blindness: double.<BR/>Duration: 21 days.<BR/>Undetaken in France.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: psychosis or schizophrenia.<BR/>History: acutely ill, 13 with chronic illness.<BR/>N=64.<BR/>Age: mean ~33.<BR/>Sex: M 33, F 26.<BR/>Setting: in hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride: dose 800-1200 mg/day. N=32.<BR/>2. Chlorpromazine: dose 200-300 mg/day. N=27.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Use of additional medication*.<BR/>Side-effects.<BR/>Unable to use - <BR/>Mental state (BPRS, NOSIE, CGI, no SD).<BR/>Cardiac evaluation (blood pressure, pulse rate, no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*Data from last day of trial.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Edwards-1980">
<CHAR_METHODS>
<P>Allocation: "double dummy technique", random code.<BR/>Blindness: double.<BR/>Duration: 6 weeks (preceeded by 1 month washout, if possible).<BR/>Undertaken in the UK.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (clinical).<BR/>N=38. <BR/>Age: range 25-74, mode 55-64 years.<BR/>Sex: M 33, F 5.<BR/>Setting: hospital.<BR/>History: long-stay, inpatients, 36 ill &gt; 10 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride: dose 600-1800 mg/day, mean 1212 mg/day. N=19.<BR/>2. Trifluoperazine: dose 15-45 mg/day, mean 27.7 mg/day. N=19.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>No improvement / severity of illness.<BR/>Behaviour.<BR/>Use of additional medication.<BR/>Side effects - specific list.<BR/>Unable to use - <BR/>Mental state (BPRS, no SD).<BR/>Life events (demoninator unclear).<BR/>Side effects (Simpson &amp; Angus Scale, no SD).<BR/>Physiological measures (handwriting, weight, pulse, blood pressure, no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Reviewers dichotomized 'severity of illness' and 'no improvement' at 'markedly ill or worse' and 'minimally improved or worse' respectivley.<BR/>Mean doses considered at the 6th week.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lepola-1989">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blindness: double.<BR/>Duration: 4 months (preceeded by 4 week washout).<BR/>Undertaken in Finland.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (RDC).<BR/>N=47.<BR/>Age: range 18-66, mean 39 years.<BR/>Sex: M 20, F 27.<BR/>Setting: unclear.<BR/>History: 30 chronic, 17 acute schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride: dose 200-2000 mg/day. N=23.<BR/>2. Perphenazine: dose 4-40 mg/day. N=24.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Unable to use - <BR/>No improvement (BPRS)*.<BR/>Use of additional medication*.<BR/>Side-effects*.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*50% of data missing in perphenazine group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mahadevan-1991">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blindness: single.<BR/>Duration: 10 weeks.<BR/>Multicentre.<BR/>Undertaken in the UK.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (RDC, BPRS &gt; 15).<BR/>History: acutely ill.<BR/>N=61.<BR/>Age: mean ~ 39 years.<BR/>Sex: M 26, F 35.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride: dose 600 mg/day (mode). N=31.<BR/>2. Zuclopenthixol dihydrocloride: dose 50-100 mg/day (mode). N=30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Use of additional medication.<BR/>No improvement (CGI).<BR/>Mental state (BPRS).<BR/>Side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nishikawa-1989">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blindness: double.<BR/>Duration: 1 year.<BR/>Undertaken in Japan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-III).<BR/>N=82. <BR/>Age: mean ~41 years.<BR/>Sex: M 59, F 23.<BR/>Setting: outpatients.<BR/>History: remitted, duration ill ~14years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride*: dose 100-600 mg/day. N=32.<BR/>2. Timiperone*: dose 1-6 mg/day. N=31.<BR/>Additional non-randomised placebo group (N=19).<BR/>*Also nitrazepan 10mg &amp; trihexyphenidyl 2 mg &amp; brief psychotherapy every 2 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.</P>
<P>Unable to use -<BR/>Relapse.<BR/>Symptom free days (no useful data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Missing data &gt;40%.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Petit-1987">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blindness: double.<BR/>Duration: 60 days (preceeded by 1 week washout).<BR/>Undertaken in France.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (Feighner's).<BR/>History: predominant negative symptoms.<BR/>N=17. <BR/>Age: mean 27, range 18-35 years.<BR/>Sex: M 11, F 6.<BR/>Setting: unclear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride: 150 mg/day (low dose). N=9.<BR/>2. Sulpiride: 1200 mg/day (normal dose). N=8.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Side-effects.<BR/>Unable to use - <BR/>Mental state (BPRS - no SD)<BR/>Global impression (CGI - no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rama-Rao-1981">
<CHAR_METHODS>
<P>Allocation: randomised, "double-dummy technique".<BR/>Blindness: double.<BR/>Duration: 12 weeks.<BR/>Undertaken in the UK.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia.<BR/>N=30.<BR/>Age: mean ~60 years.<BR/>Sex: F 30.<BR/>Setting: hospital.<BR/>History: in hospital ~27 years, BPRS mean ~10, Wing score ~5.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride: dose 1200 mg/day. N=15.<BR/>2. Haloperidol: dose 5-40 mg/day, mean 9.8. N=15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Use of additional medication.<BR/>Psychotic symptoms (BPRS).<BR/>Behaviour (Wing score).<BR/>Side-effects checklist.</P>
<P>Unable to use - <BR/>Extrapyramidal score (EPS, unpublished scale).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shiloh-1997">
<CHAR_METHODS>
<P>Allocation: randomised, "table of random numbers".<BR/>Blindness: double.<BR/>Duration: 10 weeks.<BR/>Undertaken in Israel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N=28.<BR/>Age: mean ~39 years.<BR/>Sex: M 19, F 9.<BR/>Setting: hospital.<BR/>History: unresponsive to typical antipsychotics, partially responsive to clozapine, duration ill ~20 years, in hospital - sulpiride 33 months, placebo 71.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride: dose 600 mg/day. N=16.<BR/>2. Placebo. N=12.<BR/>All participants taking clozapine: dose ~420 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>No improvement*.<BR/>Leaving the study early**.<BR/>Mental state (BPRS).<BR/>Positive symptoms (SAPS).<BR/>Negative symptoms (SANS).<BR/>Side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*No improvement = reduction &lt; 20% BPRS.<BR/>** zero losses implied but not specifically reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Soni-1990">
<CHAR_METHODS>
<P>Allocation: randomised - by hospital pharmacy staff who kept code until end of study.<BR/>Blindness: double.<BR/>Duration: 12 weeks (preceeded by ~14 month washout).<BR/>Undertaken in the UK.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-III).<BR/>N=24.<BR/>Age: range 51-64, mean 59 years.<BR/>Sex: M 16, F 10.<BR/>Setting: hospital.<BR/>History: chronicly ill, mean ~30 years, in hospital mean ~29 years, poverty of speech &amp; flattening of affect &gt;= 3 (Manchester Scale).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride: dose 400 mg/day. N=12.<BR/>2. Placebo. N=12.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Relapse.<BR/>Negative symptoms (SANS, Manchester Scale).<BR/>Positive symptoms (Manchester Scale).<BR/>Behaviour (CBS).<BR/>Abnormal involuntary movements (AIMS).<BR/>Unable to use - <BR/>Extrapyramidal effects (EPS - data unclear).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Taverna-1972">
<CHAR_METHODS>
<P>Allocation: controlled study, 'technique psychometrique'*.<BR/>Blindness: single.<BR/>Duration: 30 days.<BR/>Undertaken in Italy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: 'syndrome dissociatif'.<BR/>N=40.<BR/>Age: range 24-75, mean 45.9 years.<BR/>Sex: M 29, F 11.<BR/>Setting: unclear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride: dose 500-600 mg/day. N=20.<BR/>2. Haloperidol: dose 4mg/day. N=20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>No improvement (Goodrich Rating Scale).<BR/>Cognitive function (Goodrich Rating Scale).<BR/>Behaviour (Goodrich Rating Scale).<BR/>Emotional state (Goodrich Rating Scale).<BR/>Thought content (Goodrich Rating Scale).<BR/>Side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* quasi-randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Toru-1972">
<CHAR_METHODS>
<P>Allocation: randomised after divided in pairs - no further details.<BR/>Blindness: double.<BR/>Duration: 8 weeks (preceeded by 3-5 day placebo washout).<BR/>Undertaken in Japan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia.<BR/>N=76.<BR/>Age: range 20-70, mean 35 years.<BR/>Sex: M 59, F 16.<BR/>Setting: hospital.<BR/>History: chronic, not responsive to conventional drugs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride: dose 300-1200 mg/day. N=38.<BR/>2. Chlorpromazine: dose 600-1500 mg/day. N=38.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>No improvement.<BR/>Therapeutic efficacy ("Three Universities" scale).<BR/>Use of additional medication.<BR/>Side-effects.<BR/>Unable to use - <BR/>Patients preference.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Reviewers dichotomized 'no improvement' at 'no change - slightly improved'.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wiesel-1984">
<CHAR_METHODS>
<P>Allocation: randomised, "double-dummy technique".<BR/>Blindness: double.<BR/>Duration: 8 weeks (preceeded by 2 week washout).<BR/>Undertaken in Sweden.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (RDC).<BR/>N=50.<BR/>Age: range 18-43, mean 27 years.<BR/>Sex: M 25, F 25.<BR/>History: acutley ill, first episode 12 (sulpiride group), 15 (chlorpromazine group).<BR/>Setting: initially in hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride: dose 800 mg/day (fixed dose). N=25.<BR/>2. Chlorpromazine: dose 400 mg/day (fixed dose). N=25.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Suicide.<BR/>Negative symptoms (CPRS A).<BR/>Positive symptoms (CPRS 6).<BR/>Psychotic symptoms (CPRS 10).<BR/>Depressive symptoms (CPRS Dep).<BR/>Use of additional medication.<BR/>Hospitalization.<BR/>Side-effects (Simpson &amp; Angus Scale).<BR/>Unable to use - <BR/>Behaviour (NOSIE - &gt; 50% data missing).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yamagami-1988">
<CHAR_METHODS>
<P>Allocation: randomly assigned and sealed in envelopes.<BR/>Blindness: single.<BR/>Duration: 8 weeks.<BR/>Undertaken in Japan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia.<BR/>N=52.<BR/>Age: range 20-58, mean 37 years.<BR/>Sex: M 18, F 34.<BR/>Setting: hospital.<BR/>History: 37 (71%) chronic, 29 hospitalization&gt; 3 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride: maximum dose 1400 mg/day. N=26.<BR/>2. Clocapramine: dose 50-900 mg/day. N=26.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>No improvement (FGIR).<BR/>Side-effects.</P>
<P>Unable to use -<BR/>Psychotic symptoms (PRS - no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Reviewers dichotomized 'no improvement' at 'no change - slightly improved'.<BR/>No drop-out related.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yamagami-1993">
<CHAR_METHODS>
<P>Allocation: randomly assigned and sealed in envelopes.<BR/>Blindness: single.<BR/>Duration: 8 weeks.<BR/>Undertaken in Japan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-III-R).<BR/>N=45. <BR/>Age: range 20-56, mean 38 years.<BR/>Sex: M 17, F 28.<BR/>Setting: hospital.<BR/>History: 31 (68%) chronic, 13 hospitalization&gt; 5 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sulpiride: dose 150-1500 mg/day, mean 441.7 mg/day. N=18.<BR/>2. Bromperidol: dose 3-36 mg/day, mean 15.1 mg/day. N=28</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>No improvement (FGIR).<BR/>Psychotic symptoms (BPRS, PES).<BR/>Use of additional medication.<BR/>Side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Reviewers dichotomized 'no improvement' at 'no change - slightly improved'.<BR/>BPRS chosen for evaluation of psychotic symptoms, dichotomized on negative/ positive symptoms.??<BR/>No drop-out.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Research Diagnostic Criteria</P>
<P>
<BR/>Mental state symptoms<BR/>BPRS - Brief Psychiatric Rating Scale <BR/>CPRS - Comprehensive Psychopathological Rating Scale<BR/>CGI - Clinical Global Impression<BR/>FGIR - Final Global Improvement Rating<BR/>IMPS - Inpatient Multidimensional Psychiatric Scale<BR/>PRS - Psychiatric Rating Scale<BR/>SAPS - Scale for the Assessment of Positive Symptoms<BR/>SANS - Scale for the Assessment of Negative Symptoms</P>
<P>Behaviour<BR/>CBS - Current Behaviour Schedule<BR/>NOSIE - Nurses Observational Scale of Inpatients Evaluation</P>
<P>Side-Effects<BR/>AIMS - Abnormal Involuntary Movement Scale<BR/>EPS - Extrapyramidal Rating Scale</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Alfredsson-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossover.<BR/>Participants: those with schizophrenia.<BR/>Interventions: 3 doses of sulpiride.<BR/>Outcomes: serum metabolities, clinical data not presented for first arm of crossover.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bente-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bjerkenstedt-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Borenstein-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bruscky-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Burchard-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case control study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carranza-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: "double-blind technique".<BR/>Participants: those with schizophrenia, N=20.<BR/>Interventions: sulpiride vs chlorpromazine.<BR/>Outcomes: clinical data not usable, no demoninators.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carrere-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Catapano-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Alocation: randomised.<BR/>Participants: those with schizophrenia.<BR/>Interventions: different doses of levo-sulpiride, not sulpiride.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Colard-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Courdec-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eckmann-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elizur-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gerlach-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossover trial.<BR/>Participants: those with schizophrenia<BR/>Interventions: sulpiride vs haloperidol.<BR/>Outcomes: clinical data not available for first arm of crossover.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goldwurm-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guazelli-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Alocation: randomised.<BR/>Participants: those with schizophrenia.<BR/>Interventions: levo-sulpiride vs haloperidol, not sulpiride.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Haase-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Halpern-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hayano-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Blindnes: "double-dummy technique".<BR/>Participants: those with schizophrenia.<BR/>Outcomes: not available, outcomes on regression analysis or displayed in graphs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lewis-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised (third/ fourth phases), crossover study.<BR/>Participants: those with chronic schizophrenia.<BR/>Interventions: morning only vs twice daily doses of sulpiride.<BR/>Outcomes: no usable data available for the first phase of the trial (no SD on BPRS).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martins-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mielke-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mouren-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nishikawa-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nishiura-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nurowska-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pinto-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Strauss-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Svestka-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossover.<BR/>Participants: those with schizophrenia.<BR/>Interventions: sulpiride vs perphenazine.<BR/>Outcomes: clinical data not presented for first arm of crossover.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Uvod-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vaisanen-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossover.<BR/>Participants: those with "oligophrenia", learning disability, not schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wagenaar-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Xia-Chia-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossover.<BR/>Participants: those with schizophrenia.<BR/>Interventions: sulpiride vs flupenthixol.<BR/>Outcomes: clinical data not presented for first arm of crossover.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yamaoka-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Asada-1976">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Blanco-1972">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bratfos-1979">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cassano-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dreyfus-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1980">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lepola-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mahadevan-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nishikawa-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Petit-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rama-Rao-1981">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Shiloh-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Soni-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Taverna-1972">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Toru-1972">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wiesel-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Yamagami-1988">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Yamagami-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Studies awaiting assessment</TITLE>
<TABLE COLS="2" ROWS="9">
<TR>
<TH>
<P>Study tag</P>
</TH>
<TH>
<P>Reason(s) for delay</P>
</TH>
</TR>
<TR>
<TD>
<P>Amakusa 1973</P>
</TD>
<TD>
<P>Awaits translation</P>
</TD>
</TR>
<TR>
<TD>
<P>Bellomo 1972</P>
</TD>
<TD>
<P>Paper not yet available. Ordered.</P>
</TD>
</TR>
<TR>
<TD>
<P>Ishimaru 1971</P>
</TD>
<TD>
<P>Paper not yet available. Ordered.</P>
</TD>
</TR>
<TR>
<TD>
<P>Kogeorgos 1995 <BR/>
</P>
</TD>
<TD>
<P>Clinical data not usable. Letter sent.</P>
</TD>
</TR>
<TR>
<TD>
<P>Lui 1996</P>
</TD>
<TD>
<P>Awaits translation.</P>
</TD>
</TR>
<TR>
<TD>
<P>Souto 1971</P>
</TD>
<TD>
<P>Reference inaccurate - paper still being sought.</P>
</TD>
</TR>
<TR>
<TD>
<P>Yang 1988</P>
</TD>
<TD>
<P>Allocation: sequentially based on time of admission to the hospital. Awaits translation.<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Zann 1986</P>
</TD>
<TD>
<P>Possibly part of another study (Petit 1984) - authors are being contacted.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>SULPIRIDE vs PLACEBO</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9164043821960568" CI_START="0.3246608887269298" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.037912842705014965" LOG_CI_START="-0.48857002684414785" LOG_EFFECT_SIZE="-0.26324143477458145" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.022036434091612947" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="12" WEIGHT="100.0" Z="2.289739294325952">
<NAME>Global impression: No improvement</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9164043821960568" CI_START="0.3246608887269298" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="-0.037912842705014965" LOG_CI_START="-0.48857002684414785" LOG_EFFECT_SIZE="-0.26324143477458145" ORDER="1788" O_E="0.0" SE="0.2647182607523659" STUDY_ID="STD-Shiloh-1997" TOTAL_1="16" TOTAL_2="12" VAR="0.07007575757575758" WEIGHT="100.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.02" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 1. BPRS change data (skewed, decrease=good)</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="1789" STUDY_ID="STD-Shiloh-1997">
<TR>
<TD>
<P>Sulpiride: mean -8.7, SD 8.3, N=16.<BR/>Placebo: mean -2.3, SD 6.2, N=12.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.0594736192775973" CI_START="-1.659473619277597" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.6653690443884456" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="0.4325123981989913">
<NAME>Mental state: 2. Manchester Scale negative symptom endpoint scores (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="1.0594736192775973" CI_START="-1.659473619277597" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="4.1" ORDER="1790" SD_1="1.7" SD_2="1.2" SE="0.6936217348894936" STUDY_ID="STD-Soni-1990" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.937065929024996" CI_START="-0.13706592902499226" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.900000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.06127459388728055" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="1.8715087811712052">
<NAME>Mental state: 3. SANS negative symptom endpoint scores (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="5.937065929024996" CI_START="-0.13706592902499226" EFFECT_SIZE="2.900000000000002" ESTIMABLE="YES" MEAN_1="21.6" MEAN_2="18.7" ORDER="1791" SD_1="4.4" SD_2="1.5" SE="1.549551906555928" STUDY_ID="STD-Soni-1990" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.05" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 4. SANS negative symptom endpoint scores (skewed, high=poor)</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="1792" STUDY_ID="STD-Shiloh-1997">
<TR>
<TD>
<P>Sulpiride: mean -8.3, SD 10.8, N=16.<BR/>Placebo: mean -1.5, SD 4.4, N=12.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.06" NO="6" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Mental state: 5. Positive symptom scores (skewed)</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_SUBGROUP ID="CMP-001.06.01" NO="1" STUDIES="1">
<NAME>Manchester scale - endpoint (high=poor)</NAME>
<OTHER_DATA ORDER="1793" STUDY_ID="STD-Soni-1990">
<TR>
<TD>
<P>Sulpiride: mean 2.5, SD 1.4, N=9.<BR/>Placebo: mean 2.5, SD 2.3, N=9.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.06.02" NO="2" STUDIES="1">
<NAME>Scale for the assessment of positive symptoms - change (decrease=good)</NAME>
<OTHER_DATA ORDER="1794" STUDY_ID="STD-Shiloh-1997">
<TR>
<TD>
<P>Sulpiride: mean -6.4, SD 7.1, N=16.<BR/>Placebo: mean -0.6, SD 7.6, N=12.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.14117186688321856" CI_END="2.396175816191149" CI_START="0.2948125413021359" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.840489548880908" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.37951868066231426" LOG_CI_START="-0.5304540455671839" LOG_EFFECT_SIZE="-0.07546768245243483" METHOD="MH" NO="7" P_CHI2="0.7071189051851023" P_Q="0.0" P_Z="0.7451089275678473" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="86" TOTAL_2="79" WEIGHT="200.0" Z="0.32509532503543037">
<NAME>Behaviour: 1. Leaving the study early</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9984381579173807" CI_START="0.2500976532599064" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.6018903833636786" LOG_CI_START="-0.6018903833636786" LOG_EFFECT_SIZE="0.0" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="3" TAU2="0.0" TOTAL_1="74" TOTAL_2="67" WEIGHT="100.0" Z="0.0">
<NAME>any reason</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1795" O_E="0.0" SE="0.0" STUDY_ID="STD-Blanco-1972" TOTAL_1="46" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1796" O_E="0.0" SE="0.0" STUDY_ID="STD-Shiloh-1997" TOTAL_1="16" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.9984381579173807" CI_START="0.2500976532599064" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6018903833636786" LOG_CI_START="-0.6018903833636786" LOG_EFFECT_SIZE="0.0" ORDER="1797" O_E="0.0" SE="0.7071067811865475" STUDY_ID="STD-Soni-1990" TOTAL_1="12" TOTAL_2="12" VAR="0.49999999999999994" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.303025227094486" CI_START="0.13455678170384458" DF="0.0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.5189118906596525" LOG_CI_START="-0.8710944087710151" LOG_EFFECT_SIZE="-0.17609125905568127" NO="2" P_CHI2="1.0" P_Z="0.6194772830713247" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.4965913116837107">
<NAME>due to deterioration</NAME>
<DICH_DATA CI_END="3.303025227094486" CI_START="0.13455678170384458" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5189118906596525" LOG_CI_START="-0.8710944087710151" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1798" O_E="0.0" SE="0.8164965809277259" STUDY_ID="STD-Soni-1990" TOTAL_1="12" TOTAL_2="12" VAR="0.6666666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.355293048614267" CI_END="0.1721625444194499" CI_START="-2.666028968772017" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2469332121762835" ESTIMABLE="YES" I2="57.542438271604944" I2_Q="57.542438271604944" ID="CMP-001.08" NO="8" P_CHI2="0.12485858026643037" P_Q="0.12485858026643037" P_Z="0.08503616925452909" Q="2.355293048614267" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="20" UNITS="" WEIGHT="200.0" Z="1.7221841272044471">
<NAME>Behaviour: 2. CBS endpoint score (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2099055504050755" CI_START="-2.2099055504050753" DF="0.0" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" NO="1" P_CHI2="1.0" P_Z="0.5665630835795308" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0" Z="0.5731205399256527">
<NAME>abnormal behaviour</NAME>
<CONT_DATA CI_END="1.2099055504050757" CI_START="-2.2099055504050757" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="10.5" ORDER="1799" SD_1="1.8" SD_2="1.9" SE="0.8724168218868267" STUDY_ID="STD-Soni-1990" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.3562382247780502" CI_START="-5.443761775221951" DF="0.0" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" NO="2" P_CHI2="1.0" P_Z="0.025453813409745736" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.0" Z="2.2344449116781866">
<NAME>social bahaviour</NAME>
<CONT_DATA CI_END="-0.3562382247780502" CI_START="-5.443761775221951" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="8.7" MEAN_2="11.6" ORDER="1800" SD_1="2.5" SD_2="3.3" SE="1.2978614889287856" STUDY_ID="STD-Soni-1990" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.3958360400094308" CI_END="3.823606674220981" CI_START="0.7028095228542686" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.63928862080222" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.582473211009656" LOG_CI_START="-0.1531623625793582" LOG_EFFECT_SIZE="0.21465542421514888" METHOD="MH" NO="9" P_CHI2="0.8204371802864256" P_Q="0.0" P_Z="0.2526988095399997" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="44" TOTAL_2="36" WEIGHT="300.0" Z="1.1438188028218046">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.444932111094823" CI_START="0.688986900914822" DF="0.0" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.6478651322349035" LOG_CI_START="-0.16178903486231475" LOG_EFFECT_SIZE="0.24303804868629442" NO="1" P_CHI2="1.0" P_Z="0.2393293009776516" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="1.1766649062175027">
<NAME>abnormal involuntary movements - general (AIMS)</NAME>
<DICH_DATA CI_END="4.444932111094823" CI_START="0.688986900914822" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6478651322349035" LOG_CI_START="-0.16178903486231475" LOG_EFFECT_SIZE="0.24303804868629442" ORDER="1801" O_E="0.0" SE="0.47559486560567094" STUDY_ID="STD-Soni-1990" TOTAL_1="12" TOTAL_2="12" VAR="0.22619047619047622" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="51.8538233955592" CI_START="0.10149638799821722" DF="0.0" EFFECT_SIZE="2.2941176470588234" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="1.714780784223131" LOG_CI_START="-0.9935494129266806" LOG_EFFECT_SIZE="0.3606156856482252" NO="2" P_CHI2="1.0" P_Z="0.6017116849197082" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="12" WEIGHT="100.0" Z="0.5219406089217288">
<NAME>abnormal involuntary movements - specific - tardive dyskinesia</NAME>
<DICH_DATA CI_END="51.8538233955592" CI_START="0.10149638799821722" EFFECT_SIZE="2.2941176470588234" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.714780784223131" LOG_CI_START="-0.9935494129266806" LOG_EFFECT_SIZE="0.3606156856482252" ORDER="1802" O_E="0.0" SE="1.5908865642564918" STUDY_ID="STD-Shiloh-1997" TOTAL_1="16" TOTAL_2="12" VAR="2.530920060331825" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.817417252673156" CI_START="0.05199947333648403" DF="0.0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="1.0341235817681607" LOG_CI_START="-1.2840010549847605" LOG_EFFECT_SIZE="-0.12493873660829993" NO="3" P_CHI2="1.0" P_Z="0.8326763704146012" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="12" WEIGHT="100.00000000000001" Z="0.21127028300705136">
<NAME>hypersalivation</NAME>
<DICH_DATA CI_END="10.817417252673156" CI_START="0.05199947333648403" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0341235817681607" LOG_CI_START="-1.2840010549847605" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="1803" O_E="0.0" SE="1.3616778865306827" STUDY_ID="STD-Shiloh-1997" TOTAL_1="16" TOTAL_2="12" VAR="1.8541666666666667" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>SULPIRIDE vs TYPICAL ANTIPSYCHOTICS</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.8107039169243295" CI_START="0.014225492643544472" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.8926901751653995" LOG_CI_START="-1.8469326846047245" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.49481017826454565" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.68267825417953">
<NAME>Death - by suicide</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours other drug</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.8107039169243295" CI_START="0.014225492643544472" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8926901751653995" LOG_CI_START="-1.8469326846047245" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="1804" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.298006329586325" CI_END="1.006878587389438" CI_START="0.9075549755486383" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9559276498557141" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="194" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.002977105105974199" LOG_CI_START="-0.042127057912498114" LOG_EFFECT_SIZE="-0.01957497640326197" METHOD="MH" NO="2" P_CHI2="0.6364175577541238" P_Q="0.0" P_Z="0.08890004691457158" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="196" TOTAL_2="212" WEIGHT="99.99999999999999" Z="1.7012287195264892">
<NAME>Global impression: 1. Not completely improved</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours other drug</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0369050334234213" CI_START="0.8668127429545098" EFFECT_SIZE="0.948051948051948" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="38" LOG_CI_END="0.015738982667932715" LOG_CI_START="-0.062074712771984696" LOG_EFFECT_SIZE="-0.023167865052025977" ORDER="1805" O_E="0.0" SE="0.04570814988541208" STUDY_ID="STD-Asada-1976" TOTAL_1="38" TOTAL_2="38" VAR="0.0020892349659472967" WEIGHT="33.59859948241286"/>
<DICH_DATA CI_END="1.4118946255920979" CI_START="0.9164325910351716" EFFECT_SIZE="1.1375" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="30" LOG_CI_END="0.14980228507868476" LOG_CI_START="-0.0378994744203848" LOG_EFFECT_SIZE="0.05595140532914999" ORDER="1806" O_E="0.0" SE="0.11025694266844792" STUDY_ID="STD-Bratfos-1979" TOTAL_1="32" TOTAL_2="39" VAR="0.012156593406593412" WEIGHT="5.774263109552022"/>
<DICH_DATA CI_END="1.1616973773727588" CI_START="0.8608093807197481" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.06509300890279698" LOG_CI_START="-0.06509300890279697" LOG_EFFECT_SIZE="0.0" ORDER="1807" O_E="0.0" SE="0.07647191129018725" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.005847953216374269" WEIGHT="12.00340807258318"/>
<DICH_DATA CI_END="1.0370472750759434" CI_START="0.8142463702874858" EFFECT_SIZE="0.918918918918919" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" LOG_CI_END="0.015798554688591857" LOG_CI_START="-0.08924416873807156" LOG_EFFECT_SIZE="-0.036722807024739845" ORDER="1808" O_E="0.0" SE="0.06170261571068898" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="0.003807212785540963" WEIGHT="18.437469298302354"/>
<DICH_DATA CI_END="1.1643351885066355" CI_START="0.5353000615401308" EFFECT_SIZE="0.7894736842105263" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" LOG_CI_END="0.0660780228941248" LOG_CI_START="-0.27140270668842026" LOG_EFFECT_SIZE="-0.10266234189714772" ORDER="1809" O_E="0.0" SE="0.19823785111334083" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.03929824561403509" WEIGHT="1.786221439372497"/>
<DICH_DATA CI_END="1.09874434404624" CI_START="0.8387756487611233" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" LOG_CI_END="0.040896652490629196" LOG_CI_START="-0.0763541864114924" LOG_EFFECT_SIZE="-0.017728766960431602" ORDER="1810" O_E="0.0" SE="0.06887372317211941" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="0.004743589743589738" WEIGHT="14.797942621487106"/>
<DICH_DATA CI_END="1.0795878557664096" CI_START="0.814632214016559" EFFECT_SIZE="0.937799043062201" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="27" LOG_CI_END="0.03325799055352347" LOG_CI_START="-0.08903842006267937" LOG_EFFECT_SIZE="-0.02789021475457795" ORDER="1811" O_E="0.0" SE="0.07183751697295349" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="0.0051606288448393794" WEIGHT="13.60209597628997"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2159358443186286" CI_START="0.5832061597259739" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8421052631578947" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.08491066112632602" LOG_CI_START="-0.23417789772013445" LOG_EFFECT_SIZE="-0.07463361829690421" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.35921787053496856" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.9168564640904516">
<NAME>Global impression: 2. Not discharged - at eight weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2159358443186286" CI_START="0.5832061597259739" EFFECT_SIZE="0.8421052631578947" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.08491066112632602" LOG_CI_START="-0.23417789772013445" LOG_EFFECT_SIZE="-0.07463361829690421" ORDER="1812" O_E="0.0" SE="0.18743419898025124" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.03513157894736841" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.96054990774703" CI_END="1.1316941198460968" CI_START="0.6428304103263374" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8529287164966188" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="96" I2="19.683149282974533" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.05372905934874786" LOG_CI_START="-0.1919035862887115" LOG_EFFECT_SIZE="-0.06908726346998183" METHOD="MH" NO="4" P_CHI2="0.2678058032328998" P_Q="0.0" P_Z="0.2702318086725537" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03658428798541804" TOTALS="YES" TOTAL_1="248" TOTAL_2="266" WEIGHT="100.0" Z="1.1025289235491105">
<NAME>Global impression: 3. No improvement</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours other drug</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.178339897874952" CI_START="0.39729117648107515" EFFECT_SIZE="0.6842105263157895" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.07127058287825706" LOG_CI_START="-0.4008910801702415" LOG_EFFECT_SIZE="-0.16481024864599217" ORDER="1813" O_E="0.0" SE="0.2773500981126146" STUDY_ID="STD-Asada-1976" TOTAL_1="38" TOTAL_2="38" VAR="0.07692307692307693" WEIGHT="18.341013658362016"/>
<DICH_DATA CI_END="2.7040901708141685" CI_START="0.5492980886997488" EFFECT_SIZE="1.21875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.4320211695307252" LOG_CI_START="-0.26019191211753867" LOG_EFFECT_SIZE="0.08591462870659322" ORDER="1814" O_E="0.0" SE="0.40660939067020646" STUDY_ID="STD-Bratfos-1979" TOTAL_1="32" TOTAL_2="39" VAR="0.16533119658119658" WEIGHT="10.310453081792053"/>
<DICH_DATA CI_END="1.2691168976288023" CI_START="0.32008960897522715" EFFECT_SIZE="0.6373626373626373" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.10350162655251342" LOG_CI_START="-0.4947284240688261" LOG_EFFECT_SIZE="-0.19561339875815634" ORDER="1815" O_E="0.0" SE="0.3514032930214845" STUDY_ID="STD-Cassano-1975" TOTAL_1="26" TOTAL_2="29" VAR="0.1234842743463433" WEIGHT="13.005927583684569"/>
<DICH_DATA CI_END="3.6394388384179948" CI_START="0.5385445633294335" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5610344253616348" LOG_CI_START="-0.26877835400515887" LOG_EFFECT_SIZE="0.14612803567823798" ORDER="1816" O_E="0.0" SE="0.48743613423955967" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.23759398496240602" WEIGHT="7.593016425876899"/>
<DICH_DATA CI_END="1.5461031505530833" CI_START="0.2968087751104663" EFFECT_SIZE="0.6774193548387096" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.1892384651460857" LOG_CI_START="-0.5275232633467926" LOG_EFFECT_SIZE="-0.16914239910035345" ORDER="1817" O_E="0.0" SE="0.42102938734449463" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.1772657450076805" WEIGHT="9.735047037278568"/>
<DICH_DATA CI_END="1.9841868635676467" CI_START="0.5039847901230231" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.29758257003327615" LOG_CI_START="-0.2975825700332762" LOG_EFFECT_SIZE="0.0" ORDER="1818" O_E="0.0" SE="0.3496029493900505" STUDY_ID="STD-Taverna-1972" TOTAL_1="20" TOTAL_2="20" VAR="0.12222222222222222" WEIGHT="13.10928706505402"/>
<DICH_DATA CI_END="0.7893012770588336" CI_START="0.1034239465130622" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" LOG_CI_END="-0.10275719452244937" LOG_CI_START="-0.9853788941781019" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="1819" O_E="0.0" SE="0.5184563554256068" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="0.26879699248120303" WEIGHT="6.8171831846744055"/>
<DICH_DATA CI_END="2.444625074608031" CI_START="0.6110659569068464" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.38821226202223147" LOG_CI_START="-0.21391191058443107" LOG_EFFECT_SIZE="0.0871501757189002" ORDER="1820" O_E="0.0" SE="0.3536907195518778" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="0.1250971250971251" WEIGHT="12.87618712887267"/>
<DICH_DATA CI_END="3.2033105170277962" CI_START="0.5160477623704103" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.5055990395989719" LOG_CI_START="-0.2873101007488357" LOG_EFFECT_SIZE="0.10914446942506809" ORDER="1821" O_E="0.0" SE="0.4657587540038479" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="0.21693121693121692" WEIGHT="8.21188483440479"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.399042417587296" CI_END="1.5517205624266057" CI_START="0.4850803637916303" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8675881366897837" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.19081351516782444" LOG_CI_START="-0.31418630539773384" LOG_EFFECT_SIZE="-0.06168639511495476" METHOD="MH" NO="5" P_CHI2="0.49350399522306587" P_Q="0.0" P_Z="0.6320635733380611" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="159" TOTAL_2="178" WEIGHT="100.00000000000003" Z="0.4788243790899461">
<NAME>Global impression: 4. Severely ill or worse</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours other drrug</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5346068008354448" CI_START="0.11968764199908583" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.18599711850876538" LOG_CI_START="-0.9219506890979542" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="1822" O_E="0.0" SE="0.6508140266182866" STUDY_ID="STD-Asada-1976" TOTAL_1="38" TOTAL_2="38" VAR="0.4235588972431078" WEIGHT="20.775134432684233"/>
<DICH_DATA CI_END="158.44417092000197" CI_START="0.4543723722546066" EFFECT_SIZE="8.484848484848484" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.199876266348382" LOG_CI_START="-0.3425880834197187" LOG_EFFECT_SIZE="0.9286440914643317" ORDER="1823" O_E="0.0" SE="1.4934561444552885" STUDY_ID="STD-Bratfos-1979" TOTAL_1="32" TOTAL_2="39" VAR="2.2304112554112554" WEIGHT="3.945233422328006"/>
<DICH_DATA CI_END="3.356775150408168" CI_START="0.04117982900229612" EFFECT_SIZE="0.3717948717948718" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5259222515228311" LOG_CI_START="-1.3853154611058796" LOG_EFFECT_SIZE="-0.4296966047915243" ORDER="1824" O_E="0.0" SE="1.1226704931773637" STUDY_ID="STD-Cassano-1975" TOTAL_1="26" TOTAL_2="29" VAR="1.260389036251105" WEIGHT="6.981569005517709"/>
<DICH_DATA CI_END="2.29925159263083" CI_START="0.43492413061929797" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3615864959812984" LOG_CI_START="-0.36158649598129833" LOG_EFFECT_SIZE="0.0" ORDER="1825" O_E="0.0" SE="0.4247953952428732" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.18045112781954886" WEIGHT="48.763857210050496"/>
<DICH_DATA CI_END="4.504828095259613" CI_START="0.22198405329879073" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6536782229056234" LOG_CI_START="-0.6536782229056235" LOG_EFFECT_SIZE="0.0" ORDER="1826" O_E="0.0" SE="0.7679476477883045" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="0.5897435897435898" WEIGHT="14.920879486305086"/>
<DICH_DATA CI_END="22.473800761530814" CI_START="0.1001165768031282" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.3516765263654276" LOG_CI_START="-0.9994940082540649" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="1827" O_E="0.0" SE="1.3810892105173393" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="1.9074074074074074" WEIGHT="4.6133264431144925"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="20.050102508288077" CI_END="1.6731753250842039" CI_START="0.4062966435094177" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8245031950116936" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="71" I2="70.07496596329226" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.22354145125954353" LOG_CI_START="-0.3911567654445941" LOG_EFFECT_SIZE="-0.08380765709252531" METHOD="MH" NO="7" P_CHI2="0.0027131034309652025" P_Q="0.0" P_Z="0.5930364056840416" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4994798814671343" TOTALS="SUB" TOTAL_1="192" TOTAL_2="190" WEIGHT="400.0" Z="0.534441080407731">
<NAME>Mental state: 1. Specific affective symptoms</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours other drug</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.735732378583655" CI_END="1.7609432161251815" CI_START="0.4489992927322823" DF="2.0" EFFECT_SIZE="0.8891919132459073" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="46" I2="70.30760891927618" ID="CMP-002.07.01" LOG_CI_END="0.24574535180992196" LOG_CI_START="-0.3477543431007057" LOG_EFFECT_SIZE="-0.05100449564539182" NO="1" P_CHI2="0.03446320634693478" P_Z="0.7362127339540956" STUDIES="3" TAU2="0.2338207028733189" TOTAL_1="85" TOTAL_2="84" WEIGHT="99.99999999999999" Z="0.3368728758307166">
<NAME>anxiety</NAME>
<DICH_DATA CI_END="1.2237888817287388" CI_START="0.6327888834110613" EFFECT_SIZE="0.88" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="25" LOG_CI_END="0.08770650326021223" LOG_CI_START="-0.19874115895987496" LOG_EFFECT_SIZE="-0.05551732784983137" ORDER="1828" O_E="0.0" SE="0.1682607747268754" STUDY_ID="STD-Asada-1976" TOTAL_1="35" TOTAL_2="35" VAR="0.028311688311688312" WEIGHT="41.51456095554883"/>
<DICH_DATA CI_END="14.729087202911595" CI_START="0.8316876552661365" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1681758333991838" LOG_CI_START="-0.08003974469863254" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="1829" O_E="0.0" SE="0.7332080093414188" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.5375939849624061" WEIGHT="21.127747988524195"/>
<DICH_DATA CI_END="0.908097157402867" CI_START="0.28567984637998245" EFFECT_SIZE="0.5093378607809848" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="-0.041867683784376136" LOG_CI_START="-0.5441203963505022" LOG_EFFECT_SIZE="-0.2929940400674392" ORDER="1830" O_E="0.0" SE="0.29502572955236644" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.08704018109790607" WEIGHT="37.35769105592696"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.45848734963950455" CI_START="0.009078398583035482" DF="0.0" EFFECT_SIZE="0.06451612903225806" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="15" I2="0.0" ID="CMP-002.07.02" LOG_CI_END="-0.3386726426712779" LOG_CI_START="-2.041990753669305" LOG_EFFECT_SIZE="-1.1903316981702914" NO="2" P_CHI2="1.0" P_Z="0.00615574953882173" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="30" WEIGHT="99.99999999999999" Z="2.7393676413188515">
<NAME>depression</NAME>
<DICH_DATA CI_END="0.45848734963950455" CI_START="0.009078398583035482" EFFECT_SIZE="0.06451612903225806" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="15" LOG_CI_END="-0.3386726426712779" LOG_CI_START="-2.041990753669305" LOG_EFFECT_SIZE="-1.1903316981702914" ORDER="1831" O_E="0.0" SE="1.000537489960873" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="1.0010752688172042" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.33390808704894" CI_START="0.551442622615033" DF="0.0" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-002.07.03" LOG_CI_END="1.054379686384768" LOG_CI_START="-0.25849966904069305" LOG_EFFECT_SIZE="0.3979400086720376" NO="3" P_CHI2="1.0" P_Z="0.2347747706017861" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="1.188148906114827">
<NAME>euphoria</NAME>
<DICH_DATA CI_END="11.333908087048945" CI_START="0.551442622615033" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0543796863847683" LOG_CI_START="-0.25849966904069305" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="1832" O_E="0.0" SE="0.7711918322345376" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.5947368421052632" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.025905120888739" CI_END="12.728033330480006" CI_START="0.07281844971033548" DF="1.0" EFFECT_SIZE="0.9627230416828259" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="75.16086519745788" ID="CMP-002.07.04" LOG_CI_END="1.1047613039126132" LOG_CI_START="-1.1377585713429377" LOG_EFFECT_SIZE="-0.016498633715162293" NO="4" P_CHI2="0.04480665583023302" P_Z="0.9769924894747477" STUDIES="2" TAU2="2.624915814455176" TOTAL_1="57" TOTAL_2="57" WEIGHT="100.0" Z="0.028839635476721373">
<NAME>irritability</NAME>
<DICH_DATA CI_END="32.56722412436301" CI_START="0.4912914879973039" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5127807429416706" LOG_CI_START="-0.3086607602857459" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="1833" O_E="0.0" SE="1.069923755276638" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="1.1447368421052633" WEIGHT="39.85868572826641"/>
<DICH_DATA CI_END="1.2878854498980923" CI_START="0.06338502625965989" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.1098772367120567" LOG_CI_START="-1.198013325412608" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="1834" O_E="0.0" SE="0.7682613903547245" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="0.5902255639097744" WEIGHT="60.1413142717336"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.08" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Mental state: 2. Scale endpoint data (skewed, high score=poor)</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_SUBGROUP ID="CMP-002.08.01" NO="1" STUDIES="1">
<NAME>BPRS</NAME>
<OTHER_DATA ORDER="1835" STUDY_ID="STD-Rama-Rao-1981">
<TR>
<TD>
<P>1. Sulpiride: mean 12.08, SD 9.16, N=13.<BR/>2. Haloperidol: mean 11.93, SD 7.03, N=14.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.08.02" NO="2" STUDIES="1">
<NAME>CPRS</NAME>
<OTHER_DATA ORDER="1836" STUDY_ID="STD-Wiesel-1984">
<TR>
<TD>
<P>1. Sulpiride: mean 0.90, SD 0.57, N=19.<BR/>2. Chlorpromazine: mean 1.20, SD 0.64, N=18.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.09" NO="9" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 3. Negative symptom endpoint data (CPRS-10, skewed, high score=poor)</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="1837" STUDY_ID="STD-Wiesel-1984">
<TR>
<TD>
<P>1. Sulpiride: mean 1.9, SD 2.14, N=19.<BR/>2. Chlorpromazine: mean 2.7, SD 2.64, N=17.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.10" NO="10" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 4. Positive symptom endpoint data (?, skewed, high score=poor)</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="1838" STUDY_ID="STD-Wiesel-1984">
<TR>
<TD>
<P>1. Sulpiride: mean 1.3, SD 1.57, N=19.<BR/>2. Chlorpromazine: mean 2.21, SD 2.35, N=17.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5623477480712817" CI_START="0.025602494738690536" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.1937777057638096" LOG_CI_START="-1.5917177144358472" LOG_EFFECT_SIZE="-0.6989700043360187" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.12489714589710033" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.5345388392194383">
<NAME>Behaviour: 1. No overall improvement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="1.5623477480712817" CI_START="0.025602494738690536" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1937777057638096" LOG_CI_START="-1.5917177144358472" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="1839" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Taverna-1972" TOTAL_1="20" TOTAL_2="20" VAR="1.0999999999999999" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.639055443748074" CI_END="1.810051264966586" CI_START="0.5061473234949543" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9571586091925904" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="54" I2="61.634511613688396" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.25769087529836365" LOG_CI_START="-0.295723055356896" LOG_EFFECT_SIZE="-0.019016090029266127" METHOD="MH" NO="12" P_CHI2="0.015828187111015857" P_Q="0.0" P_Z="0.8928535784220053" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.411051806407773" TOTALS="SUB" TOTAL_1="191" TOTAL_2="191" WEIGHT="300.0" Z="0.1346943021112714">
<NAME>Behaviour: 2. Specific symptoms</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours other drug</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.590785725357225" CI_END="18.033372921793692" CI_START="0.12154426882634636" DF="1.0" EFFECT_SIZE="1.4804908396380736" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" I2="82.11342646411109" ID="CMP-002.12.01" LOG_CI_END="1.2560769637897355" LOG_CI_START="-0.9152655146139318" LOG_EFFECT_SIZE="0.1704057245879019" NO="1" P_CHI2="0.018055313064340717" P_Z="0.7583610586488616" STUDIES="2" TAU2="2.7257303106604227" TOTAL_1="50" TOTAL_2="49" WEIGHT="100.0" Z="0.3076337208649666">
<NAME>agitation</NAME>
<DICH_DATA CI_END="45.19567399906184" CI_START="0.796536411886396" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6550968673722677" LOG_CI_START="-0.09879436660498032" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="1840" O_E="0.0" SE="1.0302443927398635" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="1.06140350877193" WEIGHT="26.728293290667875"/>
<DICH_DATA CI_END="1.0351304797235055" CI_START="0.25734840501537704" EFFECT_SIZE="0.5161290322580645" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.014995096703383766" LOG_CI_START="-0.5894785190600795" LOG_EFFECT_SIZE="-0.2872417111783479" ORDER="1841" O_E="0.0" SE="0.35507079409211384" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.1260752688172043" WEIGHT="73.27170670933212"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.028664035311476" CI_START="0.6907845636058596" DF="0.0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-002.12.06" LOG_CI_END="1.1148998852568432" LOG_CI_START="-0.16065737581751863" LOG_EFFECT_SIZE="0.4771212547196624" NO="6" P_CHI2="1.0" P_Z="0.14258123407873372" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="1.4662461718440771">
<NAME>restlessness</NAME>
<DICH_DATA CI_END="13.028664035311476" CI_START="0.6907845636058596" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1148998852568432" LOG_CI_START="-0.16065737581751863" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1842" O_E="0.0" SE="0.7492686492653552" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.5614035087719298" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.619037662051272" CI_END="1.5594253864998233" CI_START="0.3720784394165333" DF="3.0" EFFECT_SIZE="0.7617273555514326" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="36" I2="54.67619081245286" ID="CMP-002.12.07" LOG_CI_END="0.19296459999306054" LOG_CI_START="-0.42936549502473137" LOG_EFFECT_SIZE="-0.11820044751583539" NO="7" P_CHI2="0.0850845297670656" P_Z="0.4565619153196495" STUDIES="4" TAU2="0.2788981960747075" TOTAL_1="122" TOTAL_2="123" WEIGHT="99.99999999999999" Z="0.744520060791632">
<NAME>weakness</NAME>
<DICH_DATA CI_END="4.327688235798439" CI_START="0.71959593240813" EFFECT_SIZE="1.7647058823529411" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6362559668976686" LOG_CI_START="-0.14291130021489162" LOG_EFFECT_SIZE="0.2466723333413885" ORDER="1843" O_E="0.0" SE="0.45768670964209407" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.2094771241830065" WEIGHT="27.34329065607554"/>
<DICH_DATA CI_END="6.3849287248835696" CI_START="0.15661881958098683" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8051560535865078" LOG_CI_START="-0.8051560535865078" LOG_EFFECT_SIZE="0.0" ORDER="1844" O_E="0.0" SE="0.9459053029269173" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.8947368421052633" WEIGHT="12.99391209210532"/>
<DICH_DATA CI_END="0.8211439747322874" CI_START="0.19337398560837057" EFFECT_SIZE="0.3984819734345351" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="-0.08558068947027579" LOG_CI_START="-0.7136019514869789" LOG_EFFECT_SIZE="-0.39959132047862733" ORDER="1845" O_E="0.0" SE="0.36890279806399573" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.1360892744194452" WEIGHT="31.010837065998917"/>
<DICH_DATA CI_END="1.465466943330091" CI_START="0.27633422884704056" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.16597602646517498" LOG_CI_START="-0.5585653167531114" LOG_EFFECT_SIZE="-0.19629464514396822" ORDER="1846" O_E="0.0" SE="0.4255991715439133" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="0.18113465481886534" WEIGHT="28.65196018582022"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.647228958335972" CI_END="1.3688217430618481" CI_START="0.7550740719436786" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0166424186009324" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="75" I2="17.074633197262678" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="0.1363468951426158" LOG_CI_START="-0.12201044246554268" LOG_EFFECT_SIZE="0.007168226338536568" METHOD="MH" NO="13" P_CHI2="0.29066387509674707" P_Q="0.0" P_Z="0.913392891238588" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.034883454428831" TOTALS="SUB" TOTAL_1="265" TOTAL_2="260" WEIGHT="199.99999999999997" Z="0.10875994919773789">
<NAME>Behaviour: 3. Use of additional medication</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours other drug</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.61832660899981" CI_END="1.6145511456405273" CI_START="0.8468703630366967" DF="5.0" EFFECT_SIZE="1.1693226735379367" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="53" I2="11.005529796173358" ID="CMP-002.13.01" LOG_CI_END="0.20805180712192078" LOG_CI_START="-0.07218306537977462" LOG_EFFECT_SIZE="0.06793437087107314" NO="1" P_CHI2="0.3451454296396054" P_Z="0.3419768154221531" STUDIES="6" TAU2="0.018283856796240183" TOTAL_1="177" TOTAL_2="178" WEIGHT="99.99999999999999" Z="0.9502666033748861">
<NAME>hypnotics/ sedatives</NAME>
<DICH_DATA CI_END="2.0411555322016333" CI_START="0.3234228061435091" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.3098760983973021" LOG_CI_START="-0.49022935909547816" LOG_EFFECT_SIZE="-0.09017663034908802" ORDER="1847" O_E="0.0" SE="0.4699859063171492" STUDY_ID="STD-Bratfos-1979" TOTAL_1="32" TOTAL_2="39" VAR="0.22088675213675216" WEIGHT="11.885245140874183"/>
<DICH_DATA CI_END="1.7421083646806332" CI_START="0.4863282832599515" EFFECT_SIZE="0.9204545454545454" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.241075166009815" LOG_CI_START="-0.31307047255285275" LOG_EFFECT_SIZE="-0.035997653271518895" ORDER="1848" O_E="0.0" SE="0.3255078911568615" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="0.10595538720538722" WEIGHT="21.58418494138914"/>
<DICH_DATA CI_END="1.856856550213263" CI_START="0.27476763435175183" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.26877835400515887" LOG_CI_START="-0.5610344253616348" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="1849" O_E="0.0" SE="0.48743613423955967" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.23759398496240602" WEIGHT="11.156489181473667"/>
<DICH_DATA CI_END="2.275192930281422" CI_START="0.5927388378235904" EFFECT_SIZE="1.1612903225806452" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.3570182295663138" LOG_CI_START="-0.22713661570028448" LOG_EFFECT_SIZE="0.06494080693301461" ORDER="1850" O_E="0.0" SE="0.34313544772271926" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.11774193548387099" WEIGHT="19.917338828767132"/>
<DICH_DATA CI_END="2.6247872571743813" CI_START="0.9017355211764495" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.41909410896886157" LOG_CI_START="-0.04492082225457267" LOG_EFFECT_SIZE="0.18708664335714445" ORDER="1851" O_E="0.0" SE="0.27256466751159897" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="0.0742914979757085" WEIGHT="27.84422193746323"/>
<DICH_DATA CI_END="9.794563998967693" CI_START="0.9188770425052671" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9909851083188251" LOG_CI_START="-0.03674259887950042" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1852" O_E="0.0" SE="0.6036923425424945" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.36444444444444446" WEIGHT="7.612519970032636"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8589823809414918" CI_END="1.152023403312477" CI_START="0.38567536153354626" DF="2.0" EFFECT_SIZE="0.666563607293142" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" I2="0.0" ID="CMP-002.13.02" LOG_CI_END="0.06146130185301475" LOG_CI_START="-0.4137781046958105" LOG_EFFECT_SIZE="-0.1761584014213978" NO="2" P_CHI2="0.6508401837888811" P_Z="0.14622060677588503" STUDIES="3" TAU2="0.0" TOTAL_1="88" TOTAL_2="82" WEIGHT="99.99999999999999" Z="1.4530113353494287">
<NAME>other</NAME>
<DICH_DATA CI_END="1.3669326736011849" CI_START="0.3616745544040169" EFFECT_SIZE="0.703125" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.13574712451401438" LOG_CI_START="-0.44168204493110136" LOG_EFFECT_SIZE="-0.1529674602085435" ORDER="1853" O_E="0.0" SE="0.3391847524525481" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="0.11504629629629631" WEIGHT="63.380396093948875"/>
<DICH_DATA CI_END="1.4561822967780442" CI_START="0.1181271712731724" EFFECT_SIZE="0.4147465437788018" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.16321574690625118" LOG_CI_START="-0.9276501957246605" LOG_EFFECT_SIZE="-0.3822172244092047" ORDER="1854" O_E="0.0" SE="0.6407800545749016" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.41059907834101383" WEIGHT="21.33104283156044"/>
<DICH_DATA CI_END="4.487151628279848" CI_START="0.222858526486512" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6519707453103448" LOG_CI_START="-0.6519707453103449" LOG_EFFECT_SIZE="0.0" ORDER="1855" O_E="0.0" SE="0.7659416862050704" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.5866666666666666" WEIGHT="15.288561074490673"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.442191028383363" CI_END="0.994206629725204" CI_START="0.6471369670703455" CI_STUDY="95" CI_TOTAL="95" DF="24.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8021146196159241" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="118" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="-0.0025233451565120075" LOG_CI_START="-0.18900379081895632" LOG_EFFECT_SIZE="-0.09576356798773414" METHOD="MH" NO="14" P_CHI2="0.4938362256502048" P_Q="0.0" P_Z="0.044113979773915256" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="753" TOTAL_2="748" WEIGHT="400.0" Z="2.0130061746716614">
<NAME>Behaviour: 4. Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="5.8531468882598885" CI_END="1.0777590988717514" CI_START="0.6613080731953087" DF="7.0" EFFECT_SIZE="0.8442338497380866" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="68" I2="0.0" ID="CMP-002.14.01" LOG_CI_END="0.03252169802846588" LOG_CI_START="-0.17959617543185313" LOG_EFFECT_SIZE="-0.07353723870169361" NO="1" P_CHI2="0.5569978771783104" P_Z="0.17415780997931746" STUDIES="10" TAU2="0.0" TOTAL_1="278" TOTAL_2="283" WEIGHT="100.0" Z="1.3589645891373416">
<NAME>any reason</NAME>
<DICH_DATA CI_END="3.306385290395756" CI_START="0.46151655753064935" EFFECT_SIZE="1.2352941176470589" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5193534601679887" LOG_CI_START="-0.335812713456698" LOG_EFFECT_SIZE="0.09177037335564536" ORDER="1856" O_E="0.0" SE="0.5023288435279716" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.2523342670401494" WEIGHT="6.152526618595546"/>
<DICH_DATA CI_END="4.024534250335345" CI_START="0.3980104382243807" EFFECT_SIZE="1.265625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6047156277565304" LOG_CI_START="-0.40010553796700515" LOG_EFFECT_SIZE="0.10230504489476258" ORDER="1857" O_E="0.0" SE="0.5902369266909938" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="0.3483796296296296" WEIGHT="4.456326267981877"/>
<DICH_DATA CI_END="20.24371955945401" CI_START="0.19759214645571213" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3062903123047387" LOG_CI_START="-0.7042303209767762" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="1858" O_E="0.0" SE="1.180989772227204" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="1.3947368421052633" WEIGHT="1.1131084000082263"/>
<DICH_DATA CI_END="1.1562752487768968" CI_START="0.23542121178740744" EFFECT_SIZE="0.5217391304347826" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.06306122923660967" LOG_CI_START="-0.6281544091765459" LOG_EFFECT_SIZE="-0.28254658996996806" ORDER="1859" O_E="0.0" SE="0.40602348757648016" STUDY_ID="STD-Lepola-1989" TOTAL_1="23" TOTAL_2="24" VAR="0.16485507246376813" WEIGHT="9.417321963748025"/>
<DICH_DATA CI_END="1.0302925471402926" CI_START="0.2272472164079782" EFFECT_SIZE="0.4838709677419355" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.012960558267443136" LOG_CI_START="-0.643501427824626" LOG_EFFECT_SIZE="-0.3152704347785914" ORDER="1860" O_E="0.0" SE="0.3856090201697205" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.14869431643625192" WEIGHT="10.440838170259852"/>
<DICH_DATA CI_END="1.2665776463928629" CI_START="0.6779244565943294" EFFECT_SIZE="0.9266304347826086" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.10263181897165875" LOG_CI_START="-0.1688186983336987" LOG_EFFECT_SIZE="-0.03309343968101996" ORDER="1861" O_E="0.0" SE="0.15945137756689856" STUDY_ID="STD-Nishikawa-1989" TOTAL_1="32" TOTAL_2="31" VAR="0.02542474180798164" WEIGHT="61.062303266377256"/>
<DICH_DATA CI_END="7.933315337564284" CI_START="0.014005634010915893" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8994547171933125" LOG_CI_START="-1.8536972266326377" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="1862" O_E="0.0" SE="1.6172150801252798" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="2.6153846153846154" WEIGHT="0.5936003774037678"/>
<DICH_DATA CI_END="2.19205941209886" CI_START="0.3351614803394235" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.34085232079637595" LOG_CI_START="-0.4747459000576024" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="1863" O_E="0.0" SE="0.4790864322059325" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.22952380952380955" WEIGHT="6.763974935625442"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1864" O_E="0.0" SE="0.0" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1865" O_E="0.0" SE="0.0" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.328020341123734" CI_END="1.4358902488316472" CI_START="0.15289769575541184" DF="5.0" EFFECT_SIZE="0.4685555574358539" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" I2="20.986347538950916" ID="CMP-002.14.02" LOG_CI_END="0.15712124620966264" LOG_CI_START="-0.8155990595729659" LOG_EFFECT_SIZE="-0.3292389066816516" NO="2" P_CHI2="0.2755967042087054" P_Z="0.18457910354406265" STUDIES="6" TAU2="0.4136317542711222" TOTAL_1="181" TOTAL_2="175" WEIGHT="100.0" Z="1.3267871464576662">
<NAME>due to adverse effects</NAME>
<DICH_DATA CI_END="60.042390771014624" CI_START="0.10791273897945941" EFFECT_SIZE="2.5454545454545454" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.778457976675619" LOG_CI_START="-0.966927284307631" LOG_EFFECT_SIZE="0.4057653461839942" ORDER="1866" O_E="0.0" SE="1.6126528921777776" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="2.6006493506493507" WEIGHT="8.913057604188724"/>
<DICH_DATA CI_END="8.112670492455225" CI_START="0.014861107907323728" EFFECT_SIZE="0.3472222222222222" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9091638368536604" LOG_CI_START="-1.8279488123721221" LOG_EFFECT_SIZE="-0.45939248775923086" ORDER="1867" O_E="0.0" SE="1.6077935190813526" STUDY_ID="STD-Lepola-1989" TOTAL_1="23" TOTAL_2="24" VAR="2.585" WEIGHT="8.967016429645518"/>
<DICH_DATA CI_END="1.5609628568553289" CI_START="0.02399863519060957" EFFECT_SIZE="0.1935483870967742" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1933925691388498" LOG_CI_START="-1.6198134560401078" LOG_EFFECT_SIZE="-0.713210443450629" ORDER="1868" O_E="0.0" SE="1.0650861947046997" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="1.1344086021505375" WEIGHT="20.43332307837849"/>
<DICH_DATA CI_END="0.9181002294344671" CI_START="0.05047871694083514" EFFECT_SIZE="0.2152777777777778" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.03710990407742724" LOG_CI_START="-1.2968916924445268" LOG_EFFECT_SIZE="-0.6670007982609769" ORDER="1869" O_E="0.0" SE="0.74000205850726" STUDY_ID="STD-Nishikawa-1989" TOTAL_1="32" TOTAL_2="31" VAR="0.5476030465949822" WEIGHT="42.32945308607431"/>
<DICH_DATA CI_END="7.933315337564284" CI_START="0.014005634010915893" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8994547171933125" LOG_CI_START="-1.8536972266326377" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="1870" O_E="0.0" SE="1.6172150801252798" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="2.6153846153846154" WEIGHT="8.862840797595222"/>
<DICH_DATA CI_END="128.87064248425733" CI_START="0.3802262412557286" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1101539936976934" LOG_CI_START="-0.4199579136691801" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="1871" O_E="0.0" SE="1.4862002586432317" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="2.208791208791209" WEIGHT="10.494309004117728"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3913368263592565" CI_END="1.5489964485705001" CI_START="0.4725130253453509" DF="5.0" EFFECT_SIZE="0.855523815076618" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" I2="0.0" ID="CMP-002.14.03" LOG_CI_END="0.19005042204067613" LOG_CI_START="-0.3255862151808736" LOG_EFFECT_SIZE="-0.06776789657009874" NO="3" P_CHI2="0.9252585952071726" P_Z="0.6064278005522248" STUDIES="6" TAU2="0.0" TOTAL_1="164" TOTAL_2="161" WEIGHT="100.0" Z="0.5151792056558621">
<NAME>due to deterioration or inefficacy</NAME>
<DICH_DATA CI_END="2.4565799847127856" CI_START="0.16429288621927052" EFFECT_SIZE="0.6352941176470588" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.39033090905862283" LOG_CI_START="-0.7843812408412713" LOG_EFFECT_SIZE="-0.19702516589132427" ORDER="1872" O_E="0.0" SE="0.6900317317701217" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.4761437908496732" WEIGHT="19.267466547518175"/>
<DICH_DATA CI_END="3.5401445607129314" CI_START="0.3142147738826339" EFFECT_SIZE="1.0546875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.54902099666931" LOG_CI_START="-0.5027733989750345" LOG_EFFECT_SIZE="0.02312379884713775" ORDER="1873" O_E="0.0" SE="0.6178292344677152" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="0.381712962962963" WEIGHT="24.0339874517039"/>
<DICH_DATA CI_END="14.848212018999854" CI_START="0.06734817624643254" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1716741602503453" LOG_CI_START="-1.1716741602503453" LOG_EFFECT_SIZE="0.0" ORDER="1874" O_E="0.0" SE="1.3764944032233706" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="1.8947368421052633" WEIGHT="4.841877963280189"/>
<DICH_DATA CI_END="2.4600162207487126" CI_START="0.3073734477517599" EFFECT_SIZE="0.8695652173913043" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.39093797074501857" LOG_CI_START="-0.5123336514522421" LOG_EFFECT_SIZE="-0.0606978403536117" ORDER="1875" O_E="0.0" SE="0.5305862221453124" STUDY_ID="STD-Lepola-1989" TOTAL_1="23" TOTAL_2="24" VAR="0.2815217391304348" WEIGHT="32.587481841869504"/>
<DICH_DATA CI_END="8.08502074838146" CI_START="0.26062765778720987" EFFECT_SIZE="1.4516129032258065" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9076811387626443" LOG_CI_START="-0.5839794988805023" LOG_EFFECT_SIZE="0.161850819941071" ORDER="1876" O_E="0.0" SE="0.8762088423908257" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.7677419354838709" WEIGHT="11.9494378748799"/>
<DICH_DATA CI_END="2.991018184415158" CI_START="0.037148256633831506" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4758190534081663" LOG_CI_START="-1.4300615628474913" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="1877" O_E="0.0" SE="1.1195237082497775" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="1.2533333333333332" WEIGHT="7.319748320748326"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.46891505633271" CI_END="2.9609689088870716" CI_START="0.15740459469880913" DF="4.0" EFFECT_SIZE="0.6826932774087823" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" I2="46.44469819470636" ID="CMP-002.14.04" LOG_CI_END="0.4714338471833984" LOG_CI_START="-0.8029825945740665" LOG_EFFECT_SIZE="-0.16577437369533407" NO="4" P_CHI2="0.11308793722896149" P_Z="0.6101222604119394" STUDIES="5" TAU2="1.2664773597522772" TOTAL_1="130" TOTAL_2="129" WEIGHT="99.99999999999999" Z="0.509898948815309">
<NAME>due to reasons not clearly linked with medication</NAME>
<DICH_DATA CI_END="69.31319328145675" CI_START="0.1298454099994229" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8408159073966481" LOG_CI_START="-0.8865733979573234" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1878" O_E="0.0" SE="1.6020819787597222" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="2.566666666666667" WEIGHT="10.490308593492216"/>
<DICH_DATA CI_END="1.6529853378273163" CI_START="0.02634861558635608" EFFECT_SIZE="0.20869565217391303" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.21826900134583932" LOG_CI_START="-1.5792421986298506" LOG_EFFECT_SIZE="-0.6804865986420057" ORDER="1879" O_E="0.0" SE="1.0558669766896625" STUDY_ID="STD-Lepola-1989" TOTAL_1="23" TOTAL_2="24" VAR="1.114855072463768" WEIGHT="24.151233693954783"/>
<DICH_DATA CI_END="1.9169132528220114" CI_START="0.006044159997421835" EFFECT_SIZE="0.1076388888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2826024599447575" LOG_CI_START="-2.218664047794674" LOG_EFFECT_SIZE="-0.9680307939249582" ORDER="1880" O_E="0.0" SE="1.469256328115041" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="2.1587141577060933" WEIGHT="12.472760830259576"/>
<DICH_DATA CI_END="185.12896813273923" CI_START="0.6145865713257692" EFFECT_SIZE="10.666666666666666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.26747438048096" LOG_CI_START="-0.21141693328047306" LOG_EFFECT_SIZE="1.0280287236002434" ORDER="1881" O_E="0.0" SE="1.4561130284133685" STUDY_ID="STD-Nishikawa-1989" TOTAL_1="32" TOTAL_2="31" VAR="2.1202651515151514" WEIGHT="12.698942568915276"/>
<DICH_DATA CI_END="2.4871873228737886" CI_START="0.10051514725120933" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.39570849545360154" LOG_CI_START="-0.9977684867815639" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1882" O_E="0.0" SE="0.818535277187245" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.6699999999999999" WEIGHT="40.186754313378145"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.15" NO="15" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Behaviour: 5. Wing endpoint score (skewed data, high=poor)</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="1883" STUDY_ID="STD-Rama-Rao-1981">
<TR>
<TD>
<P>1. Sulpiride: mean 6.27, SD 5.00, N=15.<BR/>2. Haloperidol: mean 5.00, SD 3.99, N=15.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="31.935694442003772" CI_END="0.9065585980748181" CI_START="0.6354097288492598" CI_STUDY="95" CI_TOTAL="95" DF="30.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7589704559392845" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="228" I2="6.0612254589267005" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="-0.04260411876312633" LOG_CI_START="-0.1969461399130224" LOG_EFFECT_SIZE="-0.11977512933807434" METHOD="MH" NO="16" P_CHI2="0.37052420617730386" P_Q="0.0" P_Z="0.002350045538117656" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.015098592773938898" TOTALS="SUB" TOTAL_1="779" TOTAL_2="846" WEIGHT="600.0" Z="3.042009402199807">
<NAME>Side-effects: 1. Movement disorders</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours other drug</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.2479494782497" CI_END="1.3103626761535558" CI_START="0.38713306712204254" DF="7.0" EFFECT_SIZE="0.7122392307796404" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="51" I2="42.84757613973814" ID="CMP-002.16.01" LOG_CI_END="0.11739151432216975" LOG_CI_START="-0.4121397316639991" LOG_EFFECT_SIZE="-0.14737410867091466" NO="1" P_CHI2="0.09269420750540158" P_Z="0.2752917619323836" STUDIES="8" TAU2="0.27677040178981377" TOTAL_1="211" TOTAL_2="221" WEIGHT="100.0" Z="1.090957134024267">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="2.548729581138765" CI_START="0.6334114358834857" EFFECT_SIZE="1.2705882352941176" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.4063237594985916" LOG_CI_START="-0.19831409995327764" LOG_EFFECT_SIZE="0.10400482977265695" ORDER="1884" O_E="0.0" SE="0.3551672716477029" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.1261437908496732" WEIGHT="30.91434485268477"/>
<DICH_DATA CI_END="6.008485209007517" CI_START="0.46230916464827443" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7787649964138754" LOG_CI_START="-0.33506749718116263" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="1885" O_E="0.0" SE="0.6542707202974901" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.4280701754385965" WEIGHT="9.852715417575387"/>
<DICH_DATA CI_END="0.8809707796149677" CI_START="0.20347625354069665" EFFECT_SIZE="0.42338709677419356" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="-0.0550384961991143" LOG_CI_START="-0.691486267313442" LOG_EFFECT_SIZE="-0.3732623817562782" ORDER="1886" O_E="0.0" SE="0.37385257121983323" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.1397657450076805" WEIGHT="28.195101710974953"/>
<DICH_DATA CI_END="1.2804065064867485" CI_START="0.004621313413620057" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.10734787237939855" LOG_CI_START="-2.3352345769930722" LOG_EFFECT_SIZE="-1.1139433523068367" ORDER="1887" O_E="0.0" SE="1.4347850217395144" STUDY_ID="STD-Taverna-1972" TOTAL_1="20" TOTAL_2="20" VAR="2.058608058608059" WEIGHT="2.105609176806948"/>
<DICH_DATA CI_END="1.3190879950675423" CI_START="0.021058320507537826" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.12027376787204506" LOG_CI_START="-1.6765762686393322" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="1888" O_E="0.0" SE="1.0554786059979133" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="1.1140350877192982" WEIGHT="3.867049429654927"/>
<DICH_DATA CI_END="2.0461619092514605" CI_START="0.37417615709603624" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3109399957067384" LOG_CI_START="-0.426923889662112" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="1889" O_E="0.0" SE="0.43342489875080187" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.18785714285714283" WEIGHT="21.51412839641298"/>
<DICH_DATA CI_END="70.4183669275211" CI_START="0.12780756488237427" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8476859491268096" LOG_CI_START="-0.8934434396874851" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1890" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="1.674437440927963"/>
<DICH_DATA CI_END="5.802456357303471" CI_START="0.014971212318527998" EFFECT_SIZE="0.29473684210526313" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.7636118826301428" LOG_CI_START="-1.8247430305233998" LOG_EFFECT_SIZE="-0.5305655739466286" ORDER="1891" O_E="0.0" SE="1.5204124885498493" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="2.3116541353383457" WEIGHT="1.8766135749620687"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4150342122774512" CI_END="0.9602341269664382" CI_START="0.2678668512679302" DF="2.0" EFFECT_SIZE="0.5071635752600039" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="20" I2="0.0" ID="CMP-002.16.02" LOG_CI_END="-0.017622863155614475" LOG_CI_START="-0.5720810273479713" LOG_EFFECT_SIZE="-0.2948519452517929" NO="2" P_CHI2="0.8125994340895933" P_Z="0.03710973767064657" STUDIES="3" TAU2="0.0" TOTAL_1="68" TOTAL_2="76" WEIGHT="100.0" Z="2.084554726710096">
<NAME>dyskinesia</NAME>
<DICH_DATA CI_END="2.9080662948391867" CI_START="0.1934275023228471" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4636043028591656" LOG_CI_START="-0.7134817760757655" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="1892" O_E="0.0" SE="0.6914261894364405" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.4780701754385965" WEIGHT="23.30324820285505"/>
<DICH_DATA CI_END="0.9499457492768423" CI_START="0.21470090741003287" EFFECT_SIZE="0.45161290322580644" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.0223011962505878" LOG_CI_START="-0.6681661200614816" LOG_EFFECT_SIZE="-0.3452336581560347" ORDER="1893" O_E="0.0" SE="0.37938425332945375" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.14393241167434714" WEIGHT="72.26536895382641"/>
<DICH_DATA CI_END="11.43063346688383" CI_START="0.021110380070131763" EFFECT_SIZE="0.49122807017543857" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.058070298947239" LOG_CI_START="-1.6755039476077833" LOG_EFFECT_SIZE="-0.3087168243302722" ORDER="1894" O_E="0.0" SE="1.6057150438371723" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="2.5783208020050123" WEIGHT="4.431382843318542"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.5266929176324684" CI_END="1.1171199283209414" CI_START="0.4216759908198741" DF="5.0" EFFECT_SIZE="0.6863400415532812" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="31" I2="0.0" ID="CMP-002.16.03" LOG_CI_END="0.048099799267946323" LOG_CI_START="-0.3750211259267616" LOG_EFFECT_SIZE="-0.16346066332940765" NO="3" P_CHI2="0.6193526934659682" P_Z="0.12993658243250406" STUDIES="6" TAU2="0.0" TOTAL_1="146" TOTAL_2="161" WEIGHT="100.0" Z="1.5143520158793278">
<NAME>dystonic reactions</NAME>
<DICH_DATA CI_END="18.726249146925504" CI_START="0.0793192246266715" EFFECT_SIZE="1.21875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2724507972405346" LOG_CI_START="-1.1006215398273484" LOG_EFFECT_SIZE="0.08591462870659322" ORDER="1895" O_E="0.0" SE="1.3939544376911945" STUDY_ID="STD-Bratfos-1979" TOTAL_1="32" TOTAL_2="39" VAR="1.9431089743589745" WEIGHT="3.3795244750007223"/>
<DICH_DATA CI_END="3.549880408511372" CI_START="0.12519983585329295" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5502137224076437" LOG_CI_START="-0.9023962405190062" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1896" O_E="0.0" SE="0.853270282758398" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.7280701754385965" WEIGHT="8.904855375145024"/>
<DICH_DATA CI_END="0.9499457492768423" CI_START="0.21470090741003287" EFFECT_SIZE="0.45161290322580644" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.0223011962505878" LOG_CI_START="-0.6681661200614816" LOG_EFFECT_SIZE="-0.3452336581560347" ORDER="1897" O_E="0.0" SE="0.37938425332945375" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.14393241167434714" WEIGHT="41.61333460236863"/>
<DICH_DATA CI_END="2.180121527093581" CI_START="0.16512840936896409" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3384807032720784" LOG_CI_START="-0.7821782025047912" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="1898" O_E="0.0" SE="0.6582805886043833" STUDY_ID="STD-Taverna-1972" TOTAL_1="20" TOTAL_2="20" VAR="0.43333333333333335" WEIGHT="14.757670038582877"/>
<DICH_DATA CI_END="3.306657646683361" CI_START="0.5376358751747167" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5193892327567986" LOG_CI_START="-0.26951175954019874" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="1899" O_E="0.0" SE="0.46340434799814917" STUDY_ID="STD-Toru-1972" TOTAL_1="26" TOTAL_2="26" VAR="0.21474358974358973" WEIGHT="28.792845280924887"/>
<DICH_DATA CI_END="11.43063346688383" CI_START="0.021110380070131763" EFFECT_SIZE="0.49122807017543857" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.058070298947239" LOG_CI_START="-1.6755039476077833" LOG_EFFECT_SIZE="-0.3087168243302722" ORDER="1900" O_E="0.0" SE="1.6057150438371723" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="2.5783208020050123" WEIGHT="2.551770227977865"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.081952234116198" CI_END="1.1541621307575158" CI_START="0.6656827725037389" DF="6.0" EFFECT_SIZE="0.8765305739798732" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="70" I2="1.3474659280698333" ID="CMP-002.16.04" LOG_CI_END="0.06226682055932436" LOG_CI_START="-0.17673268220016167" LOG_EFFECT_SIZE="-0.057232930820418644" NO="4" P_CHI2="0.41407283887161206" P_Z="0.3478845188494336" STUDIES="7" TAU2="0.002055095079889825" TOTAL_1="193" TOTAL_2="211" WEIGHT="100.0" Z="0.9387005566331934">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="6.642492748325587" CI_START="0.6848165790324596" EFFECT_SIZE="2.1328125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.8223310889590331" LOG_CI_START="-0.16442573417325776" LOG_EFFECT_SIZE="0.3289526773928877" ORDER="1901" O_E="0.0" SE="0.5796258424329588" STUDY_ID="STD-Bratfos-1979" TOTAL_1="32" TOTAL_2="39" VAR="0.3359661172161172" WEIGHT="6.448013123987346"/>
<DICH_DATA CI_END="1.454492708647968" CI_START="0.5352702754532682" EFFECT_SIZE="0.8823529411764706" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.16271154847624392" LOG_CI_START="-0.2714268731214293" LOG_EFFECT_SIZE="-0.0543576623225927" ORDER="1902" O_E="0.0" SE="0.2550150578663191" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.0650326797385621" WEIGHT="28.249518401589672"/>
<DICH_DATA CI_END="2.427899066052217" CI_START="0.1029696841584531" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.38523062805078434" LOG_CI_START="-0.9872906193787466" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1903" O_E="0.0" SE="0.8062257748298549" STUDY_ID="STD-Taverna-1972" TOTAL_1="20" TOTAL_2="20" VAR="0.6499999999999999" WEIGHT="3.4035102193549447"/>
<DICH_DATA CI_END="1.4036378994250276" CI_START="0.3634869661482125" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.14725508602452012" LOG_CI_START="-0.4395111573809961" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="1904" O_E="0.0" SE="0.3446693959161489" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="0.11879699248120301" WEIGHT="16.906232218718824"/>
<DICH_DATA CI_END="1.3101453654070934" CI_START="0.503880155157343" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.11731948488607073" LOG_CI_START="-0.2976727455842467" LOG_EFFECT_SIZE="-0.09017663034908802" ORDER="1905" O_E="0.0" SE="0.24376849042293575" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.05942307692307692" WEIGHT="30.375994882939942"/>
<DICH_DATA CI_END="3.6105443967053508" CI_START="0.6231747218101354" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5575726896230815" LOG_CI_START="-0.20539017151171904" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="1906" O_E="0.0" SE="0.44816816135765475" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="0.20085470085470086" WEIGHT="10.48221964735288"/>
<DICH_DATA CI_END="1.5671881498724582" CI_START="0.0897307703682193" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.1951211391272757" LOG_CI_START="-1.047058603671838" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="1907" O_E="0.0" SE="0.7296625298090943" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="0.5324074074074074" WEIGHT="4.134511506056399"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9418586473000183" CI_END="1.5466285215369775" CI_START="0.3233612671101588" DF="2.0" EFFECT_SIZE="0.7071914581447576" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" I2="32.01576826828299" ID="CMP-002.16.05" LOG_CI_END="0.18938601478546183" LOG_CI_START="-0.49031200201694625" LOG_EFFECT_SIZE="-0.15046299361574225" NO="5" P_CHI2="0.22971196466432198" P_Z="0.3855343236734776" STUDIES="3" TAU2="0.1663096670806508" TOTAL_1="68" TOTAL_2="76" WEIGHT="100.00000000000001" Z="0.8677443252822217">
<NAME>rigidity / stiffness</NAME>
<DICH_DATA CI_END="2.898107700162788" CI_START="0.345052739048942" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4621145207891526" LOG_CI_START="-0.46211452078915255" LOG_EFFECT_SIZE="0.0" ORDER="1908" O_E="0.0" SE="0.542896714030637" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.2947368421052632" WEIGHT="26.40983861227679"/>
<DICH_DATA CI_END="0.9022905894991113" CI_START="0.2594852657761735" EFFECT_SIZE="0.4838709677419355" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" LOG_CI_END="-0.044653572112469" LOG_CI_START="-0.5858872974447139" LOG_EFFECT_SIZE="-0.3152704347785914" ORDER="1909" O_E="0.0" SE="0.3179233694103098" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.1010752688172043" WEIGHT="70.43498184059804"/>
<DICH_DATA CI_END="102.87570120195453" CI_START="0.18999342063118593" EFFECT_SIZE="4.421052631578948" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.012312808386564" LOG_CI_START="-0.7212614381684584" LOG_EFFECT_SIZE="0.6455256851090527" ORDER="1910" O_E="0.0" SE="1.6057150438371723" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="2.5783208020050123" WEIGHT="3.1551795471251842"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.701877305616924" CI_END="1.3080444305130765" CI_START="0.4785877827466687" DF="3.0" EFFECT_SIZE="0.7912105179618015" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="33" I2="18.96003696697222" ID="CMP-002.16.06" LOG_CI_END="0.1166224959752056" LOG_CI_START="-0.3200383921275727" LOG_EFFECT_SIZE="-0.10170794807618352" NO="6" P_CHI2="0.295507826515941" P_Z="0.36122275176891583" STUDIES="4" TAU2="0.05167335139383381" TOTAL_1="93" TOTAL_2="101" WEIGHT="99.99999999999999" Z="0.913037648216707">
<NAME>tremor</NAME>
<DICH_DATA CI_END="3.268740668680464" CI_START="0.440536630451416" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5143804664266098" LOG_CI_START="-0.3560179743313601" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="1911" O_E="0.0" SE="0.5112763526430005" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.26140350877192986" WEIGHT="19.495212802394434"/>
<DICH_DATA CI_END="0.9592462149305652" CI_START="0.24407822494297218" EFFECT_SIZE="0.4838709677419355" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.018069905799713636" LOG_CI_START="-0.6124709637574693" LOG_EFFECT_SIZE="-0.3152704347785914" ORDER="1912" O_E="0.0" SE="0.3491541237770759" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.12190860215053764" WEIGHT="39.344410437111804"/>
<DICH_DATA CI_END="2.2592866762432777" CI_START="0.5464414561534956" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.353971341151137" LOG_CI_START="-0.26245636002978673" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="1913" O_E="0.0" SE="0.3620926830400072" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.1311111111111111" WEIGHT="36.86805435420325"/>
<DICH_DATA CI_END="4.437220362753942" CI_START="0.056341578637496045" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.6471109973331007" LOG_CI_START="-1.2491709886610631" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1914" O_E="0.0" SE="1.11388542532019" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="1.2407407407407407" WEIGHT="4.292322406290499"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.904044833467061" CI_END="0.9170236790627295" CI_START="0.5843149841401959" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7320045604282277" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="115" I2="9.128036561508443" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="-0.037619449985913406" LOG_CI_START="-0.2333529765239562" LOG_EFFECT_SIZE="-0.13548621325493482" METHOD="MH" NO="17" P_CHI2="0.35830924088419336" P_Q="0.0" P_Z="0.0066604011802521585" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.012497472772186805" TOTALS="YES" TOTAL_1="253" TOTAL_2="258" WEIGHT="100.0" Z="2.713363449564923">
<NAME>Side effects: 2. Movement disorders - use of antiparkinsonian medication</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="1.2436851960372972" CI_START="0.3774194089610362" EFFECT_SIZE="0.6851211072664359" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.09471046481980322" LOG_CI_START="-0.42317576980983684" LOG_EFFECT_SIZE="-0.16423265249501676" ORDER="1915" O_E="0.0" SE="0.3042089377996568" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.09254307783719547" WEIGHT="12.584867753236516"/>
<DICH_DATA CI_END="1.6562089428261844" CI_START="0.5044715266906604" EFFECT_SIZE="0.9140625" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.2191151253185938" LOG_CI_START="-0.2971633411220073" LOG_EFFECT_SIZE="-0.03902410790170672" ORDER="1916" O_E="0.0" SE="0.30326452680683447" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="0.09196937321937321" WEIGHT="12.653980558128676"/>
<DICH_DATA CI_END="5.169895635269663" CI_START="0.343871115240617" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7134817760757654" LOG_CI_START="-0.46360430285916565" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="1917" O_E="0.0" SE="0.6914261894364405" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.4780701754385965" WEIGHT="2.694677162196864"/>
<DICH_DATA CI_END="1.4741237394803681" CI_START="0.26498793116085095" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.16853394018380938" LOG_CI_START="-0.576773905495659" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="1918" O_E="0.0" SE="0.4377975178854566" STUDY_ID="STD-Lepola-1989" TOTAL_1="15" TOTAL_2="15" VAR="0.1916666666666667" WEIGHT="6.474797394780166"/>
<DICH_DATA CI_END="0.7270878826056673" CI_START="0.24348742836683082" EFFECT_SIZE="0.42075736325385693" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="23" LOG_CI_END="-0.13841309309694777" LOG_CI_START="-0.6135234571674585" LOG_EFFECT_SIZE="-0.37596827513220316" ORDER="1919" O_E="0.0" SE="0.2790821796892501" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.07788686302010286" WEIGHT="14.625559025892526"/>
<DICH_DATA CI_END="1.4741237394803681" CI_START="0.26498793116085095" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.16853394018380938" LOG_CI_START="-0.576773905495659" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="1920" O_E="0.0" SE="0.4377975178854566" STUDY_ID="STD-Rama-Rao-1981" TOTAL_1="15" TOTAL_2="15" VAR="0.1916666666666667" WEIGHT="6.474797394780166"/>
<DICH_DATA CI_END="1.0834290693444453" CI_START="0.5805761516512221" EFFECT_SIZE="0.7931034482758621" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="29" LOG_CI_END="0.03480048390626823" LOG_CI_START="-0.2361408076689946" LOG_EFFECT_SIZE="-0.10067016188136318" ORDER="1921" O_E="0.0" SE="0.15915225585233297" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="0.025329440542886453" WEIGHT="34.94658491258562"/>
<DICH_DATA CI_END="20.6706293264143" CI_START="0.1935112829336326" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3153536991153598" LOG_CI_START="-0.7132937077873972" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="1922" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="0.9228089146908055"/>
<DICH_DATA CI_END="3.6105443967053508" CI_START="0.6231747218101354" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5575726896230815" LOG_CI_START="-0.20539017151171904" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="1923" O_E="0.0" SE="0.44816816135765475" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="0.20085470085470086" WEIGHT="6.195959552106613"/>
<DICH_DATA CI_END="1.5671881498724582" CI_START="0.0897307703682193" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.1951211391272757" LOG_CI_START="-1.047058603671838" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="1924" O_E="0.0" SE="0.7296625298090943" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="0.5324074074074074" WEIGHT="2.4259673316020467"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="28.521008747552212" CI_END="0.7989856549277834" CI_START="0.578357512666939" CI_STUDY="95" CI_TOTAL="95" DF="37.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6797789023208929" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="262" I2="0.0" I2_Q="0.0" ID="CMP-002.19" LOG_CI_END="-0.09746101798467287" LOG_CI_START="-0.2378036187080692" LOG_EFFECT_SIZE="-0.16763231834637107" METHOD="MH" NO="19" P_CHI2="0.8398355975806386" P_Q="0.0" P_Z="2.8386676619282515E-6" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1124" TOTAL_2="1150" WEIGHT="1000.0" Z="4.682160725400714">
<NAME>Side-effects: 3. Anticholinergic symptoms</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours other drug</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.4864740451812652" CI_END="0.9271174596695022" CI_START="0.37150855956435397" DF="4.0" EFFECT_SIZE="0.5868833546700569" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="37" I2="0.0" ID="CMP-002.19.01" LOG_CI_END="-0.032865240122248326" LOG_CI_START="-0.43003117563492155" LOG_EFFECT_SIZE="-0.2314482078785849" NO="1" P_CHI2="0.6470595399877135" P_Z="0.0223518125626317" STUDIES="5" TAU2="0.0" TOTAL_1="154" TOTAL_2="155" WEIGHT="100.0" Z="2.284335644963143">
<NAME>blurred vision / problems of vision</NAME>
<DICH_DATA CI_END="2.702303953726994" CI_START="0.41487089743911476" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4317341966483207" LOG_CI_START="-0.38208702919825643" LOG_EFFECT_SIZE="0.024823583725032145" ORDER="1925" O_E="0.0" SE="0.47804261654231783" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.22852474323062555" WEIGHT="23.816939820144135"/>
<DICH_DATA CI_END="0.8809707796149677" CI_START="0.20347625354069665" EFFECT_SIZE="0.42338709677419356" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="-0.0550384961991143" LOG_CI_START="-0.691486267313442" LOG_EFFECT_SIZE="-0.3732623817562782" ORDER="1926" O_E="0.0" SE="0.37385257121983323" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.1397657450076805" WEIGHT="38.94201727782874"/>
<DICH_DATA CI_END="5.284718511186434" CI_START="0.04730620930344959" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7230218597050971" LOG_CI_START="-1.3250818510330595" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1927" O_E="0.0" SE="1.2030662579644695" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="1.4473684210526314" WEIGHT="3.7604524029751385"/>
<DICH_DATA CI_END="1.2458124628441516" CI_START="0.23881657153902142" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.09545267114991443" LOG_CI_START="-0.6219355406990773" LOG_EFFECT_SIZE="-0.26324143477458145" ORDER="1928" O_E="0.0" SE="0.4213973867690182" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.17757575757575755" WEIGHT="30.65035526944439"/>
<DICH_DATA CI_END="15.149704352020958" CI_START="0.06600788878540728" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.180404157621246" LOG_CI_START="-1.180404157621246" LOG_EFFECT_SIZE="0.0" ORDER="1929" O_E="0.0" SE="1.3867504905630728" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="1.923076923076923" WEIGHT="2.830235229607604"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8243796549050353" CI_END="1.0156398228138332" CI_START="0.3276664824281559" DF="3.0" EFFECT_SIZE="0.5768805146261782" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="25" I2="0.0" ID="CMP-002.19.02" LOG_CI_END="0.006739721041026588" LOG_CI_START="-0.48456798108017507" LOG_EFFECT_SIZE="-0.2389141300195743" NO="2" P_CHI2="0.6096442368421366" P_Z="0.05662546632847747" STUDIES="4" TAU2="0.0" TOTAL_1="133" TOTAL_2="134" WEIGHT="100.00000000000001" Z="1.9061907159785119">
<NAME>cardiac - dizziness / vertigo</NAME>
<DICH_DATA CI_END="4.874950216680204" CI_START="0.012055407891937275" EFFECT_SIZE="0.24242424242424243" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6879701850127149" LOG_CI_START="-1.9188180907846026" LOG_EFFECT_SIZE="-0.6154239528859439" ORDER="1930" O_E="0.0" SE="1.5312403370134193" STUDY_ID="STD-Bratfos-1979" TOTAL_1="32" TOTAL_2="39" VAR="2.3446969696969697" WEIGHT="3.552185416406178"/>
<DICH_DATA CI_END="2.953632957516148" CI_START="0.34708315648742727" EFFECT_SIZE="1.0125" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.47035652536001904" LOG_CI_START="-0.45956646158660686" LOG_EFFECT_SIZE="0.005395031886706145" ORDER="1931" O_E="0.0" SE="0.5462413657254728" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="0.29837962962962966" WEIGHT="27.913428245713828"/>
<DICH_DATA CI_END="0.9499457492768423" CI_START="0.21470090741003287" EFFECT_SIZE="0.45161290322580644" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.0223011962505878" LOG_CI_START="-0.6681661200614816" LOG_EFFECT_SIZE="-0.3452336581560347" ORDER="1932" O_E="0.0" SE="0.37938425332945375" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.14393241167434714" WEIGHT="57.8660378490258"/>
<DICH_DATA CI_END="3.7671046652370506" CI_START="0.11798038120517075" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5760076868089018" LOG_CI_START="-0.9281902049202644" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1933" O_E="0.0" SE="0.8835732875013622" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="0.7807017543859649" WEIGHT="10.668348488854205"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.115385721990542" CI_END="1.3165492362307754" CI_START="0.3583621458221592" DF="1.0" EFFECT_SIZE="0.6868780163727657" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" I2="0.0" ID="CMP-002.19.03" LOG_CI_END="0.11943710546524682" LOG_CI_START="-0.4456778715791164" LOG_EFFECT_SIZE="-0.16312038305693485" NO="3" P_CHI2="0.7340940040194291" P_Z="0.2578502637650698" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="66" WEIGHT="100.0" Z="1.1314868263025055">
<NAME>cardiac - hypotension</NAME>
<DICH_DATA CI_END="9.592728762651543" CI_START="0.017017957260787708" EFFECT_SIZE="0.40404040404040403" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9819421648338768" LOG_CI_START="-1.7690925713730519" LOG_EFFECT_SIZE="-0.3935752032695875" ORDER="1934" O_E="0.0" SE="1.6159714218895198" STUDY_ID="STD-Bratfos-1979" TOTAL_1="32" TOTAL_2="39" VAR="2.6113636363636363" WEIGHT="4.219699133213441"/>
<DICH_DATA CI_END="1.3669326736011849" CI_START="0.3616745544040169" EFFECT_SIZE="0.703125" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.13574712451401438" LOG_CI_START="-0.44168204493110136" LOG_EFFECT_SIZE="-0.1529674602085435" ORDER="1935" O_E="0.0" SE="0.3391847524525481" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="0.11504629629629631" WEIGHT="95.78030086678656"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.072179254246499" CI_END="1.775540006312419" CI_START="0.25635199153048494" DF="2.0" EFFECT_SIZE="0.6746578515516131" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" I2="50.88624848932214" ID="CMP-002.19.04" LOG_CI_END="0.24933046223323144" LOG_CI_START="-0.5911633042920801" LOG_EFFECT_SIZE="-0.17091642102942428" NO="4" P_CHI2="0.13053842014225725" P_Z="0.4253774329300801" STUDIES="3" TAU2="0.35048590729041396" TOTAL_1="103" TOTAL_2="104" WEIGHT="100.0" Z="0.7971267436498417">
<NAME>cardiac - palpitations / tachycardia</NAME>
<DICH_DATA CI_END="3.647021006535942" CI_START="0.5464952302723854" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5619382648208746" LOG_CI_START="-0.2624136241542105" LOG_EFFECT_SIZE="0.14976232033333212" ORDER="1936" O_E="0.0" SE="0.4842283801916266" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.23447712418300648" WEIGHT="36.64466825176128"/>
<DICH_DATA CI_END="0.9499457492768423" CI_START="0.21470090741003287" EFFECT_SIZE="0.45161290322580644" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.0223011962505878" LOG_CI_START="-0.6681661200614816" LOG_EFFECT_SIZE="-0.3452336581560347" ORDER="1937" O_E="0.0" SE="0.37938425332945375" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.14393241167434714" WEIGHT="59.69702257024505"/>
<DICH_DATA CI_END="4.03219258176421" CI_START="0.00992016110066319" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6055412662946563" LOG_CI_START="-2.0034812749666937" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="1938" O_E="0.0" SE="1.5325527556067846" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="2.348717948717949" WEIGHT="3.658309177993656"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.058459912982523" CI_END="1.0788974014172348" CI_START="0.4692141940409865" DF="6.0" EFFECT_SIZE="0.7115012119869526" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="52" I2="14.995621226603744" ID="CMP-002.19.05" LOG_CI_END="0.03298014707687033" LOG_CI_START="-0.32862885866128905" LOG_EFFECT_SIZE="-0.14782435579220937" NO="5" P_CHI2="0.3154749111678261" P_Z="0.10905584514867409" STUDIES="7" TAU2="0.047535752784483465" TOTAL_1="204" TOTAL_2="209" WEIGHT="100.0" Z="1.602451315055791">
<NAME>constipation</NAME>
<DICH_DATA CI_END="1.8978266384276994" CI_START="0.496379123054046" EFFECT_SIZE="0.9705882352941176" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.27825653822146773" LOG_CI_START="-0.30418649255020297" LOG_EFFECT_SIZE="-0.012964977164367647" ORDER="1939" O_E="0.0" SE="0.3421299194147804" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.11705288175876412" WEIGHT="29.84751947966578"/>
<DICH_DATA CI_END="4.510143188928016" CI_START="0.48340744962566373" EFFECT_SIZE="1.4765625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6541903301649111" LOG_CI_START="-0.31568666111415955" LOG_EFFECT_SIZE="0.1692518345253758" ORDER="1940" O_E="0.0" SE="0.569710545645862" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="0.3245701058201058" WEIGHT="10.764201957595395"/>
<DICH_DATA CI_END="0.9499457492768423" CI_START="0.21470090741003287" EFFECT_SIZE="0.45161290322580644" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.0223011962505878" LOG_CI_START="-0.6681661200614816" LOG_EFFECT_SIZE="-0.3452336581560347" ORDER="1941" O_E="0.0" SE="0.37938425332945375" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.14393241167434714" WEIGHT="24.273463688987928"/>
<DICH_DATA CI_END="6.737499470352221" CI_START="0.14842301723368037" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8284987440540728" LOG_CI_START="-0.8284987440540728" LOG_EFFECT_SIZE="0.0" ORDER="1942" O_E="0.0" SE="0.9733285267845753" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="0.9473684210526316" WEIGHT="3.687834733359379"/>
<DICH_DATA CI_END="1.234163048732814" CI_START="0.2757154155013477" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.09137253934649828" LOG_CI_START="-0.5595389514132343" LOG_EFFECT_SIZE="-0.23408320603336794" ORDER="1943" O_E="0.0" SE="0.3823486317361109" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.14619047619047615" WEIGHT="23.898534702723225"/>
<DICH_DATA CI_END="1.2481847418628311" CI_START="0.06540109834974692" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.09627886934782945" LOG_CI_START="-1.1844149580483807" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="1944" O_E="0.0" SE="0.7522858937492222" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="0.5659340659340659" WEIGHT="6.173401423855558"/>
<DICH_DATA CI_END="102.87570120195453" CI_START="0.18999342063118593" EFFECT_SIZE="4.421052631578948" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.012312808386564" LOG_CI_START="-0.7212614381684584" LOG_EFFECT_SIZE="0.6455256851090527" ORDER="1945" O_E="0.0" SE="1.6057150438371723" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="2.5783208020050123" WEIGHT="1.3550440138127295"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.08744828718550168" CI_END="2.8293122172858274" CI_START="0.5860728993265159" DF="1.0" EFFECT_SIZE="1.2877046300625925" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" ID="CMP-002.19.06" LOG_CI_END="0.45168087490931946" LOG_CI_START="-0.23204836042194255" LOG_EFFECT_SIZE="0.10981625724368847" NO="6" P_CHI2="0.7674465592557761" P_Z="0.5289602595165748" STUDIES="2" TAU2="0.0" TOTAL_1="53" TOTAL_2="55" WEIGHT="100.00000000000003" Z="0.6295939912832158">
<NAME>micturition disturbance</NAME>
<DICH_DATA CI_END="3.247572838223813" CI_START="0.5706597027867365" EFFECT_SIZE="1.361344537815126" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.511558900432957" LOG_CI_START="-0.24362279413275656" LOG_EFFECT_SIZE="0.1339680531501002" ORDER="1946" O_E="0.0" SE="0.44359746559757735" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.1967787114845938" WEIGHT="81.97197366199563"/>
<DICH_DATA CI_END="6.3849287248835696" CI_START="0.15661881958098683" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8051560535865078" LOG_CI_START="-0.8051560535865078" LOG_EFFECT_SIZE="0.0" ORDER="1947" O_E="0.0" SE="0.9459053029269173" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.8947368421052633" WEIGHT="18.028026338004388"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9499457492768423" CI_START="0.21470090741003287" DF="0.0" EFFECT_SIZE="0.45161290322580644" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" I2="0.0" ID="CMP-002.19.07" LOG_CI_END="-0.0223011962505878" LOG_CI_START="-0.6681661200614816" LOG_EFFECT_SIZE="-0.3452336581560347" NO="7" P_CHI2="1.0" P_Z="0.03614291606635641" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="30" WEIGHT="100.0" Z="2.0953159439107716">
<NAME>nasal congestion</NAME>
<DICH_DATA CI_END="0.9499457492768423" CI_START="0.21470090741003287" EFFECT_SIZE="0.45161290322580644" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.0223011962505878" LOG_CI_START="-0.6681661200614816" LOG_EFFECT_SIZE="-0.3452336581560347" ORDER="1948" O_E="0.0" SE="0.37938425332945375" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.14393241167434714" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.05886075663422239" CI_END="2.620077361493739" CI_START="0.5931129099372591" DF="1.0" EFFECT_SIZE="1.24659604850019" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" I2="0.0" ID="CMP-002.19.08" LOG_CI_END="0.41831411466853496" LOG_CI_START="-0.2268626228331399" LOG_EFFECT_SIZE="0.09572574591769754" NO="8" P_CHI2="0.8083057086984913" P_Z="0.5608327642390882" STUDIES="2" TAU2="0.0" TOTAL_1="53" TOTAL_2="55" WEIGHT="100.0" Z="0.5816050191717651">
<NAME>perspiration - excessive</NAME>
<DICH_DATA CI_END="2.7291467053680267" CI_START="0.5199065998512181" EFFECT_SIZE="1.1911764705882353" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4360268818110885" LOG_CI_START="-0.2840746694662616" LOG_EFFECT_SIZE="0.07597610617241342" ORDER="1949" O_E="0.0" SE="0.42299121578048277" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.17892156862745096" WEIGHT="80.27307637604893"/>
<DICH_DATA CI_END="7.987230919150586" CI_START="0.2816996306699092" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.902396240519006" LOG_CI_START="-0.5502137224076437" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="1950" O_E="0.0" SE="0.853270282758398" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.7280701754385965" WEIGHT="19.72692362395107"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.074627484588754" CI_END="0.977700976538451" CI_START="0.5101023503706934" DF="7.0" EFFECT_SIZE="0.7062064613779642" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="54" I2="0.0" ID="CMP-002.19.09" LOG_CI_END="-0.009793951036888333" LOG_CI_START="-0.29234267538927783" LOG_EFFECT_SIZE="-0.1510683132130831" NO="9" P_CHI2="0.7711428846696875" P_Z="0.03609639053331714" STUDIES="8" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.00000000000001" Z="2.095839956676522">
<NAME>salivation - too little</NAME>
<DICH_DATA CI_END="2.051449316176467" CI_START="0.3074035670282168" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3120607916042747" LOG_CI_START="-0.5122910973708104" LOG_EFFECT_SIZE="-0.10011515288326783" ORDER="1951" O_E="0.0" SE="0.4842283801916266" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.23447712418300648" WEIGHT="11.747932076716534"/>
<DICH_DATA CI_END="2.953632957516148" CI_START="0.34708315648742727" EFFECT_SIZE="1.0125" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.47035652536001904" LOG_CI_START="-0.45956646158660686" LOG_EFFECT_SIZE="0.005395031886706145" ORDER="1952" O_E="0.0" SE="0.5462413657254728" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="0.29837962962962966" WEIGHT="9.231934940950971"/>
<DICH_DATA CI_END="6.3849287248835696" CI_START="0.15661881958098683" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8051560535865078" LOG_CI_START="-0.8051560535865078" LOG_EFFECT_SIZE="0.0" ORDER="1953" O_E="0.0" SE="0.9459053029269173" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.8947368421052633" WEIGHT="3.0786944259099975"/>
<DICH_DATA CI_END="1.0356570918169463" CI_START="0.31289980723628236" EFFECT_SIZE="0.5692599620493358" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="0.015215983417557876" LOG_CI_START="-0.5045947044033263" LOG_EFFECT_SIZE="-0.24468936049288417" ORDER="1954" O_E="0.0" SE="0.3053393711303905" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.09323213156230234" WEIGHT="29.545836636857466"/>
<DICH_DATA CI_END="2.134821670344876" CI_START="0.029276450051166695" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3293616026304415" LOG_CI_START="-1.5334815852863661" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="1955" O_E="0.0" SE="1.094243309804831" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="1.1973684210526314" WEIGHT="2.3005628677129657"/>
<DICH_DATA CI_END="1.2401168732106815" CI_START="0.4535862805766677" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.09346261661273818" LOG_CI_START="-0.34334008982933806" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="1956" O_E="0.0" SE="0.2565800719723441" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.0658333333333333" WEIGHT="41.84234929284743"/>
<DICH_DATA CI_END="3.973711466115117" CI_START="0.010066156121573125" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5991963295017" LOG_CI_START="-1.9971363381737377" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="1957" O_E="0.0" SE="1.5250986610465322" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="2.3259259259259255" WEIGHT="1.1843117176438898"/>
<DICH_DATA CI_END="102.87570120195453" CI_START="0.18999342063118593" EFFECT_SIZE="4.421052631578948" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.012312808386564" LOG_CI_START="-0.7212614381684584" LOG_EFFECT_SIZE="0.6455256851090527" ORDER="1958" O_E="0.0" SE="1.6057150438371723" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="2.5783208020050123" WEIGHT="1.0683780413607478"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8322701850224058" CI_END="0.9301099027145583" CI_START="0.28552218711381505" DF="3.0" EFFECT_SIZE="0.5153319451375767" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="24" I2="0.0" ID="CMP-002.19.10" LOG_CI_END="-0.03146573174450882" LOG_CI_START="-0.5443601383228387" LOG_EFFECT_SIZE="-0.28791293503367377" NO="10" P_CHI2="0.8417339394085499" P_Z="0.02777505697186993" STUDIES="4" TAU2="0.0" TOTAL_1="106" TOTAL_2="114" WEIGHT="99.99999999999999" Z="2.2004489661481244">
<NAME>salivation - too much</NAME>
<DICH_DATA CI_END="2.5285233639658946" CI_START="0.25311215594076375" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4028669709385392" LOG_CI_START="-0.596686996954652" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="1959" O_E="0.0" SE="0.5871429486123998" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.3447368421052632" WEIGHT="26.329549640806174"/>
<DICH_DATA CI_END="0.9499457492768423" CI_START="0.21470090741003287" EFFECT_SIZE="0.45161290322580644" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.0223011962505878" LOG_CI_START="-0.6681661200614816" LOG_EFFECT_SIZE="-0.3452336581560347" ORDER="1960" O_E="0.0" SE="0.37938425332945375" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.14393241167434714" WEIGHT="63.062695133336845"/>
<DICH_DATA CI_END="3.0631432650827097" CI_START="0.03627356003151584" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48616730949995557" LOG_CI_START="-1.4404098189392804" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="1961" O_E="0.0" SE="1.1316809419557992" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="1.2807017543859647" WEIGHT="7.087337677285499"/>
<DICH_DATA CI_END="11.43063346688383" CI_START="0.021110380070131763" EFFECT_SIZE="0.49122807017543857" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.058070298947239" LOG_CI_START="-1.6755039476077833" LOG_EFFECT_SIZE="-0.3087168243302722" ORDER="1962" O_E="0.0" SE="1.6057150438371723" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="2.5783208020050123" WEIGHT="3.5204175485714604"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.27855966252711684" CI_END="3.032351901017537" CI_START="0.6925298575665673" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4491356838141087" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.20" LOG_CI_END="0.48177959926936686" LOG_CI_START="-0.15956149779149703" LOG_EFFECT_SIZE="0.16110905073893492" METHOD="MH" NO="20" P_CHI2="0.869984554517544" P_Q="0.0" P_Z="0.32476587616252883" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="77" TOTAL_2="77" WEIGHT="200.0" Z="0.9847113758305809">
<NAME>Side-effects: 4. Problems due to high prolactin levels</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours other drug</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.149704352020958" CI_START="0.06600788878540728" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.20.01" LOG_CI_END="1.180404157621246" LOG_CI_START="-1.180404157621246" LOG_EFFECT_SIZE="0.0" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="0.0">
<NAME>amenorrhoea</NAME>
<DICH_DATA CI_END="15.149704352020958" CI_START="0.06600788878540728" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.180404157621246" LOG_CI_START="-1.180404157621246" LOG_EFFECT_SIZE="0.0" ORDER="1963" O_E="0.0" SE="1.3867504905630728" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="1.923076923076923" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.20450398223041175" CI_END="3.2147529719328904" CI_START="0.6930187546416811" DF="1.0" EFFECT_SIZE="1.4926098288198342" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" I2="0.0" ID="CMP-002.20.02" LOG_CI_END="0.5071476064831855" LOG_CI_START="-0.15925501224651983" LOG_EFFECT_SIZE="0.17394629711833282" NO="2" P_CHI2="0.6511096735560856" P_Z="0.3062177082658464" STUDIES="2" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="1.0231906898742762">
<NAME>galactorrhoea</NAME>
<DICH_DATA CI_END="3.150715076978177" CI_START="0.6477311583781613" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.4984091311679766" LOG_CI_START="-0.1886052111964903" LOG_EFFECT_SIZE="0.15490195998574316" ORDER="1964" O_E="0.0" SE="0.40355562548072954" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.16285714285714284" WEIGHT="94.08963477860132"/>
<DICH_DATA CI_END="70.4183669275211" CI_START="0.12780756488237427" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8476859491268096" LOG_CI_START="-0.8934434396874851" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1965" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="5.9103652213986715"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.554749199373944" CI_END="1.0637889104684888" CI_START="0.6218501543616329" CI_STUDY="95" CI_TOTAL="95" DF="17.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8133371368522546" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="99" I2="3.1601089430188396" I2_Q="0.0" ID="CMP-002.21" LOG_CI_END="0.026855458679198484" LOG_CI_START="-0.2063142535310229" LOG_EFFECT_SIZE="-0.08972939742591218" METHOD="MH" NO="21" P_CHI2="0.41743608982047165" P_Q="0.0" P_Z="0.13143070470037246" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.010891942337330528" TOTALS="SUB" TOTAL_1="540" TOTAL_2="550" WEIGHT="500.0" Z="1.508483976261129">
<NAME>Side-effects: 5. Gastrointestinal</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours other drug</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.893677002162993" CI_END="2.4785716136714804" CI_START="0.3931835235098483" DF="2.0" EFFECT_SIZE="0.9871846434861328" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="30.883785629666992" ID="CMP-002.21.01" LOG_CI_END="0.39420147154580554" LOG_CI_START="-0.4054046897175263" LOG_EFFECT_SIZE="-0.005601609085860399" NO="1" P_CHI2="0.23531310178074727" P_Z="0.9780921260598652" STUDIES="3" TAU2="0.21279353499262496" TOTAL_1="98" TOTAL_2="100" WEIGHT="100.0" Z="0.027460899116666684">
<NAME>anorexia</NAME>
<DICH_DATA CI_END="4.327688235798439" CI_START="0.71959593240813" EFFECT_SIZE="1.7647058823529411" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6362559668976686" LOG_CI_START="-0.14291130021489162" LOG_EFFECT_SIZE="0.2466723333413885" ORDER="1966" O_E="0.0" SE="0.45768670964209407" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.2094771241830065" WEIGHT="58.40214492118398"/>
<DICH_DATA CI_END="1.7924955578972024" CI_START="0.18216536761070407" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2534580880870492" LOG_CI_START="-0.7395341854596381" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="1967" O_E="0.0" SE="0.5832885768723526" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="0.34022556390977443" WEIGHT="36.654470170476934"/>
<DICH_DATA CI_END="7.824262991946792" CI_START="0.01420084054248603" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8934434396874849" LOG_CI_START="-1.84768594912681" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="1968" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="4.943384908339076"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.0584599129825225" CI_END="1.0788974014172348" CI_START="0.46921419404098663" DF="6.0" EFFECT_SIZE="0.7115012119869527" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="52" I2="14.995621226603731" ID="CMP-002.21.02" LOG_CI_END="0.03298014707687033" LOG_CI_START="-0.32862885866128894" LOG_EFFECT_SIZE="-0.14782435579220932" NO="2" P_CHI2="0.3154749111678262" P_Z="0.10905584514867414" STUDIES="7" TAU2="0.04753575278448342" TOTAL_1="204" TOTAL_2="209" WEIGHT="100.0" Z="1.6024513150557909">
<NAME>constapation</NAME>
<DICH_DATA CI_END="1.8978266384276994" CI_START="0.496379123054046" EFFECT_SIZE="0.9705882352941176" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.27825653822146773" LOG_CI_START="-0.30418649255020297" LOG_EFFECT_SIZE="-0.012964977164367647" ORDER="1969" O_E="0.0" SE="0.3421299194147804" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.11705288175876412" WEIGHT="29.179750760575736"/>
<DICH_DATA CI_END="4.510143188928016" CI_START="0.48340744962566373" EFFECT_SIZE="1.4765625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6541903301649111" LOG_CI_START="-0.31568666111415955" LOG_EFFECT_SIZE="0.1692518345253758" ORDER="1970" O_E="0.0" SE="0.569710545645862" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="0.3245701058201058" WEIGHT="11.129122053406226"/>
<DICH_DATA CI_END="0.9499457492768423" CI_START="0.21470090741003287" EFFECT_SIZE="0.45161290322580644" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.0223011962505878" LOG_CI_START="-0.6681661200614816" LOG_EFFECT_SIZE="-0.3452336581560347" ORDER="1971" O_E="0.0" SE="0.37938425332945375" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.14393241167434714" WEIGHT="24.113764930988527"/>
<DICH_DATA CI_END="6.737499470352221" CI_START="0.14842301723368037" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8284987440540728" LOG_CI_START="-0.8284987440540728" LOG_EFFECT_SIZE="0.0" ORDER="1972" O_E="0.0" SE="0.9733285267845753" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="0.9473684210526316" WEIGHT="3.896016386425917"/>
<DICH_DATA CI_END="1.234163048732814" CI_START="0.2757154155013477" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.09137253934649828" LOG_CI_START="-0.5595389514132343" LOG_EFFECT_SIZE="-0.23408320603336794" ORDER="1973" O_E="0.0" SE="0.3823486317361109" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.14619047619047615" WEIGHT="23.767128830963735"/>
<DICH_DATA CI_END="1.2481847418628311" CI_START="0.06540109834974692" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.09627886934782945" LOG_CI_START="-1.1844149580483807" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="1974" O_E="0.0" SE="0.7522858937492222" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="0.5659340659340659" WEIGHT="6.472312317223366"/>
<DICH_DATA CI_END="102.87570120195453" CI_START="0.18999342063118593" EFFECT_SIZE="4.421052631578948" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.012312808386564" LOG_CI_START="-0.7212614381684584" LOG_EFFECT_SIZE="0.6455256851090527" ORDER="1975" O_E="0.0" SE="1.6057150438371723" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="2.5783208020050123" WEIGHT="1.4419047204164852"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2511140566663075" CI_END="1.372972151780398" CI_START="0.4288704579187812" DF="3.0" EFFECT_SIZE="0.7673507642817551" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" I2="7.723938695765102" ID="CMP-002.21.03" LOG_CI_END="0.13766172845980046" LOG_CI_START="-0.36767386843738575" LOG_EFFECT_SIZE="-0.11500606998879265" NO="3" P_CHI2="0.3545048746990578" P_Z="0.37233337960444846" STUDIES="4" TAU2="0.0328255654033092" TOTAL_1="122" TOTAL_2="123" WEIGHT="100.0" Z="0.892111129972057">
<NAME>non-specific upset</NAME>
<DICH_DATA CI_END="3.647021006535942" CI_START="0.5464952302723854" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5619382648208746" LOG_CI_START="-0.2624136241542105" LOG_EFFECT_SIZE="0.14976232033333212" ORDER="1976" O_E="0.0" SE="0.4842283801916266" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.23447712418300648" WEIGHT="32.19389792243771"/>
<DICH_DATA CI_END="6.3849287248835696" CI_START="0.15661881958098683" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8051560535865078" LOG_CI_START="-0.8051560535865078" LOG_EFFECT_SIZE="0.0" ORDER="1977" O_E="0.0" SE="0.9459053029269173" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.8947368421052633" WEIGHT="8.722543735998364"/>
<DICH_DATA CI_END="1.123603828961626" CI_START="0.2721634577639793" EFFECT_SIZE="0.5529953917050692" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.05061321049934484" LOG_CI_START="-0.5651701861011541" LOG_EFFECT_SIZE="-0.2572784878009046" ORDER="1978" O_E="0.0" SE="0.36171421534010667" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.13083717357910907" WEIGHT="55.73580721082649"/>
<DICH_DATA CI_END="4.03219258176421" CI_START="0.00992016110066319" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6055412662946563" LOG_CI_START="-2.0034812749666937" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="1979" O_E="0.0" SE="1.5325527556067846" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="2.348717948717949" WEIGHT="3.34775113073744"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7786447771263636" CI_END="2.530495149243139" CI_START="0.5074877067554364" DF="2.0" EFFECT_SIZE="1.1332233584978542" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" ID="CMP-002.21.04" LOG_CI_END="0.40320550913780906" LOG_CI_START="-0.29457447351906874" LOG_EFFECT_SIZE="0.0543155178093701" NO="4" P_CHI2="0.4109341501875373" P_Z="0.7602678954253461" STUDIES="3" TAU2="0.0" TOTAL_1="90" TOTAL_2="92" WEIGHT="100.0" Z="0.3051290130240313">
<NAME>weight - gain</NAME>
<DICH_DATA CI_END="86.3345588638639" CI_START="0.1531616153470894" EFFECT_SIZE="3.6363636363636362" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9361846742732016" LOG_CI_START="-0.8148500619337269" LOG_EFFECT_SIZE="0.5606673061697374" ORDER="1980" O_E="0.0" SE="1.6159714218895198" STUDY_ID="STD-Bratfos-1979" TOTAL_1="32" TOTAL_2="39" VAR="2.6113636363636363" WEIGHT="6.681004182742403"/>
<DICH_DATA CI_END="3.1038543975471105" CI_START="0.5160701616322155" EFFECT_SIZE="1.265625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.49190134021985366" LOG_CI_START="-0.2872912504303285" LOG_EFFECT_SIZE="0.10230504489476258" ORDER="1981" O_E="0.0" SE="0.4577015848134467" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="0.20949074074074076" WEIGHT="79.49490515692872"/>
<DICH_DATA CI_END="2.999080110798954" CI_START="0.03704839717719681" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4769880666975893" LOG_CI_START="-1.4312305761369144" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="1982" O_E="0.0" SE="1.12089707663561" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="1.2564102564102562" WEIGHT="13.824090660328874"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.4183669275211" CI_START="0.12780756488237427" DF="0.0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.21.05" LOG_CI_END="1.8476859491268096" LOG_CI_START="-0.8934434396874851" LOG_EFFECT_SIZE="0.4771212547196624" NO="5" P_CHI2="1.0" P_Z="0.4950473474801439" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="0.6823030531321287">
<NAME>weight - loss</NAME>
<DICH_DATA CI_END="70.4183669275211" CI_START="0.12780756488237427" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8476859491268096" LOG_CI_START="-0.8934434396874851" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1983" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.72834045371374" CI_END="1.213645484527267" CI_START="0.6963639213107538" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9193143796800404" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="117" I2="32.31176921872439" I2_Q="0.0" ID="CMP-002.22" LOG_CI_END="0.08409184440115194" LOG_CI_START="-0.15716373781540055" LOG_EFFECT_SIZE="-0.03653594670712431" METHOD="MH" NO="22" P_CHI2="0.12419152016552915" P_Q="0.0" P_Z="0.5527548223765819" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0746621868346491" TOTALS="SUB" TOTAL_1="411" TOTAL_2="417" WEIGHT="200.0" Z="0.5936371629549414">
<NAME>Side-effects: 6. Sleep problems</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="14.276414014291081" CI_END="1.3074328823526093" CI_START="0.52196786436003" DF="6.0" EFFECT_SIZE="0.8260980265051295" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="74" I2="57.97263938973865" ID="CMP-002.22.01" LOG_CI_END="0.11641940341153273" LOG_CI_START="-0.28235623408724464" LOG_EFFECT_SIZE="-0.082968415337856" NO="1" P_CHI2="0.026696390615570165" P_Z="0.4147450233191511" STUDIES="7" TAU2="0.1964990434784371" TOTAL_1="218" TOTAL_2="221" WEIGHT="100.00000000000001" Z="0.8155719187687683">
<NAME>drowsiness / somnolence</NAME>
<DICH_DATA CI_END="1.7157946405893965" CI_START="0.4149179894019536" EFFECT_SIZE="0.84375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.23446530694166248" LOG_CI_START="-0.38203773526349977" LOG_EFFECT_SIZE="-0.07378621416091866" ORDER="1984" O_E="0.0" SE="0.36213693873058905" STUDY_ID="STD-Bratfos-1979" TOTAL_1="32" TOTAL_2="39" VAR="0.1311431623931624" WEIGHT="16.208700251894"/>
<DICH_DATA CI_END="3.647021006535942" CI_START="0.5464952302723854" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5619382648208746" LOG_CI_START="-0.2624136241542105" LOG_EFFECT_SIZE="0.14976232033333212" ORDER="1985" O_E="0.0" SE="0.4842283801916266" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.23447712418300648" WEIGHT="10.790724754120466"/>
<DICH_DATA CI_END="2.577718779946625" CI_START="0.37591150290066333" EFFECT_SIZE="0.984375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4112355356010762" LOG_CI_START="-0.4249143846616871" LOG_EFFECT_SIZE="-0.0068394245303054655" ORDER="1986" O_E="0.0" SE="0.4911586021712055" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="0.2412367724867725" WEIGHT="10.559823378448696"/>
<DICH_DATA CI_END="0.7225831962046744" CI_START="0.17592199530228028" EFFECT_SIZE="0.3565365025466893" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="-0.14111214224272678" LOG_CI_START="-0.754679857863638" LOG_EFFECT_SIZE="-0.4478960000531824" ORDER="1987" O_E="0.0" SE="0.3604127133648991" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.1298973239550489" WEIGHT="16.307416863640448"/>
<DICH_DATA CI_END="1.8050352245988852" CI_START="0.3545637178034688" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.25648568142154166" LOG_CI_START="-0.4503057074376544" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="1988" O_E="0.0" SE="0.41517276048969254" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="0.1723684210526316" WEIGHT="13.503740465198115"/>
<DICH_DATA CI_END="1.7797645557955455" CI_START="0.8779251136966095" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.2503625534988184" LOG_CI_START="-0.056542527482705586" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="1989" O_E="0.0" SE="0.18027756377319948" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.03250000000000001" WEIGHT="31.128864708753536"/>
<DICH_DATA CI_END="1.9648360816800108" CI_START="0.0062833124490413676" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.29332632479222454" LOG_CI_START="-2.2018113436708746" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="1990" O_E="0.0" SE="1.4656562175858798" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="2.148148148148148" WEIGHT="1.5007295779447503"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.549441650286132" CI_END="1.3883806787166453" CI_START="0.6864304112582383" DF="5.0" EFFECT_SIZE="0.976230874473072" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="43" I2="0.0" ID="CMP-002.22.02" LOG_CI_END="0.14250856121866912" LOG_CI_START="-0.1634034839748106" LOG_EFFECT_SIZE="-0.010447461378070762" NO="2" P_CHI2="0.4732957462665799" P_Z="0.8935031745931634" STUDIES="6" TAU2="0.0" TOTAL_1="193" TOTAL_2="196" WEIGHT="99.99999999999997" Z="0.1338727804453797">
<NAME>insomnia</NAME>
<DICH_DATA CI_END="33.475049475349834" CI_START="0.3993471039480903" EFFECT_SIZE="3.65625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5247212275617328" LOG_CI_START="-0.3986494607092216" LOG_EFFECT_SIZE="0.5630358834262557" ORDER="1991" O_E="0.0" SE="1.1297974631288157" STUDY_ID="STD-Bratfos-1979" TOTAL_1="32" TOTAL_2="39" VAR="1.2764423076923077" WEIGHT="3.7350911586111004"/>
<DICH_DATA CI_END="2.055969309626167" CI_START="0.4416879578704733" EFFECT_SIZE="0.9529411764705882" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.31301662746356684" LOG_CI_START="-0.3548844411348529" LOG_EFFECT_SIZE="-0.02093390683564301" ORDER="1992" O_E="0.0" SE="0.39232839385832247" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.153921568627451" WEIGHT="22.07724009812273"/>
<DICH_DATA CI_END="3.989646628900468" CI_START="0.5781468328025059" EFFECT_SIZE="1.51875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6009344310464382" LOG_CI_START="-0.23796184916166327" LOG_EFFECT_SIZE="0.1814862909423874" ORDER="1993" O_E="0.0" SE="0.49277182759779814" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="0.24282407407407408" WEIGHT="15.89517114039217"/>
<DICH_DATA CI_END="1.2030541193321485" CI_START="0.34598035436823127" EFFECT_SIZE="0.6451612903225806" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.08028516449583095" LOG_CI_START="-0.460948560836414" LOG_EFFECT_SIZE="-0.1903316981702915" ORDER="1994" O_E="0.0" SE="0.31792336941030985" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.10107526881720433" WEIGHT="28.716123339493286"/>
<DICH_DATA CI_END="2.060673511657609" CI_START="0.5695279259289631" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.31400918861690436" LOG_CI_START="-0.2444849760984805" LOG_EFFECT_SIZE="0.03476210625921191" ORDER="1995" O_E="0.0" SE="0.32806223694451914" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="0.10762483130904182" WEIGHT="27.684354614267516"/>
<DICH_DATA CI_END="70.4183669275211" CI_START="0.12780756488237427" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8476859491268096" LOG_CI_START="-0.8934434396874851" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1996" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="1.8920196491131704"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.95032837420926" CI_END="2.8502152767843247" CI_START="0.34594059664952115" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9929779319956459" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.23" LOG_CI_END="0.4548776635132969" LOG_CI_START="-0.4609984698840949" LOG_EFFECT_SIZE="-0.0030604031853989576" METHOD="MH" NO="23" P_CHI2="0.7076438597879515" P_Q="0.0" P_Z="0.9895492458058659" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="172" TOTAL_2="186" WEIGHT="200.0" Z="0.013098452515196254">
<NAME>Side-effects: 7. Skin problems</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="2.603229802542732" CI_END="3.3982837131873396" CI_START="0.36305842807506306" DF="4.0" EFFECT_SIZE="1.1107544927043438" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-002.23.01" LOG_CI_END="0.5312596340763232" LOG_CI_START="-0.4400234770337439" LOG_EFFECT_SIZE="0.045618078521289684" NO="1" P_CHI2="0.6262512239584497" P_Z="0.8539298688659038" STUDIES="5" TAU2="0.0" TOTAL_1="140" TOTAL_2="147" WEIGHT="100.0" Z="0.18410654920883496">
<NAME>erythema/rash</NAME>
<DICH_DATA CI_END="2.5918989375554142" CI_START="0.03581716528801395" EFFECT_SIZE="0.3046875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.4136180636654967" LOG_CI_START="-1.445908788908235" LOG_EFFECT_SIZE="-0.5161453626213691" ORDER="1997" O_E="0.0" SE="1.0922952780081834" STUDY_ID="STD-Bratfos-1979" TOTAL_1="32" TOTAL_2="39" VAR="1.1931089743589745" WEIGHT="27.28266346712945"/>
<DICH_DATA CI_END="26.327436276978744" CI_START="0.34184870510425597" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4204085702731564" LOG_CI_START="-0.4661660608338316" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1998" O_E="0.0" SE="1.1081832770072813" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="1.2280701754385965" WEIGHT="26.50596951059613"/>
<DICH_DATA CI_END="15.411181903959992" CI_START="0.0648879499464635" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1878359466149053" LOG_CI_START="-1.1878359466149053" LOG_EFFECT_SIZE="0.0" ORDER="1999" O_E="0.0" SE="1.3954814298487213" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="1.9473684210526314" WEIGHT="16.715476267943508"/>
<DICH_DATA CI_END="70.29633525231894" CI_START="0.12802943379190027" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.846932684604724" LOG_CI_START="-0.8926901751653996" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="2000" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="12.569271628266012"/>
<DICH_DATA CI_END="15.149704352020958" CI_START="0.06600788878540728" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.180404157621246" LOG_CI_START="-1.180404157621246" LOG_EFFECT_SIZE="0.0" ORDER="2001" O_E="0.0" SE="1.3867504905630728" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="1.923076923076923" WEIGHT="16.9266191260649"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.720120734024766E-33" CI_END="9.592728762651543" CI_START="0.017017957260787708" DF="0.0" EFFECT_SIZE="0.40404040404040403" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="100.0" ID="CMP-002.23.02" LOG_CI_END="0.9819421648338768" LOG_CI_START="-1.7690925713730519" LOG_EFFECT_SIZE="-0.3935752032695875" NO="2" P_CHI2="0.0" P_Z="0.5749323609076331" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="39" WEIGHT="100.0" Z="0.5608022417630423">
<NAME>itching</NAME>
<DICH_DATA CI_END="9.592728762651543" CI_START="0.017017957260787708" EFFECT_SIZE="0.40404040404040403" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9819421648338768" LOG_CI_START="-1.7690925713730519" LOG_EFFECT_SIZE="-0.3935752032695875" ORDER="2002" O_E="0.0" SE="1.6159714218895198" STUDY_ID="STD-Bratfos-1979" TOTAL_1="32" TOTAL_2="39" VAR="2.6113636363636363" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1436169537775056" CI_END="2.3841697215087594" CI_START="0.7380588340510744" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.326520834678683" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-002.24" LOG_CI_END="0.37733716822050284" LOG_CI_START="-0.13190901719417142" LOG_EFFECT_SIZE="0.12271407551316572" METHOD="MH" NO="24" P_CHI2="0.887291591048931" P_Q="0.0" P_Z="0.34486675892533225" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="149" TOTAL_2="146" WEIGHT="100.0" Z="0.9445929112108488">
<NAME>Side-effects: 8. Headache</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="2.9751208684263926" CI_START="0.4921828164852638" EFFECT_SIZE="1.2100840336134453" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.47350461424080836" LOG_CI_START="-0.3078735528353706" LOG_EFFECT_SIZE="0.08281553070271887" ORDER="2003" O_E="0.0" SE="0.458985403224855" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.2106676003734827" WEIGHT="42.474964511855006"/>
<DICH_DATA CI_END="4.996356642835089" CI_START="0.5699465537720604" EFFECT_SIZE="1.6875" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.6986534310005686" LOG_CI_START="-0.24416586799444354" LOG_EFFECT_SIZE="0.22724378150306254" ORDER="2004" O_E="0.0" SE="0.553816723260469" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="0.30671296296296297" WEIGHT="29.17417889097128"/>
<DICH_DATA CI_END="5.169895635269663" CI_START="0.343871115240617" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7134817760757654" LOG_CI_START="-0.46360430285916565" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="2005" O_E="0.0" SE="0.6914261894364405" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.4780701754385965" WEIGHT="18.717124199291586"/>
<DICH_DATA CI_END="5.284718511186434" CI_START="0.04730620930344959" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7230218597050971" LOG_CI_START="-1.3250818510330595" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="2006" O_E="0.0" SE="1.2030662579644695" STUDY_ID="STD-Toru-1972" TOTAL_1="38" TOTAL_2="38" VAR="1.4473684210526314" WEIGHT="6.182322841584193"/>
<DICH_DATA CI_END="70.4183669275211" CI_START="0.12780756488237427" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8476859491268096" LOG_CI_START="-0.8934434396874851" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="2007" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Yamagami-1988" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="3.451409556297942"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>HIGH DOSE SULPIRIDE vs LOW DOSE SULPIRIDE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.674562832319093" CI_START="0.3710512653578078" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.8850536460490437" LOG_CI_START="-0.4305660830429185" LOG_EFFECT_SIZE="0.22724378150306254" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.4983554679844773" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="9" WEIGHT="100.0" Z="0.6770795809881917">
<NAME>Behaviour: Leaving the study early - by 60 days</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2/>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours low dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.674562832319093" CI_START="0.3710512653578078" EFFECT_SIZE="1.6875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8850536460490437" LOG_CI_START="-0.4305660830429185" LOG_EFFECT_SIZE="0.22724378150306254" ORDER="2008" O_E="0.0" SE="0.7728015412913085" STUDY_ID="STD-Petit-1987" TOTAL_1="8" TOTAL_2="9" VAR="0.5972222222222221" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>SENSITIVITY ANALYSIS: HIGH or LOW DOSE SULPIRIDE vs TYPICAL ANTIPSYCHOTICS</NAME>
<DICH_OUTCOME CHI2="2.3654700507804125" CI_END="1.416904443285787" CI_START="0.6479322711329207" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.958153491835461" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.15134056220720513" LOG_CI_START="-0.18847038889874773" LOG_EFFECT_SIZE="-0.01856491334577127" METHOD="MH" NO="1" P_CHI2="0.5000948930091287" P_Q="0.0" P_Z="0.8304241013057339" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="83" TOTAL_2="95" WEIGHT="200.0" Z="0.21415767452693638">
<NAME>Global impression: No improvement</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other drug</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7174768534372982" CI_END="1.876076955860454" CI_START="0.41151128279131816" DF="1.0" EFFECT_SIZE="0.8786505760092385" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" I2="41.77505228098795" ID="CMP-004.01.01" LOG_CI_END="0.27325064897911605" LOG_CI_START="-0.3856182528287839" LOG_EFFECT_SIZE="-0.056183801924833944" NO="1" P_CHI2="0.19001824929890088" P_Z="0.738180008172296" STUDIES="2" TAU2="0.12953264666672915" TOTAL_1="45" TOTAL_2="48" WEIGHT="100.0" Z="0.3342644583316904">
<NAME>high dose</NAME>
<DICH_DATA CI_END="1.2691168976288023" CI_START="0.32008960897522715" EFFECT_SIZE="0.6373626373626373" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.10350162655251342" LOG_CI_START="-0.4947284240688261" LOG_EFFECT_SIZE="-0.19561339875815634" ORDER="2009" O_E="0.0" SE="0.3514032930214845" STUDY_ID="STD-Cassano-1975" TOTAL_1="26" TOTAL_2="29" VAR="0.1234842743463433" WEIGHT="65.80124359114214"/>
<DICH_DATA CI_END="3.6394388384179948" CI_START="0.5385445633294335" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5610344253616348" LOG_CI_START="-0.26877835400515887" LOG_EFFECT_SIZE="0.14612803567823798" ORDER="2010" O_E="0.0" SE="0.48743613423955967" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.23759398496240602" WEIGHT="34.198756408857854"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.18852982178598285" CI_END="1.8937789418790436" CI_START="0.6329019963820977" DF="1.0" EFFECT_SIZE="1.094795174003623" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.2773292830489245" LOG_CI_START="-0.1986635344149441" LOG_EFFECT_SIZE="0.03933287431699021" NO="2" P_CHI2="0.6641430684287298" P_Z="0.7460010825415886" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="47" WEIGHT="100.0" Z="0.32391672412406963">
<NAME>low dose</NAME>
<DICH_DATA CI_END="1.9841868635676467" CI_START="0.5039847901230231" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.29758257003327615" LOG_CI_START="-0.2975825700332762" LOG_EFFECT_SIZE="0.0" ORDER="2011" O_E="0.0" SE="0.3496029493900505" STUDY_ID="STD-Taverna-1972" TOTAL_1="20" TOTAL_2="20" VAR="0.12222222222222222" WEIGHT="63.96255850234009"/>
<DICH_DATA CI_END="3.2033105170277962" CI_START="0.5160477623704103" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.5055990395989719" LOG_CI_START="-0.2873101007488357" LOG_EFFECT_SIZE="0.10914446942506809" ORDER="2012" O_E="0.0" SE="0.4657587540038479" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="0.21693121693121692" WEIGHT="36.037441497659906"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.8268413733094695" CI_END="1.1555810568360856" CI_START="0.6905497531773205" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8933007408339848" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.06280041394492816" LOG_CI_START="-0.16080502562705584" LOG_EFFECT_SIZE="-0.04900230584106383" METHOD="MH" NO="2" P_CHI2="0.5746063063850222" P_Q="0.0" P_Z="0.39031970914214253" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="173" TOTAL_2="168" WEIGHT="199.99999999999997" Z="0.8590377299563264">
<NAME>Behaviour: 1. Leaving the study early - for any reason</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other drug</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6373835471515334" CI_END="1.9747479764515135" CI_START="0.6341033963481265" DF="3.0" EFFECT_SIZE="1.1190149234033901" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="18" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.29551167747111073" LOG_CI_START="-0.1978399206636933" LOG_EFFECT_SIZE="0.04883587840370876" NO="1" P_CHI2="0.8878234392612845" P_Z="0.6979969761366926" STUDIES="4" TAU2="0.0" TOTAL_1="110" TOTAL_2="107" WEIGHT="99.99999999999999" Z="0.38802575358636143">
<NAME>high dose</NAME>
<DICH_DATA CI_END="3.306385290395756" CI_START="0.46151655753064935" EFFECT_SIZE="1.2352941176470589" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5193534601679887" LOG_CI_START="-0.335812713456698" LOG_EFFECT_SIZE="0.09177037335564536" ORDER="2013" O_E="0.0" SE="0.5023288435279716" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.2523342670401494" WEIGHT="33.28220191089486"/>
<DICH_DATA CI_END="4.024534250335345" CI_START="0.3980104382243807" EFFECT_SIZE="1.265625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6047156277565304" LOG_CI_START="-0.40010553796700515" LOG_EFFECT_SIZE="0.10230504489476258" ORDER="2014" O_E="0.0" SE="0.5902369266909938" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="0.3483796296296296" WEIGHT="24.106576017651424"/>
<DICH_DATA CI_END="20.24371955945401" CI_START="0.19759214645571213" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3062903123047387" LOG_CI_START="-0.7042303209767762" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="2015" O_E="0.0" SE="1.180989772227204" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="1.3947368421052633" WEIGHT="6.021379640327939"/>
<DICH_DATA CI_END="2.19205941209886" CI_START="0.3351614803394235" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.34085232079637595" LOG_CI_START="-0.4747459000576024" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="2016" O_E="0.0" SE="0.4790864322059325" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.22952380952380955" WEIGHT="36.58984243112577"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9286215082247864" CI_END="1.4283326014528495" CI_START="0.36729913139775494" DF="1.0" EFFECT_SIZE="0.7243102400634188" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="37" I2="65.85424244165439" ID="CMP-004.02.02" LOG_CI_END="0.15482934900624976" LOG_CI_START="-0.43498009868876025" LOG_EFFECT_SIZE="-0.1400753748412552" NO="2" P_CHI2="0.08702192055765612" P_Z="0.3518774450563946" STUDIES="2" TAU2="0.1679048803608365" TOTAL_1="63" TOTAL_2="61" WEIGHT="99.99999999999999" Z="0.9309538559706967">
<NAME>low dose</NAME>
<DICH_DATA CI_END="1.0302925471402926" CI_START="0.2272472164079782" EFFECT_SIZE="0.4838709677419355" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.012960558267443136" LOG_CI_START="-0.643501427824626" LOG_EFFECT_SIZE="-0.3152704347785914" ORDER="2017" O_E="0.0" SE="0.3856090201697205" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.14869431643625192" WEIGHT="14.601929314549144"/>
<DICH_DATA CI_END="1.2665776463928629" CI_START="0.6779244565943294" EFFECT_SIZE="0.9266304347826086" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.10263181897165875" LOG_CI_START="-0.1688186983336987" LOG_EFFECT_SIZE="-0.03309343968101996" ORDER="2018" O_E="0.0" SE="0.15945137756689856" STUDY_ID="STD-Nishikawa-1989" TOTAL_1="32" TOTAL_2="31" VAR="0.02542474180798164" WEIGHT="85.39807068545085"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.534813026104654" CI_END="12.27986352379859" CI_START="0.10937882463047427" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1589465211370729" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="63.8650846818654" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="1.0891935401609676" LOG_CI_START="-0.9610667478039643" LOG_EFFECT_SIZE="0.06406339617850168" METHOD="MH" NO="3" P_CHI2="0.06282477111503104" P_Q="0.0" P_Z="0.9025157872955172" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="2.7640718658440235" TOTALS="SUB" TOTAL_1="89" TOTAL_2="83" WEIGHT="200.0" Z="0.12248391092022354">
<NAME>Behaviour: 2. Leaving the study early - due to adverse effects</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other drug</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2161053224337441" CI_END="37.46168352942952" CI_START="0.5165014515058376" DF="1.0" EFFECT_SIZE="4.398751404524093" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="1.5735872906877026" LOG_CI_START="-0.28692845366015934" LOG_EFFECT_SIZE="0.6433294185137718" NO="1" P_CHI2="0.6420236420957388" P_Z="0.17527954851691221" STUDIES="2" TAU2="0.0" TOTAL_1="57" TOTAL_2="52" WEIGHT="100.0" Z="1.3554332924218848">
<NAME>high dose</NAME>
<DICH_DATA CI_END="60.042390771014624" CI_START="0.10791273897945941" EFFECT_SIZE="2.5454545454545454" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.778457976675619" LOG_CI_START="-0.966927284307631" LOG_EFFECT_SIZE="0.4057653461839942" ORDER="2019" O_E="0.0" SE="1.6126528921777776" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="2.6006493506493507" WEIGHT="48.104691914365226"/>
<DICH_DATA CI_END="128.87064248425733" CI_START="0.3802262412557286" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1101539936976934" LOG_CI_START="-0.4199579136691801" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="2020" O_E="0.0" SE="1.4862002586432317" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="2.208791208791209" WEIGHT="51.89530808563477"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9181002294344671" CI_START="0.05047871694083514" DF="0.0" EFFECT_SIZE="0.21527777777777776" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="-0.03710990407742724" LOG_CI_START="-1.2968916924445268" LOG_EFFECT_SIZE="-0.667000798260977" NO="2" P_CHI2="1.0" P_Z="0.037946246875642305" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="2.075434895666289">
<NAME>low dose</NAME>
<DICH_DATA CI_END="0.9181002294344671" CI_START="0.05047871694083514" EFFECT_SIZE="0.2152777777777778" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.03710990407742724" LOG_CI_START="-1.2968916924445268" LOG_EFFECT_SIZE="-0.6670007982609769" ORDER="2021" O_E="0.0" SE="0.74000205850726" STUDY_ID="STD-Nishikawa-1989" TOTAL_1="32" TOTAL_2="31" VAR="0.5476030465949822" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.261133384735338" CI_END="1.4150491995129613" CI_START="0.40749517358914716" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7593587552617787" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="45" I2="46.010927687951785" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.1507715400055625" LOG_CI_START="-0.3898775307179036" LOG_EFFECT_SIZE="-0.11955299535617055" METHOD="MH" NO="4" P_CHI2="0.09909094386356887" P_Q="0.0" P_Z="0.3860470339075106" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2449785002811323" TOTALS="SUB" TOTAL_1="147" TOTAL_2="157" WEIGHT="200.0" Z="0.8668083525175596">
<NAME>Side-effects: 1. Akathisia</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other drug</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7965986918240432" CI_END="1.9140114312059786" CI_START="0.7091503175866538" DF="2.0" EFFECT_SIZE="1.16504155046256" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="21" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.2819445272207898" LOG_CI_START="-0.14926169827384325" LOG_EFFECT_SIZE="0.06634141447347328" NO="1" P_CHI2="0.671461221368292" P_Z="0.5464528272149913" STUDIES="3" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0" Z="0.6030839786800352">
<NAME>high dose</NAME>
<DICH_DATA CI_END="2.548729581138765" CI_START="0.6334114358834857" EFFECT_SIZE="1.2705882352941176" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.4063237594985916" LOG_CI_START="-0.19831409995327764" LOG_EFFECT_SIZE="0.10400482977265695" ORDER="2022" O_E="0.0" SE="0.3551672716477029" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.1261437908496732" WEIGHT="41.51400499155736"/>
<DICH_DATA CI_END="6.008485209007517" CI_START="0.46230916464827443" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7787649964138754" LOG_CI_START="-0.33506749718116263" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="2023" O_E="0.0" SE="0.6542707202974901" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.4280701754385965" WEIGHT="22.89102289668297"/>
<DICH_DATA CI_END="2.0461619092514605" CI_START="0.37417615709603624" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3109399957067384" LOG_CI_START="-0.426923889662112" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="2024" O_E="0.0" SE="0.43342489875080187" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.18785714285714283" WEIGHT="35.59497211175967"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.535063444763105" CI_END="0.7469987009871679" CI_START="0.18800257248318927" DF="2.0" EFFECT_SIZE="0.3747501533384453" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="24" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="-0.12668015341163658" LOG_CI_START="-0.7258362081426484" LOG_EFFECT_SIZE="-0.4262581807771425" NO="2" P_CHI2="0.4641574526880262" P_Z="0.0052910551280159375" STUDIES="3" TAU2="0.0" TOTAL_1="69" TOTAL_2="77" WEIGHT="100.00000000000001" Z="2.7887582069543955">
<NAME>low dose</NAME>
<DICH_DATA CI_END="0.8809707796149677" CI_START="0.20347625354069665" EFFECT_SIZE="0.42338709677419356" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="-0.0550384961991143" LOG_CI_START="-0.691486267313442" LOG_EFFECT_SIZE="-0.3732623817562782" ORDER="2025" O_E="0.0" SE="0.37385257121983323" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="30" VAR="0.1397657450076805" WEIGHT="75.90084834171759"/>
<DICH_DATA CI_END="1.2804065064867485" CI_START="0.004621313413620057" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.10734787237939855" LOG_CI_START="-2.3352345769930722" LOG_EFFECT_SIZE="-1.1139433523068367" ORDER="2026" O_E="0.0" SE="1.4347850217395144" STUDY_ID="STD-Taverna-1972" TOTAL_1="20" TOTAL_2="20" VAR="2.058608058608059" WEIGHT="12.676933931276462"/>
<DICH_DATA CI_END="5.802456357303471" CI_START="0.014971212318527998" EFFECT_SIZE="0.29473684210526313" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.7636118826301428" LOG_CI_START="-1.8247430305233998" LOG_EFFECT_SIZE="-0.5305655739466286" ORDER="2027" O_E="0.0" SE="1.5204124885498493" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="2.3116541353383457" WEIGHT="11.42221772700596"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.8157613641962165" CI_END="0.9542349522254476" CI_START="0.46725628124301993" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6677366810419909" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="61" I2="14.026733786195525" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="-0.020344679916438457" LOG_CI_START="-0.33044485176647104" LOG_EFFECT_SIZE="-0.1753947658414547" METHOD="MH" NO="5" P_CHI2="0.32456116479057084" P_Q="0.0" P_Z="0.026613668620354174" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.02862394213980099" TOTALS="SUB" TOTAL_1="159" TOTAL_2="161" WEIGHT="200.0" Z="2.2171379143403804">
<NAME>Side-effects: 2. Use of additional anti-parkinson drugs</NAME>
<GROUP_LABEL_1>Sulpiride</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Sulpiride</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other drug</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5141071292166304" CI_END="1.2634267936965615" CI_START="0.572053476457943" DF="3.0" EFFECT_SIZE="0.8501456872702645" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="33" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="0.10155008280940074" LOG_CI_START="-0.2425633707786021" LOG_EFFECT_SIZE="-0.07050664398460069" NO="1" P_CHI2="0.6790182923590329" P_Z="0.4218775593720079" STUDIES="4" TAU2="0.0" TOTAL_1="110" TOTAL_2="107" WEIGHT="100.0" Z="0.8031681495723004">
<NAME>high dose</NAME>
<DICH_DATA CI_END="1.2436851960372972" CI_START="0.3774194089610362" EFFECT_SIZE="0.6851211072664359" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.09471046481980322" LOG_CI_START="-0.42317576980983684" LOG_EFFECT_SIZE="-0.16423265249501676" ORDER="2028" O_E="0.0" SE="0.3042089377996568" STUDY_ID="STD-Cassano-1975" TOTAL_1="34" TOTAL_2="36" VAR="0.09254307783719547" WEIGHT="42.96395122012389"/>
<DICH_DATA CI_END="1.6562089428261844" CI_START="0.5044715266906604" EFFECT_SIZE="0.9140625" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.2191151253185938" LOG_CI_START="-0.2971633411220073" LOG_EFFECT_SIZE="-0.03902410790170672" ORDER="2029" O_E="0.0" SE="0.30326452680683447" STUDY_ID="STD-Dreyfus-1985" TOTAL_1="32" TOTAL_2="27" VAR="0.09196937321937321" WEIGHT="43.168345776666776"/>
<DICH_DATA CI_END="5.169895635269663" CI_START="0.343871115240617" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7134817760757654" LOG_CI_START="-0.46360430285916565" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="2030" O_E="0.0" SE="0.6914261894364405" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.4780701754385965" WEIGHT="10.274076124386802"/>
<DICH_DATA CI_END="20.6706293264143" CI_START="0.1935112829336326" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3153536991153598" LOG_CI_START="-0.7132937077873972" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="2031" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Wiesel-1984" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="3.593626878822537"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03882109004466808" CI_END="0.7174006874089641" CI_START="0.25414750347402126" DF="1.0" EFFECT_SIZE="0.4269960113344561" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="28" I2="0.0" ID="CMP-004.05.02" LOG_CI_END="-0.14423821152152852" LOG_CI_START="-0.5949141520749182" LOG_EFFECT_SIZE="-0.3695761817982233" NO="2" P_CHI2="0.8438036131169098" P_Z="0.0013065757377492013" STUDIES="2" TAU2="0.0" TOTAL_1="49" TOTAL_2="54" WEIGHT="100.0" Z="3.2145315100641985">
<NAME>low dose</NAME>
<DICH_DATA CI_END="0.7599527322675284" CI_START="0.24954999675728143" EFFECT_SIZE="0.43548387096774194" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="20" LOG_CI_END="-0.11921341923733726" LOG_CI_START="-0.602842431441196" LOG_EFFECT_SIZE="-0.3610279253392666" ORDER="2032" O_E="0.0" SE="0.284086075770767" STUDY_ID="STD-Mahadevan-1991" TOTAL_1="31" TOTAL_2="27" VAR="0.08070489844683396" WEIGHT="83.69103025571873"/>
<DICH_DATA CI_END="1.5671881498724582" CI_START="0.0897307703682193" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.1951211391272757" LOG_CI_START="-1.047058603671838" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="2033" O_E="0.0" SE="0.7296625298090943" STUDY_ID="STD-Yamagami-1993" TOTAL_1="18" TOTAL_2="27" VAR="0.5324074074074074" WEIGHT="16.308969744281274"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK>
<FEEDBACK_ITEM ID="FBK-01" NO="1">
<TITLE>General comments</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>a. Category: Background<BR/>As this pioneering review notes, sulpiride is a relatively poorly investigated drug whose relationship to other antipsychotic drugs is unclear. The reasons for this are however not discussed, and it would be helpful to do so. The drug was developed in France and I believe used mainly in Southern and Eastern Europe and in Japan. In these countries the science and practice of controlled clinical trials in psychiatry developed later than in the Anglo-Saxon countries and Scandinavia.<BR/>Last line: replace 'wherever' with 'whether'.</P>
<P>b. Category: Description of studies<BR/>The 18 trials reviewed were performed in many different countries, asked many different questions, used differing methods. It is thus difficult to summarise their findings. I think it would help to describe briefly how these research efforts came about in the various locations. Some were presumably instigated or sponsored by industry, others resulted from academic initiatives. </P>
<P>c. Category: Comparisons<BR/>Three of the Japanese trials compare sulpiride with obscure drugs not used outside Japan - clocapramine, bromperidol and timiperone. In these it seems possible that sulpiride played the role of the local 'gold standard' against which newer untried drugs were compared. If so, it seems rash to use the results to draw conclusions about sulpiride. That deserves mention.</P>
<P>d. Category: Characteristics of studies<BR/>The table of included studies would be improved by addition of the country of origin and the identity or nature of the sponsor, if stated. The exclusion of two RCTs of levosulpiride is in my opinion unjustified, because this isomer is present in the racemic sulpiride that was used in all the other trials. It seems quite straightforward to include them: this might throw light on the hypothesis that levosulpiride is twice as potent an antipsychotic as racemic sulpiride, while causing less unwanted effects (which are assumed to be caused by both isomers, or more by dexsulpiride).</P>
<P>Levosulpiride is marketed in Italy. It would be interesting to know what claims are made for it there, together with the evidence supporting them.</P>
<P>e. Category: Results<BR/>Sensitivity analysis 2: Replace "trails" with "trials".</P>
<P>f. Category: Implications for practice<BR/>The second sentence: "although" seems wrong. The sentence would better end "but no direct comparison has been made."</P>
<P>g. Category: References<BR/>The references to the trials by Cassano and Dreyfus cite more than one article without indicating with an asterisk which is the major publication.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>a. Category: Background<BR/>It is interesting that this drug has not been used in countries such as the USA, and one reason for that seems exactly that it is a French drug. We found in our search several studies from Japan and Europe, most of them uncontrolled trials. All of the included trials in this review are from the 1970's and 80's. </P>
<P>b. Category: Description of studies<BR/>Edwards 1980, Yamagami 1988, Yamagami 1983 were sponsored by the manufacturers of sulpiride. The results are not significantly different between academic institutions and the pharmaceutical industry.</P>
<P>c. Category: Comparisons<BR/>Sulpiride was compared to three obscure antipsychotic drugs used in Japan. In two of these trials sulpiride was the comparison and reference antipsychotic (Yamagami 1988, Yamagami 1993) but the drugs clocapramine and bromperidol had already been investigated in previous trials. They were described to have at least equal antipsychotic effect compared to haloperidol and chlorpromazine. Nishikawa 1989 compared sulpiride and timiperone, which were described as new neuroleptic drugs. This was based on previous efficacy studies on these drugs mentioned in the paper, comparing to haloperidol and chlorpromazine.</P>
<P>d. Category: Characteristics of studies <BR/>The suggested improvement in the included studies table has been incorporated into Issue 2, 2000.</P>
<P>Some papers described the higher potency/antipsychotic effect of levosulpiride when compared to the racemic compound. The authors of this review therefore decided not to include the l-sulpiride trials in the meta-analysis, considering it as an unfair comparison. L-sulpiride, however, could have been compared in a subgroup analysis. As l-sulpiride was considered a different drug when the review was first planned we focused the search on sulpiride only. We found one interesting trial in the search, not on the subject of schizophrenia, comparing levosulpiride to the racemic one that suggested the isomer was more potent (Altamura et al 1991). The subject is very interesting and could be the subject to another review.</P>
<P>e. Category: Results<BR/>The typing error has been amended.</P>
<P>f. Category: Implications for practice<BR/>The error has been amended.</P>
<P>g. Category: References<BR/>This omission has been rectified.</P>
<P>References<BR/>Altamura AC, Mauri MC, Regazzetti G, Coppola MT. L-sulpiride in the treatment of somatoform disturbances: a double-blind study with racemic sulpiride. Minerva Psichiatrica 1991;32:25-9.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Comment received from Andrew Herxheimer, London, March 1999.<BR/>Reply by Bernardo Garcia de Oliveira Soares, Pelatos, and Mark Fenton, York, January 2000.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>